Genetic variation, pathogenicity, and pathophysiology of human channelopathies by Bersell, Kevin Richard
Genetic variation, pathogenicity, and pathophysiology of human channelopathies 
By 
 
Kevin Richard Bersell 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements  
for the degree of 
 
DOCTOR OF PHILOSOPHY 
in 
 
Pharmacology 
December, 2016 
Nashville, Tennessee 
 
 
Approved: 
 
Dan M. Roden, MD 
Charles C. Hong, MD, PhD 
Björn C. Knollmann, MD, PhD 
Katherine T. Murray, MD 
P. Anthony Weil, PhD	
 
	
	
 ii	
 
 
 
 
 
 
 
To my loving wife, Liz, and our energetic son, Benjamin,  
for being my biggest fans and my source of perspective 
& 
To my supportive family 
for believing in me more than I believe in myself
 iii	
ACKNOWLEDGEMENTS  
 
Training in the laboratory of my dissertation mentor, Dan Roden, MD, has been 
an incredible and formative experience. Each day in the lab was inspiring as the energy, 
enthusiasm, and work ethic trickled down from the top. I hope to reflect many of Dr. 
Roden’s professional characteristics to be a thorough scientist who is forward thinking in 
the pursuit of addressing clinically relevant questions. I was provided unlimited support 
to pursue ambitious projects within the lab with enough freedom to challenge myself in 
developing my approach to the scientific process and team management. With the 
aspiration to become a productive physician-scientist, Dr. Roden has been a terrific 
mentor for guiding my scientific training and will remain a valued friend and career 
mentor. 
The scientific questions addressed were important and the projects completed 
during training benefitted from intellectual contributions provided by my dissertation 
committee: Charles Hong, MD/PhD, (chair), Björn Knollmann, MD/PhD, Kathy Murray, 
MD, and Tony Weil, PhD. Thank you for the critical evaluation, enthusiastic 
conversations about various topics, career advice, and encouragement throughout the 
process. I am also grateful for the institutional support provided by the Medical Scientist 
Training Program and the Department of Pharmacology that permitted me to focus on my 
training. 
During my PhD training, I have come to appreciate the importance of 
constructing a talented team within a lab. The individuals within the Roden lab have 
taught me so much about science, functioning well as a team, and how to balance career 
 iv	
and personal life. Thank you to Tao Yang, PhD, for sharing his technical expertise in 
patch-clamp experimentation and enthusiasm for ion channel biology. I must also 
acknowledge the immensely generous and knowledgeable individuals who have 
contributed to my training as a budding physician-scientist including Quinn Wells, MD, 
(a valued clinical mentor and collaborator), Marcia Blair, Laura Short, Lynn Hall, Sara 
Van Driest, MD/PhD, Jonathan Mosely, MD/PhD, Tracy McGregor, MD, Wei Zhang, 
Andrew Glazer, PhD, Laura Daniel, PhD, Brett Kroncke, PhD, Dina Stroud, PhD, 
Christie Ingram, and Robin North. Without everyone’s effort and contribution to my 
training, I would have not been as productive or efficient – certainly above and beyond 
expectations! 
My dissertation work would not have been possible with fruitful collaborations 
with Jonathan Brown, MD, Prince Kannankeril, MD, Wenbiao Chen, PhD, Amanda 
Meyers, TK Feaster, PhD, Lili Wang, PhD, Shan Parikh, Kyungsoo Kim, PhD, Jay 
Montgomery, MD, Wendy Chung, MD, Courtney Campbell, MD/PhD, Benjamin 
Shoemaker, MD, Elijah Behr MD, and Ivan Moskowitz, MD/PhD. Thank you all for 
enthusiastically sharing your expertise, data generated, and providing career advice based 
on your experience. 
The foundation of my electrophysiology training began in the laboratory of Al 
George, Jr, MD. During my “extended rotation” prior to Dr. George accepting the Chair 
of Pharmacology position at Northwestern University, the laboratory instilled exceptional 
practice in performing and designing experiments in electrophysiology. Many 
individuals, including Carlos Vanoye, PhD, Christopher Thompson, PhD, Rick Welch, 
Franck Potet, PhD, Jennifer Kunic, and Lisa Scudder, PhD, spent numerous hours 
 v	
involved in my training and discussion of data. My time working in the George lab was 
foundational and I am grateful for the friendship and continued mentorship provided by 
Dr. George. 
After college, I was fortunate to work for Dr. Bernhard Kühn, MD, who saw 
potential in me as a budding scientist. Dr. Kühn was the first physician-scientist that I 
encountered in my professional development. Working for him as a research assistant 
exposed me to the level of dedication and effort required to advance scientific 
understanding. Through his example I learned to aim high and work diligently to achieve 
my goals. Without the training and support provided by Dr. Kühn, I would have never 
made it to Vanderbilt University. Now as a collaborator and friend, I look forward to 
continuing a relationship with my first scientific mentor.  
My family has always been important in my professional development. My 
journey as a scientist began in first grade during exploratory adventures in the creek 
behind our home with my grandmother, Jeanne Odom. We collected critters to observe 
their movements and water samples to look at under my microscope. This was my first 
lesson in observation, a trait that has benefited me throughout my academic career.  I 
have watched the compassion that my mother, Linda, has for others and I hope to emulate 
that characteristic. My older sister, Karen, is a terrific example of discipline and work 
ethic required of a student striving to care for patients while my younger brother, Dave, 
inspires me to be thoughtful and have integrity in every aspect of life. There are many 
additional family members who I need to thank for showing me love, providing support, 
and sharing laughs during my PhD education. Thank you Doug, Ryan, Jack, Baby 
Charlie, Mark, and Charlie Odom. Also, thank you to my in-laws who have accepted me 
 vi	
so willingly (after proper vetting) into their family. Thank you, Anne, Michael, Katie, 
Jill, James, Gavin, Ryan, Mikey, Teddy, and Auntie Martha.  
Most importantly, thank you to my wife and best friend, Liz. We met during our 
undergraduate studies at Saint Anselm College. During college if I wanted to spend time 
with Liz, it had to be in the library as she was a very dedicated student. Without this 
influence, I may have never made it to where I am today. Even though my dream of 
becoming a doctor seemed like a long shot after college, she supported me and believed 
in me. Once again, she was right. We made it to the MD/PhD program at Vanderbilt 
University because she wouldn’t let me stop pursuing my career ambitions. She knew we 
would be here someday and for that, Liz, this PhD is as much yours as it is mine. We 
have grown and sacrificed together. Vanderbilt will always be important to us as we think 
fondly of our time here when we were newlyweds and later started our family together. 
We are blessed with a beautiful, smart, and kind little boy, Benjamin Francis. I must 
thank Ben and Liz for making every day in lab a little better by being able to end the day 
in a loving home. 
Thank you everyone for helping me reach this achievement. 
 
 
 vii	
TABLE OF CONTENTS 
 
Page 
DEDICATION ............................................................................................................................... iii 
ACKNOWLEDGEMENTS ........................................................................................................... iv 
LIST OF TABLES ...........................................................................................................................x 
LIST OF FIGURES ...................................................................................................................... xii 
LIST OF ABBREVIATIONS ...................................................................................................... xiii 
Chapter 
 I. Introduction ..............................................................................................................................1 
     Basic principles in cardiac electrophysiology .......................................................................1 
 
     Ion channel dysfunction in arrhythmia syndromes .............................................................12 
 
     Genetic approaches to the study of inherited arrhythmia syndromes ..................................20  
 
     TBX5 as a Brugada Syndrome Candidate Gene .................................................................27 
 
     Modern tools in molecular cardiology ................................................................................33 
 
     Genome editing ...................................................................................................................37  
 
     Objective ..............................................................................................................................40 
 
II. Identification of Genetic Variation: a partial duplication and poly(A) insertion in KCNQ1 
not detected by next-generation sequencing in Jervell and Lange-Nielsen Syndrome .............41 
 
     Abstract ................................................................................................................................41 
   
     Introduction .........................................................................................................................43  
   
     Materials and Methods ........................................................................................................45  
   
     Results .................................................................................................................................47  
 
          Case report ......................................................................................................................47 
 
 viii	
          Causative mutation identification ...................................................................................47 
 
          The Two KCNQ1 Variants are Located in Trans ...........................................................50 
 
          Re-evaluation of NGS data .............................................................................................55  
   
     Discussion ............................................................................................................................60  
   
     Conclusion ...........................................................................................................................65 
 
 III. De Novo KCNB1 Variants in Epileptic Encephalopathy .....................................................66 
 
     Abstract ................................................................................................................................66 
 
     Introduction .........................................................................................................................67  
 
     Materials and Methods ........................................................................................................68  
 
     Results .................................................................................................................................78  
 
          Genome-wide evaluation identifies de novo variants in a case of epileptic  
          encephalopathy ...............................................................................................................78 
 
          Additional unrelated cases with rare missense KCNB1 variants ...................................82 
 
          Missense variants in pore region of KV2.1 alter channel function ................................83 
 
     Discussion ............................................................................................................................93  
 
     Conclusion ...........................................................................................................................95 
 
IV. Functional and transcriptional mechanisms of rare missense TBX5 variant causing the 
Brugada Syndrome ....................................................................................................................96 
 
     Abstract ................................................................................................................................96 
 
     Introduction .........................................................................................................................98  
 
     Materials and Methods ......................................................................................................101  
 
     Results ...............................................................................................................................115  
 
          Clinical presentation of Brugada syndrome and TBX5 genotyping .............................115 
 
          TBX5-G145R decreases DNA binding and transcriptional activation ........................115 
 
 ix	
          TBX5-G145R causes subtle features of Holt-Oram syndrome ....................................117 
 
          Generation of a human iPSC-CM model of BrS ..........................................................119 
 
          TBX5 variant correction in patient-derived iPSCs .......................................................121 
 
          TBX5-G145R containing iPSC-CMs recapitulate the BrS phenotype of reduced sodium         
          channel expression and current ....................................................................................123 
 
          Unexpected arrhythmogenic late sodium current and APD lability in patient-derived  
          iPSC-CMs are caused by TBX5-G145R ......................................................................125  
 
          Calcium handling is not impacted by TBX5-G145R ...................................................130 
 
          Tissue-level model of TBX5-G145R containing cardiomyocytes exhibit  
               arrhythmogenic features observed in single-cell assays ...............................................134 
 
          Discrete transcriptional changes in TBX5-G145R relative to iPSC-CMs with TBX5  
          heterozygous deletion ...................................................................................................134  
 
     Discussion ..........................................................................................................................147  
 
     Conclusion .........................................................................................................................155 
 
 V. Summary and future directions ..........................................................................................156 
  
 
REFERENCES ............................................................................................................................171 
        
 x	
LIST OF TABLES 
 
Table                                                                                                                                           Page  
1. Proposed mechanisms of Brugada syndrome associated genes .................................................19 
2. KCNQ1 primers used for Sanger sequencing ............................................................................51 
3. Common SNVs in KCNQ1 used to determine maternally-inherited allele ...............................59 
4. Whole exome sequencing variant filtration for individual ID9 .................................................79 
5. Whole exome and whole genome sequencing coverage ............................................................80 
6. Inheritance of validated candidate variants in individual ID9. ..................................................81 
7. Clinical features in three individuals with epileptic encephalopathy and KCNB1 missense  
mutations ........................................................................................................................................84 
8. Biophysical properties of voltage-dependence of activation for wild-type and mutant KV2.1  
channels ..........................................................................................................................................92 
9. Primers for Sanger sequencing to genotype rare and common BrS SNVs ..............................102 
10. In silico predicted CRISPR/Cas9 off-target sites .....................................................................51 
11. Poincaré analysis of single iPSC-CM APD ...........................................................................131 
12. Calcium handling properties in TBX5G145R/WT iPSC-CMs ..............................................133 
13. Poincaré analysis of iPSC-CM monolayer FPD ....................................................................136 
14. Gene ontology terms enriched in differentially expressed among pairwise comparisons .....146 
15. Genotypes of TBX5-G145R carriers for common variants associated with BrS ..................151 
16. Genotypes of population control iPSC for common variants associated with BrS ...............165 
17. Gene ontology terms enriched in differentially expressed among pairwise comparisons .....146 
18. Genotypes of TBX5-G145R carriers for common variants associated with BrS ..................151 
 
 xi	
LIST OF FIGURES 
 
Figure                                                                                                                                         Page  
1. Electrical activity in the healthy human heart ..............................................................................2 
 
2. Application of patch clamp techniques to cellular electrophysiology .........................................5 
 
3. Ionic currents contributing to ventricular cardiac action potential morphology ..........................7 
 
4. Cardiac sodium channel structure and functional states ............................................................10 
 
5. Schematic representation of the theory of mean allele frequency on impact of disease risk ....22 
 
6. Shared cis-regulatory enhancer of SCN5A-SCN10A is disrupted by common single  
    nucleotide variant .......................................................................................................................25 
 
7. Structural features of the TBX5–DNA interaction ....................................................................29 
 
8. Marked QT prolongation at baseline .........................................................................................48 
 
9. Exercise stress test .....................................................................................................................49 
 
10. Compound heterozygous variation in KCNQ1 identified by Sanger sequencing ....................53 
 
11. Predicted KCNQ1 amino acid sequence resulting from frameshifting exon 15 insertion .......54 
 
12. Screening of the proband for common SNVs located between exons 12 and 15 ....................56 
 
13. Compound heterozygous variants in KCNQ1 located on separate alleles ...............................57 
 
14. Next generating sequencing confirms complex 52-bp insertion by ad hoc alignment ............58 
 
15. KV2.1 mutations identified in three individuals with epileptic encephalopathy ......................85 
 
16. Functional consequences of KV2.1 mutations .........................................................................86 
 
17. GdCl3 block of mutant KV2.1 channels ...................................................................................87 
 
18. Extracellular cations are conducted through mutant KV2.1 channels ......................................89 
 
19. Ion selectivity of mutant KV2.1 channels ................................................................................90 
 
 
 xii	
20. Expanded view of whole-cell current traces for evaluation of activation kinetics  
      of wild-type KV2.1 channel alone or co-expressed with mutant channels ..............................91 
 
21. Familial Brugada syndrome-associated TBX5 variant ...........................................................116 
 
22. TBX5-G145R impairs DNA binding and transcriptional regulation .....................................118 
 
23. iPSC generation and validation ..............................................................................................120 
 
24. TBX5 variant correction in patient-derived iPSCs .................................................................122 
 
25. BrS iPSC-CM have reduced sodium channel expression and current density ......................126 
 
26. BrS iPSC-CM have increased late sodium current ................................................................128 
 
27. Arrhythmogenic changes in cardiac action potential in TBX5-G145R containing  
      iPSC-CMs ..............................................................................................................................129 
 
28. TBX5-G145R iPSC-CMs reduced capture efficiency and arrhythmia activity by  
      calcium evaluation .................................................................................................................132 
 
29. TBX5-G145R containing iPSC-CM monolayers have arrhythmogenic features  
      observed at single-cell level ...................................................................................................135 
 
30. iPSC model of Holt-Oram syndrome .....................................................................................138 
 
31. Predicted amino acid sequence in TBX5 heterozygous deletion model ................................139 
 
32. RNA sequencing analysis ......................................................................................................142 
 
33. Differentially expressed genes in iPSC-CMs with TBX5 variants ........................................143 
 
34. JLNS iPSC-CM model preliminary data ...............................................................................158 
 
35. Sanger sequencing of exon 5 of TBX5 ..................................................................................166 
 
36. Construction of genetically-encoded doxycycline-inducible dCas9-activator ......................170 
 
 
 
 
 
 xiii	
LIST OF ABBREVIATIONS 
 
µm micrometer 
ACMG American College of Medical Genetics and Genomics 
ACTH Adrenocorticotropic hormone 
ANOVA analysis of variance 
ANP atrial natriuretic peptide 
APD action potential duration 
APD50 time to 50% repolarization of action potential duration 
APD90 time to 90% repolarization of action potential duration 
ATP adenosine triphosphate 
ATX-II 47 amino acid peptidyl sea anemone toxin 
BrS Brugada syndrome 
Ca+2 calcium 
CaMK Ca2+/calmodulin-dependent protein kinase II 
Cas9 CRISPR-associated protein 9 
CaV voltage-gated calcium channel 
CDG congenital disorders of glycosylation 
ChIP chromatin immunoprecipitation 
CHO cells Chinese hamster ovarian cells 
Cl- chloride 
CNV copy number variant 
CRISPR clustered regularly interspaced palindromic repeat 
 xiv	
CSF cerebrospinal fluid 
DCM dilated cardiomyopathy 
de novo from the beginning 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
EEG electroencephalogram 
EFP electric field potential 
EGTA ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
EMSA electrophoretic mobility shift assay 
Erev reversal potential 
ESC embryonic stem cell 
et. al. and others 
ExAC exome aggregation consortium 
FDA Food and Drug Administration 
FPD field potential duration 
FRET fluorescence resonance energy transfer 
GATA4 GATA binding protein 4 
Gd+3 gadolinium 
GO gene ontology 
GTCS generalized tonic-clonic seizures 
GWAS genome wide association studies 
HCN Hyperpolarization-activated Cyclic Nucleotide-gated  
HDR homology-directed repair 
 xv	
HEK human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hERG human ether-a-go-go 
HOS Holt-Oram syndrome 
ICD internal cardiac defibrillator 
If funny current 
IK1 transient inward rectifying potassium current 
IKr rapid delayed rectifying potasisum current 
IKs slow delayed rectifying potassium current 
IKur ultrarapid delayed rectifying potassium current 
in silico by means of computer modeling 
in vitro in glass 
INa-L late sodium current 
indel inserton/deletion type variant 
iPSC induced pluripotent stem cell 
iPSC-CM induced pluripotent stem cell-derived cardiomyocyte 
JLNS Jervell and Lange-Nielsen syndrome 
K Kelvin 
K+ potassium 
KV voltage-gated potassium channel 
LQTS long QT syndrome 
LTV long term variability 
Mg+2 magnesium 
 xvi	
MMEJ microdomain-mediated end joining 
mol moles 
msec milliseconds 
Na+ sodium 
NaV voltage-gated sodium channel 
NCL neuronal ceroid lipofuscinosis 
NGS next-generation sequencing 
NHEJ non-homologous end joining 
NHLBI National Heart, Lung, and Blood Institute 
NKX2.5 Homeobox transcription factor 2.5 
NMDG+ N-methyl-D-glucamine 
PAM protospacer adjacent motif 
PCR polymerase chain reaction 
PI3K phosphoinositol 3-kinase  
PIP3 3,4,5-triphosphate  
PKC protein kinase C 
QTc heart rate corrected QT interval 
Rb+  Rubidium 
RFLP restriction fragment length polymorphisms 
RNA-seq RNA sequencing 
S. pyogenes Streptococcus pyogenes 
SC-ADVISER Scripps Genome Annotation and Distributed Variant Interpretation Server 
SCD sudden cardiac death 
 xvii	
SEM standard error of the mean 
SINE short interspersed elements 
SNV single nucleotide variant 
SR sarcoplasmic reticulum 
STV short term variability 
TALEN trascription activator-like effector nuclease 
TBX3 T-box transcription factor 3 
TBX5 T-box transcription factor 5 
TF transcription factor 
TSD target site duplication 
VLCFA very long chain fatty acid 
VUS variant of unknown significance 
WES whole exome sequencing 
WGS whole genome sequencing 
ZFN zinc-finger nuclease 
 	
 1	
CHAPTER I 
 
INTRODUCTION 	
Basic principles in cardiac electrophysiology 
The primary function of the heart is to distribute blood throughout the body for the 
delivery of oxygen, nutrients, and signaling molecules while contributing to waste removal. This 
seemingly simple pump function of the heart requires complex coordination through a process 
known as excitation-contraction coupling. The adult human heart is comprised of approximately 
4 billion cardiomyocytes,1 the functional cells of the heart, which work in harmony to propagate 
the electrical signal governing excitation and subsequent contraction. At rest a human ventricular 
cardiomyocyte has a membrane potential of -90 mV. When excited, the cardiomyocyte 
membrane becomes depolarized leading to a release of intracellular calcium stores from the 
sarcoplasmic reticulum, providing the signal for a cell to contract. Disruption of this coordinated 
process can have severe consequences on cardiac pump function and electrical rhythms. 
Therefore, it is critical to understand normal cardiac electrical activity at the tissue and cellular 
level in order to define the molecular mechanisms of disease.  
The surface electrocardiogram (ECG) was invented in 1901 by Dr. Willem Einthoven to 
provide a timed record of the cardiac electrical activity in health and disease. Einthoven first 
identified and named the repeating rhythmic series of distinct waves now commonly known as 
the P wave, QRS complex, and the T wave (Fig 1A). The heart has automaticity, meaning that it 
is self-excitable, that originates from a specialized structure located in the upper right atrium 
called the sinoatrial node (Fig 1B-1). The signal is propagated through the right and left atria and 
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Figure 1. Electrical activity in the healthy human heart. (A) Representative 
electrocardiogram in normal sinus rhythm. The schematic drawing below illustrates the phases of 
the ECG. The P-wave represents depolarization of the atria, the QRS complex the depolarization 
of the ventricles, and the T-wave the repolarization of the ventricles. (B) Order of depolarization 
in the human heart. Purple shading represents depolarized tissue. Modified from From Human 
Physiology: An Integrated Approach (4th edition), San Francisco: Pearson/Benjamin Cummings. 
QRS
complex
QT	interval
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Q
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SA	node
AV	node
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this collective atrial activation/depolarization is observed as the P wave on surface ECG 
recordings (Fig 1B-2/3). Electrical communication between the atria and ventricles relays 
through the atrioventricular node at the base of the right atrium that delays the transmission 
before proceeding through the rapid His-Purkinje system to the ventricular myocardium (Fig 1B-
4). The QRS complex represents ventricular activation/depolarization (Fig 1B-5). While the 
return to rest or repolarization of the atria cannot be observed on surfaced ECGs, ventricular 
repolarization is represented as the T wave. 
The features on an ECG can be evaluated quantitatively to describe electrical conduction 
within the heart to identify individuals who are at increased risk of arrhythmia onset. The PR 
interval defines the conduction time from the sinoatrial node through the atrioventricular node 
and the normal range is between 120-200 msec. The QRS duration is normally 70-110 msec and 
represents the time required for the entire ventricle to depolarize.  The entirety of excitation-
contraction coupling within the ventricles occurs between the initiation of the QRS complex and 
the end of the T wave and is measured as the QT interval. The depolarization and repolarization 
of individual cardiomyocytes within both ventricles are additive events comprising the whole 
organ QT duration determined by ECG. Therefore, the QT interval is a representation of the 
duration of a single cell action potential (APD).  
As the ECG allows one to record electrical activity in the entire heart, the electrical 
properties of a single cell can be evaluated using patch-clamp techniques. Electrical activity in 
excitable cells was first recorded and systematically analyzed by Hodgkin and Huxley in the 
1940s for which they shared the Nobel Prize in Physiology or Medicine in 1963.2,3 The patch 
clamp was developed during the late 1970s by Erwin Neher and Bert Sakmann  and was awarded 
the Nobel Prize in 1991.4 The patch clamp system uses a differential amplifier to define zero 
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current based on a reference electrode set in the extracellular solution while the recording 
electrode is housed within a fine tipped glass pipette (Fig 2A). The glass pipettes have a small 
0.1-1 µm opening that, with a small amount of negative pressure, creates a tight seal (thereby 
isolating a “patch” of membrane) with >1GigaOhm resistance with the cell membrane. The 
GigaOhm seal essentially has infinite resistance that is impermeable to ion passage between the 
pipette and membrane. This seal allows for the study of a single or few ion channels present 
within the small opening of the pipette (Fig 2B). Alternatively, one can gain access to the 
intracellular environment of the cell in whole-cell patch-clamp experiments by applying 
additional negative pressure to rupture the underlying membrane or using perforating antifungal 
agents within the pipette to record ion currents resulting from the summative function of all 
channels contained within a cell (Fig 2C). Patch-clamp experiments either clamp or hold the 
voltage to study ion currents generated at a given test voltage or clamp the current and study the 
resulting changes in membrane potential, and both are important experimental designs 
contributing to the understanding of cardiac electrophysiology. 
Decades of patch-clamp experiments have guided the understanding that the cardiac 
action potential duration and morphology is constructed by the summation of multiple ionic 
currents within a single cardiomyocyte.5 There are many cellular features that contribute to the 
excitability of cardiomyocytes. The cell membrane is a lipid bilayer that is itself impermeable to 
ions but enables differences in intracellular and extracellular ionic composition and charge.  
These electrochemical gradients are generated and maintained by a collection of ion channels, 
ATP-consuming ion pumps, primarily the Na-K ATPase, and exchangers. Ionic gradients are 
utilized by a cell to translate stimuli received from the extracellular environment or neighboring 
cells to a secondary signal through ion channels.  
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Figure 2. Application of patch clamp techniques to cellular electrophysiology. (A) 
Schematic of cellular patch clamp methodology. Fine-tipped glass pipette forms high resistance 
seal with the cell membrane. The recording electrode is contained within the pipette. A reference 
electrode is located in the extracellular space. (B) Representative single sodium channel 
recordings for a test voltage step protocol. Red asterisk indicated downward deflection resulting 
from single channel opening. (C) Representative whole-cell patch clamp sodium current 
recording. Sodium current is represented as a downward deflection by convention. The whole 
cell current is the product of the single channel current, the number of channels present, and the 
probability that a channel will be open at any given time.  Modified from Sigworth and Neher. 
Nature 1980. 
A
B
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Pipette/recording
electrode
Voltage-step	protocol
Single	channel	recordings
Whole-cell	summative	recording
*
*
 6	
Ion channels are transmembrane proteins that selectively allow ions to travel through a 
central pore until the chemical driving force created by internal and external concentration 
differences are equal to the opposing electrical driving force or electric potential. The electric 
equilibrium potential in an idealized setting for an individual ionic species can be described by 
the Nernst equation: 
  
Where R is the gas constant (8.314 Joules K-1 mol-1), T is temperature in Kelvin (K), F is 
Faraday’s constant (9.648x104 C mol-1), and x is the valence of the ion. While the Nernst 
equation provides understanding of the electrochemical force for an individual ion channel, its 
utility is best appreciated in experimental conditions that can isolate the function of one type of 
ion channel. During the cardiac action potential, changes in permeability of multiple ionic 
species occur throughout the action potential and the cumulative behavior of the channels can be 
described by the Goldman-Hodgkin-Katz equation:  
 
Where px represents the membrane permeability of a given ion, in this case either K+, Na+, or Cl-, 
at a given voltage dependent upon ion concentrations inside (subscript i) and outside (subscript 
o) the cell. The unique time-dependent changes in cell permeability to different ions, often 
simultaneously, generate five distinct phases of the cardiac action potential (summarized in Fig 
3A). To appreciate the complexity of this process, it is critical to understand the expression,  
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Figure 3. Ionic currents contributing to ventricular cardiac action potential morphology. 
(A) Schematic of ventricular action potential labeled with five distinct phases. (B) Ionic currents 
contributing to the phases of the action potential. Red indicates inward/depolarizing currents. 
Green indicates outward/repolarizing currents. Channel protein name and encoding gene 
provided for major ionic currents. Modified from Napolitano et. al. Pharmacology and 
Therapeutics 2006.  
 	  
Figure	3.	Ionic	currents	contributing	to	ventricular	cardiac	action	
potential	morphology.	(a)	Schematic	of	ventricular	action	potential	
labeled	with	four	distinct	phases.	(b)	Ionic	currents	contributing	to	the	
phases	of	the	action	potential.	Re 	indicates	inward/depolarizing	
current .	Green	indicates	outward/repolarizing	currents.	Channel	
protein	name	and	encoding	gene	provided	for	major	ionic	currents.	
Modified	from	Napolitano	et.	al.	Pharmacology	and	Therapeutics	2006	
A
B
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distribution, and characteristics of individual ion channels within a cardiomyocyte. For example, 
the regulation of ion channel function can vary from channels (e.g. Kir2.X family) where the 
pore is always open, to gated channels that must be activated by either a voltage change (e.g. 
KV1.X, NaV1.X) or ligand binding (e.g. KATP). The biophysical properties of select ion channels 
in relation to their role during unique phases of the cardiac action potential will be discussed 
further.  
 Excitation originates from the SA node due to the property of automaticity inherent to 
nodal cells (Fig 1B). A slowly activated inward cationic current, known as the “funny” current 
(If), depolarizes the membrane during phase 4 of the action potential.6 If is conducted by the 
Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) family of proteins.7 As the name 
suggests, behavior of the HCN family is modified by the secondary messenger of adrenergic 
signaling, cyclic AMP, to modify heart rate. The upstroke of the action potential is triggered 
when If depolarizes the membrane potential to a voltage that activates voltage-gated sodium 
channels. 
The initiation or upstroke of the cardiac action potential (phase 0) results from the 
opening of voltage-gated sodium channels, primarily NaV1.5, in atrial, ventricular, and Purkinje 
cardiomyocytes (Fig 3B). Like other sodium channels, NaV1.5 is comprised of the alpha pore-
forming subunit of the channel as a single protein containing four structurally homologous 
domains (D1-D4) whose function can be modified by interactions with auxiliary beta subunits or 
other regulating proteins (Fig 4A). Each of the four domains contains six helical transmembrane 
segments (S1-S6) with S4 serving as the voltage sensor due to the distribution of positively-
charged residues (lysine, arginine or occasionally histidine) every three amino acids. Upon local 
membrane depolarization, these positive changes cause the S4 helix to move outward relative to 
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the pore.8,9 This structural change is propagated to other portions of the channel shifting it from 
the closed to the open state allowing sodium to enter the cell along its electrochemical gradient 
(INa). Segment five, segment six, and the S5-S6 pore loop of each domain face one another 
forming the central pore and the selectivity filter of the channel providing NaV1.5 a preference 
for conducting sodium over other monovalent cations.10 After opening, sodium channels are very 
rapidly inactivated, even if the membrane is still depolarized, when the inactivation gate present 
in the D3-D4 linker blocks the cytoplasmic face of the pore rendering the channel non-
conductive (Fig 4B).11,12 There are physiologic conditions and genetic variants in the sodium 
channel that prevent complete inactivation and generate what is known as a late sodium current 
with important implications to probability of experiencing sudden cardiac death; this will be 
discussed further later in this and subsequent chapters. The sodium channel remains in the 
inactivated state, unable to transition to open state again, until the process of recovery from 
inactivation occurs with membrane repolarization. This inability to be re-excited contributes 
importantly to the phenomenon of cellular and whole organ refractoriness.  
The process of membrane repolarization begins early in the cardiac action potential as 
sodium channels inactivate and KV4.3 potassium channels activate, generating a transient 
outward current (ITO), to create a small notch during phase 1 (Fig 3B). The KV4.X family has 
similar topology to other KV channels comprised of six transmembranous segmented subunits 
interacting as a tetramer to form a functional channel. All K+-selective channels share a S5-S6 
linker that contains a conserved selectivity filter (containing a required GxG motif, where x is 
usually T or Y).13,14 However, there are significant differences in the accessory beta subunits that 
modify function of each voltage-gated K+ channel. KV4.3 has an obligatory beta subunit 
(KChIP2) that enhances ITO.15 While Kv4.3 is uniformly expressed across the ventricular wall,  
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Figure 4. Cardiac sodium channel structure and functional states. (A) Topologic view of 
NaV1.5 demonstrating four domains comprised of six transmembranous domains. The 
inactivation gate in intracellular DIII-DIV linker is highlighted. Figure modified from Savio-
Galimberti et. al. 2012 (B) Schematic demonstrating the three major gating states of NaV1.5. 
Figure modified from George. JCI. 2005.  	  Fig	1	from	Eli’s	(S vio-Galimberti)	2012	Frontiers	in	phar 	review
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there is a gradient of ITO due to decreasing expression of the KChIP2 beta subunit within 
cardiomyocytes from to epicardial surface to the endocardium.16,17 Genetic variants that cause a 
decrease or increase in ITO are associated with inherited arrhythmia syndromes, highlighting the 
significance of maintaining proper ion transport during an action potential. 
Voltage-gated ion channels that open during phase 2 of the action potential activate more 
slowly than those involved in phase 0 (NaV1.5) and phase 1 (KV4.3). During phase 2 there is a 
concurrent depolarizing Ca+2 influx and repolarizing K+ efflux to create a plateau where the 
membrane voltage is relatively stable (Fig 3B). The former is a result of calcium entering the cell 
from the extracellular environment through the voltage gated L-type calcium channel, CaV1.2. 
CaV1.2 is localized primarily in the t-tubule system, a perfect position that overlies the 
sarcoplasmic reticulum to serve the primary function of stimulating calcium-induced calcium 
release. Calcium release from the sarcoplasmic reticulum provides the chemical signal to elicit 
heart muscle contraction.  
During the plateau of the action potential, outward potassium currents are generated by 
three predominant outward currents, the ultrarapid (IKur), rapid (IKr), and delayed (IKs) rectifiers. 
These channels are critical to initial repolarization that occurs during phase 3 of the action 
potential. At rest, IKr is a main driver of repolarization as it is activated more rapidly than IKs but 
does inactivate with prolonged depolarization. This current is conducted by hERG alpha subunits 
(also called KV11.1; encoded by KCNH2) and an accessory beta subunit, either KCNE1 or 
KCNE2. Inhibition of this channel is a common cause of medication-induced arrhythmias. IKs 
contributes little to repolarization except for during times of sympathetic stimulation e.g. during 
the fight or flight response; it has been described as providing “repolarization reserve” within the 
myocardium.18 This current is conducted through a tetramer of KCNQ1 (also called KV7.1) alpha 
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subunits with the KCNE1 beta subunit that activate slowly, hence the name slow rectifying 
potassium current. IKs has little to no inactivation but remains open until the membrane potential 
is more negative than -40 mV. The remainder of repolarization is carried out by the potassium-
conducting transient inward rectifying currents (IK1) by the Kir2.X family of proteins, mainly 
Kir2.1 in ventricular cardiomyocytes.  
Inward rectification means these channels have preference for conducting K+ into the 
cardiomyocyte through a mechanism of magnesium (or polyamine) block of outward current. At 
more depolarized potentials, the electrochemical gradient for Mg+2 is outward and this drives 
Mg+2 into the vestibule of Kir2.1 only allowing K+ to enter the cell along its electrochemical 
gradient. In addition to completing repolarization, IK1 is largely responsible for setting and 
maintaining the resting membrane potential during phase 4 of the action potential. At rest, the 
cardiomyocyte membrane is most permeable to K+, consistent with the resting membrane 
potential being at or near the equilibrium potential predicted by the Nernst equation of -90 mV at 
physiologic concentrations of K+. The maintenance of the hyperpolarized state allows inactivated 
sodium and calcium channels to return to the closed state in order to repeat the excitation 
process. 
Ion channel dysfunction in arrhythmia syndromes 
The magnitude of individual ion currents increases or decreases after opening as a 
function of modulators such as transmembrane voltage, ligand concentration (if ligand gated) 
and time after opening.  Heart rate and rhythm are governed by complex coordination of multiple 
ion channels in cells, and the transmission of electrical activity from cell to cell.  Environmental 
factors or genetic variation that alters ion channel function can have devastating outcomes. In the 
United States, sudden cardiac death (SCD) accounts for 8-18% of all deaths and is commonly 
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associated with structural heart disease.19 Ischemia-induced ventricular fibrillation is a common 
cause of SCD shortly after ischemic insult due to combined effects of mild membrane 
depolarization, intracellular acidosis, elevated intracellular concentrations of calcium and 
sodium.20 Medication exposure is another environmental factor that can lead to arrhythmia onset 
through a multitude of mechanisms. One of the most prominent mechanisms of drug 
arrhythmogenesis is inhibition of IKr, leading to prolongation of the QT interval and increased 
risk of the morphologically distinctive polymorphic ventricular tachyarrhythmia torsades de 
pointes (TdP). Evaluation of the effect of any new drug candidate on IKr function is now a 
required part of drug development prior to receiving FDA approval.21 An additional mechanism 
of drug-induced arrhythmias is a reduction in sodium current. In patients, exposure to sodium 
channel blocking drugs, such as flecainide, was associated with increased mortality after myocardial 
infarction in the landmark Cardiac Arrhythmia Suppression Trial.22 Similarly, genetic variants that 
reduce the same ion currents (IKr or INa) affected by medications increases an individual’s risk of 
experiencing SCD. Approximately 5-10% of cases of sudden death result from high-penetrance 
genetic conditions altering ion channel function predisposing to ventricular arrhythmias, including 
the Long QT (LQTS) and the Brugada (BrS) syndromes.  
 Genetic variants that alter cardiac repolarization result in a prolonged QT interval on ECG. 
The diagnosis of LQTS is made in individuals with a QTc (corrected for heart rate) longer than 480 
msec and has a prevalence of 1:3,000.23-25 The delayed repolarization increases an individual’s risk of 
TdP, syncope, and sudden cardiac death.26 Activities or experiences that increase sympathetic 
nervous system activity, such as exercise, emotional state, or arousing sounds, are arrhythmogenic 
triggers for LQTS.27,28 Therefore, the mainstay of pharmacologic therapy is to dampen sympathetic 
tone through beta-adrenergic receptor blockade with propranolol and nodalol being more effective 
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that other beta blockers at preventing cardiac events of syncope or cardiac arrest.29,30 However, 
approximately 20% of patients on beta blocker therapy still experience syncopal episodes and require 
alternative or complementary therapies of permanent cardiac pacing or internal cardiac defibrillator 
placement.24,31 The severity and significance of properly identifying individuals at risk for this 
syndrome is highlighted by the fact that 10-15% of affected individuals present clinically for the first 
time with sudden death.28,32  
This genetic condition is inherited in an autosomal dominant fashion. To date, variants in at 
least 15 genes are known to be causal for LQTS by multiple mechanisms that prolong the action 
potential duration in individual cardiomyocytes.33 Single nucleotide variants (SNVs), very short 
insertions/deletions (indels), altered splicing, and occasionally large deletions (e.g. entire exons) 
that contribute to the underlying mechanism of delayed repolarization in cardiomyocytes through 
either reduced repolarizing potassium current or enhanced depolarizing current through calcium 
or sodium channels have been reported.34 In 1991, Keating et. al. identified the first genetic locus 
associated with the syndrome on the short arm of chromosome 11 using linkage analysis in a large 
family pedigree affected by LQTS later recognized to contain the gene KCNQ1.35 KCNQ1 encodes 
the pore forming subunit of a voltage gated potassium channel, that along with an accessory subunit 
encoded by KCNE1, generates IKs.36,37 Heterozygous loss of function variants in KCNQ1 causes 
type 1 LQTS (LQT1), the most common form, accounting for >50% of all cases. Homozygous or 
compound heterozygous variants in KCNQ1 or KCNE1 cause a particularly severe form of LQTS 
known as the Jervell and Lange-Nielsen Syndrome (JLNS).38,39 Patients with JLNS have severely 
prolonged QT intervals and congenital deafness as IKs is required for generating and maintaining the 
endolymph balance in the cochlea of the inner ear.40 LQTS type 2 (LQTS2) is caused by reduced IKr 
due to loss of function variants in KCNH2 and is the second most common form of this condition. 
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Even though the majority of LQTS cases are due to decreased repolarizing currents, approximately 
10% are a result of genetic variants that enhance depolarizing currents, primarily due to gain of 
function variants in SCN5A, the gene encoding the cardiac sodium channel.39,41 
Through the study of LQTS-associated SCN5A variants using patch-clamp methods, several 
alterations in sodium channel function have been described that result in a “gain of function” to 
prolong a cardiac action potential. The most common biophysical alteration is impaired inactivation 
that results in either sustained late sodium current (INa-L) or a severely slowed rate of inactivation.42 
Both of these parameters are influenced by interactions with auxiliary subunits.43-45 Alternative and 
less common mechanisms include shifts in voltage-dependence of activation/inactivation and faster 
recovery from inactivation.46 Unlike LQT1 that typically responds well to beta blockade, this 
pharmacologic therapy had variable efficacy on preventing the occurrence of cardiac events in 
patients with LQT3.47 Further, in a mouse model of LQT3, adrenergic stimulation had a protective 
effect with a shortening of the action potential duration after isoproterenol injections, presumably 
through enhanced IKs.48 The differential responses to beta blocker therapy have motivated genetic 
variant class specific interventions. The scientific community rationalized that since LQT3 is a result 
of increased sodium current, a logical therapy would be to treat with sodium channel blockers. 
Mexiletine, a class IB antiarrhythmic, showed variable efficacy in a small trial of five patients with 
the greatest effect in variants that resulted in a hyperpolarizing shift in V1/2 of inactivation but long-
term studies investigating the effect on patient survival are yet to be completed.49,50 More recently, 
ranolazine, a medication that specifically blocks the late sodium current gained by many SCN5A 
variants, shortened the QTc specifically in a LQT3 patient population.51 Larger, multi-center studies 
investigating the efficacy of ranolazine are currently ongoing (Clinical trial NCT01648205). The 
example of LQT3 demonstrates the power of understanding the genetic basis and mechanisms 
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driving disease in order to tailor therapy unique to the patient. Fortunately, the genetic basis of LQTS 
is relatively well understood as the causative variant is identified in 80% of cases.34 However, a 
subset of patients with LQTS has undefined genetic etiology either due to limitations of current 
methodology or contributions of yet to be discovered causal genes.  Chapter II describes 
identification of a novel variant in one such case.  
The problem of undefined genetic contributions to an inherited condition is even more 
significant in another arrhythmia condition, the Brugada Syndrome. The Brugada Syndrome (BrS) 
was first described in 1992 as an inherited arrhythmia condition that increases risk of ventricular 
tachyarrhythmias and sudden cardiac death .52 Patients with BrS are typically diagnosed based on 
a structurally normal heart and a characteristic ECG pattern (ST segment elevation in the 
precordial leads often with prolonged duration of the QRS complex, an index of conduction 
velocity within the ventricle). This rare condition has a prevalence of 0.4-1% of the population 
but is thought to cause 20% of sudden death events in individuals with a structurally normal 
heart.53 Typically, patients come to medical attention because the ECG pattern is noted 
incidentally, or during evaluation for syncope or cardiac arrest, or after sudden death in a family 
member. The current first line of care for patients with BrS is placement of an implantable 
cardiac defibrillator based an initial clinical trial involving 63 patients diagnosed with BrS. This 
trial looked at the efficacy of ICD placement, pharmacologic therapy with beta-blockers and/or 
amiodarone, or no treatment. While the incidence of arrhythmic events was similar in the three 
groups, only ICD placement reduced mortality due to sudden cardiac death.54 Additional reports 
support the finding that currently available pharmacologic therapies have been largely ineffective 
in reducing total mortality in BrS patients.55,56  
 17	
The clinical picture for BrS is highly variable and can range from overt basal presence of the 
Brugada ECG pattern or only appearing after drug challenge with sodium channel blockers such as 
flecainide or procainamide.57 Further, patients with baseline Brugada ECG pattern can experience 
symptoms of syncope or polymorphic ventricular tachycardia, often presented as palpitations, or can 
be completely asymptomatic. While many individual with BrS do not develop arrhythmias under 
normal conditions, stressors such as medication and fever are known to trigger arrhythmic events.58-61 
The exact tissue and cellular mechanisms causing BrS remain debated in the field complicating full 
understanding of the heterogeneity in clinical presentation. There are two major competing 
pathophysiologic theories that underlie the Brugada ECG pattern: the repolarization hypothesis and 
the depolarization hypothesis.  
The repolarization hypothesis is based on experimental evidence collected from canine 
wedge preparations studying transmural (from epicardium to endocardium) repolarization 
dispersion.62 Medication or genetic variants that accentuate a gradient in repolarization by decreasing 
depolarizing currents (INa or ICa) or enhance repolarizing currents (IK) generate a transmural 
dispersion that is vulnerable to ventricular tachycardia through a phase 2 reentry mechanism.63 The 
repolarization hypothesis has received criticism after clinical observations constructed the counter 
depolarization hypothesis. 
The depolarization hypothesis is formulated on clinical and genetic evidence of slowed right 
ventricular conduction and theoretical involvement of mild structural abnormalities. Sodium channel 
blocking drugs that are used to unmask the Brugada ECG pattern cause conduction slowing and 
make the tissue susceptible to late potentials, a feature associated with arrhythmia onset.64 Sodium 
channel blockade produces the same acute effect on slowed conduction as loss of function variants in 
SCN5A, the most common type of variant identified in this syndrome. The depolarization hypothesis 
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contends that decreased sodium current is required but perhaps not sufficient to cause the Brugada 
phenotype. Microscopic structural abnormalities have been observed in explanted hearts with 
Brugada Syndrome.65 Perhaps the structural remodeling that takes place during the natural aging 
process is the final stressor necessary to unveil the BrS, consistent with the average age of onset to be 
in the early 40s.66 More recent evidence using contact electrode methods in BrS patients or control 
volunteers, demonstrated slowed kinetics of action potential duration restitution (supporting the 
repolarization hypothesis) and conduction delay (supporting the depolarization hypothesis).67 It is 
possible that a spectrum of the two mechanisms contributes to the phenotype of BrS and may depend 
on the particular genetics of the individual. Technologic and genetic advances are beginning to reveal 
the complexity of BrS pathophysiology.  
Genotype-phenotype studies have identified the cellular electrophysiologic hallmark of BrS 
as decreased peak sodium current due to abnormal gating or reduced cell surface expression.68,69 
Over 300 loss of function mutations have been identified in SCN5A, the gene encoding the cardiac 
sodium channel NaV1.5, in patients with BrS, contributing to the understanding that BrS is a 
monogenic disease with autosomal dominant inheritance.46,70-72  Importantly, however, SCN5A 
mutations are identified in only ~20% of probands.68 Scn5a heterozygous knockout mice have many 
of the features seen in patients with BrS including localized ST elevation, disordered QRS 
complexes, and increased susceptibility to ventricular tachyarrhythmias.73,74 An additional 10% of 
BrS cases can be explained by rare loss of function variants distributed among 15 other genes, many 
of which encode ion channels or ion channel-associated proteins (Table 1). The remaining 70% of 
BrS cases are a result of unknown genetic etiology. It is conceivable that a portion of those cases are 
monogenic and driven by rare, large effect variants and others are polygenic resulting from a 
cumulative risk from multiple small effect variants.  
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Table 1. Proposed mechanisms of Brugada syndrome associated genes. Modified from 
Nielsen et. al. 2013. 
 
Brugada syndrome 
subtype Associated gene Proposed mechanism 
BrS1 SCN5A Decreased sodium current75  
BrS2 GPD1L Decreased sodium current76  
BrS3 CACNA1C Decreased L-type calcium current77,78 
BrS4 CACNB2 Decreased L-type calcium current77-79 
BrS5 SCN1B Decreased sodium current79-81 
BrS6 KCNE3 Increased potassium current82  
BrS7 SCN3B Decreased sodium current83  
BrS8 KCNH2 Increased potassium current84  
BrS9 KCNJ8 Increased potassium current85  
BrS10 CACNA2D1 Undefined mechanism78  
BrS11 RANGRF Decreased sodium current86  
BrS12 KCNE5 Increased potassium current87  
BrS13 KCND3 Increased potassium current 88 
BrS14 HCN4 Undefined mechanism79 
BrS15 SNMAP Decreased sodium current89 
BrS16 TRPM4 Increased or decreased calcium current90  
BrS17 SCN2B Decreased sodium current91 
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Genetic approaches to the study of inherited arrhythmia syndromes  
The first arrhythmia locus was identified in 1991 using linkage analysis in a large family 
with long QT syndrome.35 Traditionally, linkage analysis utilized differences in restriction 
endonuclease target sites within the genome due to genetic variation. Restriction enzymes are 
bacterially derived and evolved to cut DNA at specific sequences. Therefore, an assay termed 
restriction fragment length polymorphisms (RFLP) was developed to correlate a clinical 
phenotype to patterns of DNA digestion by restriction enzymes. Current approaches perform 
genotyping with genome sequencing in place of RFLP. Statistical analysis determines a 
logarithm of odds score that represents the likelihood that a genotype is linked to a particular 
phenotype. Linkage analysis isolated the short arm of chromosome 11 as a genetic locus causing 
the long QT syndrome but it took an additional five years of positional cloning to identify the 
gene responsible, KCNQ1.92 The study of human genetics using solely linkage analysis is 
restrictive based on two major limitations: (1) it requires large family pedigrees and therefore 
cannot be applied to small families or de novo variant identification and (2) it is too labor 
intensive to be applied to large datasets used in studying population genetics. Fortunately, major 
technologic and computational advances have developed alternative methods to identify the 
contributing common and rare polymorphisms. 
The human genome project, a 13-year effort completed in 2003, provided the entire 
sequence of a human genome.93 Having a defined human genome was critical for the 
development of next-generation sequencing (NGS), a technique that maps short reads to a 
reference genomic sequence and has emerged as a powerful tool for identifying genetic variation. 
Rapid technologic improvements in NGS now allow affordable and scalable massively parallel 
sequencing to identify both rare and common genetic variants. Rare variants in the coding region 
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of a gene that segregate with the presence of disease within a family are generally considered to 
have a large effect on protein function and to be potentially causative of Mendelian diseases. 
Alternatively, common genetic variants associated with disease are considered small effect 
variants that are modifiers rather than major drivers of disease susceptibility (Fig 5). Genome-
wide association studies (GWAS) utilize advanced chip-based genotyping approaches in large 
population-based studies to determine if the presence or absence of common single nucleotide 
variants (SNVs) associates to a defined trait/disease compared to a control group. The SNVs 
identified contribute to the understanding of disease pathology by either identifying modifiers of 
health and disease that may provide more accurate risk stratification or discover novel molecular 
pathways that are potential therapeutic targets.  
A genetic contribution to electrocardiographic variability was first established through 
twin studies. The exact variation underlying this heritability could not be determined due to 
small sample sizes between 73-350 twin pairs.94-97 The genetic contribution to variation of heart 
rate, PR interval, QRS duration, and QT interval within the general population has been studied 
using GWAS approaches. Some of the signals detected in these GWAS are not surprising based 
on the biologic plausibility of the genes in which the SNVs occur in or near, such as ion channel 
or ion channel associated proteins. The sensitivity of GWAS approaches to identify genetic loci 
contributing a small to moderate effect on a phenotype increases with the number of individuals 
included in the analysis. The first QT interval GWAS studied only 200 subjects with extreme QT 
values drawn from a normal population of 3,966 subjects, and identified variants near NOS1AP 
as QT modulators.98  Subsequent studies, enabled by cheaper and denser genotyping, included 
larger numbers of subjects.99,100 A meta-analysis of QT interval GWAS combined more than 
100,000 individuals to validate many previous GWAS loci and to identify 22 new associations in  
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Figure 5. Schematic representation of the theory of mean allele frequency on impact of 
disease risk. Modified from Manolio et. al. Nature 2009.101 
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genes with unknown biologic contributions to the physiology governing QT interval.102 QT 
interval GWAS data found common variants in or near five genes known to cause monogenic 
LQTS leading to the hypothesis that other QT interval GWAS loci may occur near previously 
unrecognized Mendelian LQTS genes. Therefore, large effect rare variants in these genes may 
explain a portion of the 20% of genetically undefined cases of inherited LQTS. Mutational 
screening of the coding region of a subset of these genes in 298 genetically undefined congenital 
long QT cases found missense variants or frameshifting single nucleotide insertions in multiple 
individuals in four genes, ATP2A2, SLC8A1, SLR, and TRPM7. While the rare variants identified 
in the four genes may contribute to the pathogenesis of LQTS in these individuals, the causative 
relationship of these variants require further functional or statistical evidence.  
GWAS has also been applied to many disease states. A GWAS comparing 312 patients 
with BrS to 1,115 population controls identified three significant association signals, two in 
sodium channel genes, SCN5A (rs11708996) and SCN10A (rs10428132), and a third near the 
gene encoding the HEY2 transcription factor (rs9388451).103 A mouse model of Hey2 
homozygous genetic deletion demonstrated that in an adult mouse the absence of Hey2 
transcription factor results in moderate alteration in isolated myocyte action potential upstroke 
velocity and reduced expression of Scn5a, Kcnj2, and Cacna1c but did not promote spontaneous 
arrhythmias.104 A report using a mouse model of Hey2 heterozygous genetic deletion found 
contradicting impact on action potential upstroke velocity as mice lacking one copy of Hey2 had 
increased upstroke velocity resulting in enhanced conduction velocity across the ventricular 
myocardium.103 While mouse model data needs further investigation to understand the role of 
Hey2 in cardiac conduction, SNVs near HEY2 still may contribute to BrS susceptibility.  
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Individual SNVs identified as GWAS signals actually detect large “neighborhoods” of 
DNA containing multiple variants inherited together (in linkage disequilibrium) that associate to 
the phenotype. A significant challenge is isolating which SNV located in linkage disequilibrium 
is the “functional” SNV. An important example of functional SNV identification is the SCN10A 
signal identified as a modifier of QRS duration105 and in BrS susceptibility.103 rs10428132 is in 
strong LD with 14 other SNVs, including one in the coding region of SCN10A (rs6801957).106 It 
was originally hypothesized that this coding variant accounted for the association but functional 
assessment using heterologous expression found the hypothesized risk allele increased sodium 
current by 40% and if anything one would speculate may protect against BrS.107 However, the 
contribution of SCN10A to cardiac function is highly debated and evidence supports little to no 
expression of this gene within cardiac myocytes.108 Closer examination of this BrS risk region 
identified another SNV (rs6801957) that was located within a presumed enhancer region based 
on overlap with binding sites for transcription factors (TBX5, NKX2.5, and GATA4) and 
transcriptional co-activators (p300 and RNA Polymerase III). Utilization of chromosome 
conformation sequencing, a method utilizing NGS, specifically defined the enhancer that 
contains rs6801957 interacts with the SCN5A promoter to participate in the regulation of SCN5A 
expression (Fig 6A).109 Multiple lines of evidence, including zebrafish models, mouse models, 
and association to human tissue samples, show the risk allele rs6801957 causes reduced SCN5A 
expression, consistent with the known pathophysiology of BrS. The mechanism is thought to be 
disruption of the binding site of cardiac transcription factors TBX3 and TBX5 (Fig 6B). This 
example highlights that SNVs can contribute to the pathogenesis of inherited conditions, adding 
complexity to the previous view of BrS as a Mendelian disease.  
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Figure 6. Shared cis-regulatory enhancer of SCN5A-SCN10A is disrupted by common 
single nucleotide variant.  (A) The enhancer in Scn10a physically contacts the promoters of 
both Scn5a and Scn10a to mediate their expression. (B) The variant in Scn10a 
alters Scn5a expression. The major allele harbors a T-box binding element that is occupied by 
Tbx5 to drive Scn5a expression in the heart (indicated by black arrowheads). The variant alters a 
base in the minor allele, disrupting the T-box binding element and causing a strongly decreased 
affinity for Tbx5. Modified from Hendrik van Weerd and Christoffels. Development. 2016. 
  
Figure 6. Regulation of the SCN5A-SCN10A locus: insights from GWAS- and chromatin-based 
analyses. (a) The enhancer in Scn10a physically contacts both Scn5a and Scn10a to mediate their 
expression. (d) The variant in Scn10a alters Scn5a expression. The major allele harbors a T-box binding 
element that is occupied by Tbx5 to drive Scn5a expression in the heart (indicated by black arrowheads). 
The variant alters a base in the minor allele, disrupting the T-box binding element and causing a strongly 
decreased affinity for Tbx5. Modified from Hendrik	van	Weerd and Christoffels.	Development.	(2016).
A
B
“Normal”	mRNA	levels Reduced	mRNA	levels
TBX5/3Key Induced	expression Reduced	expression
Transcription	(co-)factor RNA	Polymerase	IIKey
 26	
When considering just the three SNVs associated with BrS, each person could carry as 
many as six risk alleles (each genome contains two copies of each chromosome) within his or her 
genome. The total genetic contribution of BrS susceptibility is cumulative based on the number 
of inherited BrS risk alleles. The initial analysis of the BrS GWAS indicated that an individual 
with ≥5 BrS risk alleles has an odds ratio of 21.5 to be diagnosed with BrS compared to those 
with 0-1 risk alleles.103 Based on the cumulative risk of just these 3 SNVs, some have postulated 
that BrS, and perhaps other diseases, can result in some cases from a combination of many 
common SNVs making BrS a polygenic disease. Rare examples of individuals in a family in 
which a loss of function variant in SCN5A has been identified have the BrS phenotype in the 
absence of the SCN5A variant.110 Alternatively, cases exist of fully and variably penetrant 
SCN5A variants within family pedigrees. The variable penetrance of some SCN5A variants in 
BrS may be explained by the genetic background of the individuals containing common SNVs 
that act as modifiers of disease risk. 
 While combinations of common variants may explain a fraction of the 70% of 
genetically undefined BrS cases, there are still efforts to identify rare variants in genes not 
currently associated with BrS. In efforts to identify these novel Mendelian BrS genes, 
sequencing of the coding region and flanking intronic regions of a list of seven candidate genes 
was performed in 156 individuals diagnosed with BrS who do not harbor coding variants in 
SCN5A. The candidate gene list was constructed based on genes implicated by GWAS as playing 
a role in variability in PR intervals or QRS duration.107 This approach identified rare non-
synonymous SNVs in five genes (but could not further establish causality), including G145R in 
TBX5, the gene encoding the cardiac transcription factor TBX5, a known regulator of SCN5A 
expression.  
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TBX5 as a Brugada Syndrome Candidate Gene 
Altered gene expression is in fact an appreciated causative or modulatory mechanism in 
inherited arrhythmia syndromes. In patients diagnosed with BrS that carry heterozygous loss of 
function SCN5A mutations, the presence of common variants in the SCN5A promoter is associated 
with a more severe phenotype.111-113 TBX5 is implicated in BrS pathogenesis through a previously 
described BrS-associated common SCN10A variant (rs6801957) that is located in a putative TBX5 
binding motif of an SCN5A enhancer, causing lower levels of SCN5A expression in human 
myocardium.103,109 Common variants located near TBX5 are associated with prolonged QRS 
duration, a feature observed in BrS.114 Missense variants in TBX5 (gain of function mutation),115 
and other transcription factors GATA4 (loss of function mutations)116-118 and NKX2.5 (loss of 
function mutations)119 have been identified in cases of familial atrial fibrillation, supporting 
transcriptional misregulation as a mechanism of arrhythmia conditions. Therefore, TBX5-G145R 
is an intriguing causal candidate variant in familial BrS.107 This is variant is not reported in the 
Exome Aggregation Server, indicating it is very rare. 
TBX5 is a T-box containing transcription factor critical to mammalian tissue patterning and 
cellular differentiation during development of the upper extremities and the heart. TBX5 variants 
that result in TBX5 haploinsufficiency (nonsense, frameshifting indels, and splice site variants) or 
severe alterations in DNA binding (missense and intragenic duplications) cause the human 
condition Holt-Oram syndrome (HOS).120 HOS is a rare developmental syndrome affecting 
1:100,000 live births with abnormal development of the upper limbs and the heart. The severity of 
developmental defects can range from mild to severe. Mild hand involvement includes hypoplastic 
thenar musculature and short radius while the severe types have gross hypoplasia of the thumb or 
radius. In the heart, isolated atrial septal defects and arrhythmia risk are the mild presentations.121 
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The most severe cases can result in complex cardiac anomalies such as tetralogy of Fallot or 
ventricular septal defects. 
The TBX5 gene contains 9 exons that encode 518 amino acids with the first 237 amino acids 
comprising the conserved T-box family DNA binding domain.122 TBX5 binds a variable octamer 
sequence (A/G)GGTGT(C/G/T)(A/G) with the TGT sequence being most conserved among TBX5 
regulated genes (Fig 7A).122 However, TBX5 can bind somewhat promiscuously as exemplified by 
its interaction with the EnhancerA of SCN5A GGTGACAG sequence within the SCN10A gene.123 
TBX5 binds the major groove of its DNA targets through hydrogen bonds with an ab-loop structure 
of TBX5. This ab-loop contains a glycine at amino acid position 80 that is mutated to an arginine in 
one form of HOS, disrupting TBX5-DNA interactions (Fig 7B and 7C).124 The terminal alpha helix 
of the DNA binding domain of TBX5 is structured by a salt bridge occurring between glutamate at 
position 228 and arginine at position 237 (Fig 7B and 7C). This helix binds the minor groove of 
TBX5 DNA targets. HOS mutations R237W and R237G alter TBX5 interactions with the minor 
groove due to an unstructured terminal.120 Comparison of the amino acid position mutated in TBX5 
and the severity of hand or heart involvement generated the hypothesis that disruption of major 
groove binding causes more severe cardiac defects and minor groove disruption is associated with 
more severe upper limb anomalies.120 Missense variants in the DNA binding domain of TBX5 can 
alter DNA binding affinity of specific target sequences, resulting in increased DNA binding 
capacity115 or, more typically, decreased DNA binding.122,125 Interestingly, some missense variants 
increased affinity for non-specific DNA target sites, either preventing appropriate TBX5 chromatin 
localization or perhaps influences expression of genes not typically regulated by TBX5.126 Further 
evaluation is required to elucidate the functional implications of aberrant mutant TBX5-DNA 
interactions. 
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Figure 7. Structural features of the TBX5–DNA interaction. (A) Overview of the TBX5–
NPPA promoter (5’ – AGGTGTGAGA – 3’) complex. TBX5 is depicted in yellow, parts 
interacting with DNA are in red, and the DNA is in marine and gray. The unstructured loop is 
depicted as yellow broken line. β-Strands involved in the β-barrel are labeled with capital letters 
(A–G), and β-strands from the β- pleated sheets are in lowercase letters (a–g). (B) Close-up view 
of the interaction between TBX5 (yellow) and the DNA (blue-gray). Hydrogen bonds are 
depicted as black broken lines, and water molecules mediating hydrogen bonds are depicted as 
red spheres. (C) Interaction diagram of the TBX5–DNA interactions. Polar interactions are 
indicated by black dashed arrows; hydrophobic interactions are in solid black. Modified from 
Stirnimann et. al. Journal of Molecular Biology 2010. 
Figure	7.	Structural	features	of	the	TBX5–DNA	interaction.	(a)	Overview	of	the	TBX5–NPPA promoter	(5’	–
AGGTGTGAGA	– 3’)	complex.	TBX5	is	depicted	in	yellow,	parts	interacting	with	DNA	are	in	red,	and	the	DNA	
is	in	marine	and	g ay.	The	unstructured	loop	is	depicted	as	yellow	broke 	line.	β-Strands	involved	in	the	β-
barrel	are	labeled	with	capital	letters	(A–G),	and	β-strands	from	the	β- pleated	sheets	are	in	lowercase	
letters	(a–g).
(b)	Interaction	diagram	of	the	TBX5–DNA	interactions.	Polar	interactions	are	indicated	by	black	dashed	
arrows;	hydrophobic	interactions	are	in	solid	black.	(c)	Close-up	view	of	the	interaction	between	TBX5	
(yellow)	and	the	DNA	(blue-gray).	Hydrogen	bonds	are	depicted	as	black	broken	lines,	and	water	molecules	
mediating	hydrogen	bonds	are	depicted	as	red	spheres.	
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Transcriptional activators and repressors work in concert to regulate gene expression and 
influence cellular differentiation. TBX3 is a transcriptional repressor that competes with TBX5 
to bind DNA targets required in cardiac conduction system precursors. In the absence of TBX3, 
the precursors differentiate into working myocardium instead of the specialized tissue of the 
conduction system. TBX5 is a crucial positive regulator of TBX3 expression127 but also auto-
regulates its own expression. The TBX5 promoter region contains two auto-regulatory T-box 
binding elements critical for TBX5 expression.128 Regulation of TBX5 can occur through 
modulation of expression levels or through interactions with other proteins. MicroRNAs are 
involved in cardiac development through posttranscriptional regulation of gene expression.129  
Specifically, miR-10a and miR-10b bind the 3’-untranslated region of TBX5 transcripts to 
decrease translation.130  At the protein level, TBX5 is degraded by the ubiquitin-proteasome 
system via the Fbxo25-mediated E3 ubiquitin ligase complex.131 A primary mode of TBX5 
regulation is nuclear availability through protein interactions with the two nuclear localization 
sequences (NLS)132 and one nuclear export sequence (NES).133 LMP4 interacts with the NLS 
located in the C-terminal half of TBX5 to mediate the dynamic shuttling of TBX5 between the 
cytoplasm and the nuclear. The export protein CRM1 binds the NES within TBX5 promoting 
nuclear export.134  
Protein function can be modulated by post-translational modifications and synergistic 
protein-protein interactions. Histone deacetylase 3 (Hdac3) lacks a DNA binding domain but 
locates to chromatin in translational machinery complexes through interactions with transcription 
factors. Hdac3 is a negative regulator of Tbx5 function that directly binds and modulates the 
acetylation state of Tbx5. In a mouse model that lacks Hdac3, enhanced acetylation of Tbx5 
increased expression of Tbx5-regulated genes and caused hypoplastic ventricular myocardium.135 
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Loss of Hdac3 induces aberrant cardiomyocyte differentiation from progenitor cells, similar 
findings were observed in progenitor cells in which Tbx5 was overexpressed or contained the 
gain of function TBX5-G125R mutant.115,136  TBX5 physically interacts with other transcription 
factors/co-factors critical to cardiogenesis, including NKX2.5, GATA4, myocardin, and MEF2C, 
through interactions in the DNA binding domain (amino acids 54-237) to synergistically activate 
gene targets.137-140 Interestingly, some TBX5 missense variants completely abolish synergistic 
activation of gene targets and others have no impact on target gene expression. TXB5 associates 
with NKX2.5 to synergistically activated NPPA expression. TBX5-G80R fails to bind the NPPA 
promoter or show synergistic activation in the presence of NKX2.5, likely due to the complete 
loss of DNA binding. In contrast, TBX5-R237Q similarly activates NPPA expression compared 
to wild-type protein and has synergy with NKX2.5.137 Recently, a crystal structure of TBX5 and 
NKX2.5 bound to the NPPA promoter identified residues important for the intermolecular 
interactions.124 Several hydrogen bonds occur between the two molecules with the highly 
conserved amino acids D140, P142, and  R150 contributing to these hydrogen bonds. The D140 
and P142 amino acids are part of a highly conserved loop (amino acids 137-143) that creates a 
small acidic domain that interacts with basic amino acid side chains of NKX2.5.124 It is 
presumed that GATA4 interacts with the same acidic patch as mutant TBX5-A143T prevents 
complex formation and synergistic activation of NPPA expression in the presence of GATA4.141 
Animal models have provided mechanistic insight into the role of TBX5 on cardiac 
development. In zebrafish, reduced Tbx5 levels dampen cardiomyocyte progenitor proliferation 
and epicardial cell migration.142 Germline haploinsufficiency of Tbx5 in murine models 
phenocopies many human HOS features and results in diminished cardiac expression of gap 
junction proteins, atrial natriuretic peptide, and the cardiac sodium channel. Surface ECGs 
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recorded from Tbx5 heterozygous knockout mice demonstrate localized ST elevation and 
disordered QRS complexes.143-145 Expression patterns of Tbx5 in the developing mouse heart show 
an anteroposterior gradient of expression with higher expression in the left ventricle compared to the 
right side. This pattern of Tbx5 expression is maintained within the adult mouse heart with highest 
expression of Tbx5 within the atria and conduction system. In the developing human heart, TBX5 is 
expressed with a similar pattern as the developing mouse with atrial levels being greater than 
ventricular and a transmyocardial gradient (epicardium higher than endocardium) present in all four 
chambers.146,147 In contrast to the adult mouse heart, TBX5 expression is present in all four chambers 
of the adult human heart without a gradient present across the myocardium.147 Based the uniform 
expression of TBX5, it is reasonable to hypothesize that TBX5 is critical to heart maintenance and 
variants in TBX5 may have implications beyond cardiac development.  
Conditional deletion of Tbx5 from the mature mouse ventricular conduction system 
(VCS) demonstrates Tbx5 serves an important role in the maintenance of the cardiac conduction 
system. Induced deletion of Tbx5 in the adult VCS results in loss of fast conduction, 
arrhythmias, and sudden death.148 Tbx5 regulates expression of Scn5a and Cx40, encoding the 
sodium channel and a major gap junction protein, the main mediators of fast conduction, through 
interactions with local and distant cis-regulatory elements.109 The significance of TBX5 in the 
maintenance of electrical and contractile function of the ventricular myocardium remains to be 
elucidated. 
Clinical evidence supports the notion that TBX5 is critical to maintenance of heart 
function. Adult victims of sudden unexplained death syndrome have been attributed to structural 
heart disease and arrhythmia conditions. Genetic analysis of unexplained sudden death in 25 
cases aged 19-50 years identified rare variants in TBX5 (D18P and D43P) in unrelated 27-year 
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old female and 36-year old male.149 Histologic analysis of the explanted hearts found conduction 
system fibrosis that was not observed in the other 23 hearts without TBX5 variants examined. 
Other missense mutations located in the DNA binding domain have been described in other cardiac 
diseases that may present in adulthood, including cardiomyopathy and Brugada.107,141,150 Two 
independent efforts identified rare missense variants in TBX5 in cases of dilated cardiomyopathy 
(DCM). TBX5-S154A completely segregated in familial DCM150 and TBX5-A143T was found in a 
case of sporadic DCM.141 Both reports looked at the functional implications of mutant TBX5 using a 
single NPPA promoter-driven luciferase reporter assay; the authors demonstrated that these variant 
results in reduced, but not null, transcriptional activity. To date, the NPPA gene or its product atrial 
natriuretic peptide (ANP) have not been implicated in the pathogenesis of DCM but ANP is a 
biomarker of disease progression151 and NPPA mutations have been reported in familial atrial 
fibrillation.152  Assessing the functional and transcriptional effects of TBX5-A143T or TBX5-S154A 
in cardiomyocytes may provide further insight into causality and pathogenesis.  In a single case of 
BrS, the novel TBX5-G145R variant (studied in Chapter IV) was identified and classified as likely 
pathogenic based on the criteria of being a nonsynonymous variant, not present in 8,600 control 
alleles, and predicted pathogenic by at least three in silico prediction tools.107 For each of these 
examples, while the variants were uniformly predicted to be deleterious to protein function and likely 
pathogenic, conclusive functional evidence that these variants cause the disease is still lacking.  
Modern tools in molecular cardiology 
NGS is used clinically to confirm diagnoses, screen family members of effected 
individuals, and to guide therapeutic approaches. Commercial and academic genetic testing is 
provided by laboratories certified by the Clinical Laboratory Improvement Amendments 
program. As part of genetic testing, the company or institution evaluates the genome for lesions 
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and interprets the findings for potential contribution to the disease state. For identified variants 
there are three possible designations: pathogenic, benign, and variant of unknown clinical 
significance (VUS). VUS pose a significant hurdle to understand mechanistic and causative 
contributions to disease. Multiple efforts have attempted to provide accurate and useful 
predictive modeling of VUS pathogenicity leading to the standard and guidelines for the 
interpretation of missense variants by the American College of Medical Genetics and Genomics 
(ACMG).153-155 A recent report tested these ACMG standards to evaluate the efficacy of 
predictive modeling to assign pathogenicity to incidentally identified rare variants in the 
Mendelian disease genes SCN5A and KCNH2.156 In a large prospective cohort study of 2,022 
individuals, 63 individuals carried at least one variant in these two genes. Three expert 
laboratories evaluated the incidentally identified SCN5A and KCNH2 variants designating 42 as 
potentially pathogenic with poor concordance across laboratories as only 33% were classified as 
potentially pathogenic by multiple locations. Review of the medical records of the variant 
carriers found only 35% had evidence of arrhythmia or ECG phenotypes highlighting the need 
for more accurate evaluation of the functional implications of identified genetic variants. One 
approach to augment predictive modeling is to use functional assessment as an additional factor 
used in determining variant pathogenicity (see Chapters III and IV).  
The majority of inherited arrhythmia syndromes are result of genetic variants affecting 
ion channel function. Classically, ion channel variants have been studied in heterologous 
expression systems. Cloning of ion channel cDNA, such as SCN5A,157 permits transient 
expression of wild-type or mutant proteins in standard laboratory cells lines for functional 
assessment. However, there are limitations to this approach as exemplified by NaV1.5-D1275N. 
In heterologous expression systems, NaV1.5-D1275N has identical function as wild-type protein 
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even though there is strong clinical evidence this mutant results in conduction disease.158 
Watanabe and colleagues generated a transgenic mouse model harboring this variant to study the 
functional implications within a cardiomyocyte. Within a mouse cardiomyocyte, NaV1.5-
D1275N resulted in a dose-dependent reduction in peak sodium current and channel abundance 
at the membrane demonstrating that some genetic variants must be studied in the correct cellular 
context to evaluate pathogenicity. Animal models provide an in vivo assessment of genetic 
variation but, as is true with all disease models, has limitations. Transgenic animal generation 
and colony maintenance is costly and labor intensive. There are also physiologic species 
differences that may complicate interpretation of results. For example, the adult mouse is more 
resistant to arrhythmic triggers compared to humans in part because of differential ion channel 
expression required to maintain the mouse resting heart rate of 350-600 beats per minute 
compared to a human rate of 60-100. Recent advances in molecular and human stem cell biology 
have extended the types of models that are now utilized in understanding the genetics and 
mechanisms of cardiac disease. 
 Embryonic stem cells (ESCs) are totipotent cells derived from an early embryo capable in 
infinite self-renewal and the ability to differentiate into any cell type. The first isolation of ESCs 
from a mouse embryo was performed in 1981 and the potential as it relates to science and 
medicine was immediately realized.159 Efforts began to isolate and culture human ESCs and were 
achieved in 1998.160 Human ESCs were employed to advance understanding of developmental 
biology and pursued for future transplantation therapeutics. For ethical concerns, the US 
government has restricted the use of public funding to support human ESC research, limiting the 
utility of these cell lines.161 Fortunately, the next breakthrough for stem cell biology occurred in 
2006 when Yamanaka (who went on to share the Nobel Prize in 2012) showed that somatic cells 
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from an adult mouse could be reprogrammed back to a stem cell like state to generate induced 
pluripotent stem cells (iPSCs).162 This same approach was reproduced using human fibroblasts 
just a year later.163 Transient expression of the four pluripotency factors OCT4, MYC, KFL4 and 
SOX2, a combination now known as the Yamanaka factors, efficiently return human fibroblasts, 
mononuclear blood cells, and keratinocytes to iPSCs.163-165 iPSCs, like ESCs, are self-renewing 
and capable of differentiation to cells derived of the three germ layers: endoderm, mesoderm, 
and ectoderm. Decades of cardiac development pathway dissection allows directed 
differentiation of stem cells to cardiomyocyte lineages, permitting mechanistic studies in human 
cardiomyocytes. 
Reprogramming of somatic cells to a stem cell-like phenotype and subsequent 
differentiation to a cardiomyocyte fate provides a renewable resource for biologic discovery. 
Early protocols utilized embryoid bodies, clusters of stem cells, to mimic normal development. 
In the presence of growth factors, iPSC-derived embryoid bodies differentiate to all three germ 
lineages, producing cardiomyocytes with an efficiency of 1-10%.166 An improved method of 
differentiating a monolayer of iPSCs with chemical modulation of Wnt-pathway signaling 
increased the efficiency and purity of cardiomyocytes to over 85%.167 Human iPSC-CMs have 
the advantage of containing the human genomic architecture, making genomic insights possible, 
but also contain an inherent limitation of being functionally immature cardiomyocytes.168 For 
example, iPSC-CMs display slower action potential upstroke and a more depolarized resting 
membrane potential compared to adult human ventricular cardiomyocytes. Further, there has 
been significant inter-laboratory variation in these key parameters creating a challenge in 
comparing results. Even though the cells have an immature phenotype, multiple studies in iPSC-
derived cardiomyocytes verify that this approach can recapitulate inherited heart disease 
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phenotypes within a petri dish, including cardiomyopathy and arrhythmia syndromes.169 Through 
mid-2016, iPSC-CM models of seven inherited arrhythmia syndromes have produced the 
individual ion channel and action potential lesions anticipated in genetic arrhythmia 
syndromes.170-172 Current arrhythmia models have established iPSC-CMs as a usable model in 
studying electrical phenotypes and have set the framework for evaluating genetic variant 
causality and advancing mechanistic insight.   
Genome editing  
Manipulation of the human genome with the programmable zinc-finger nucleases 
(ZFNs), transcription activator-like effector nucleases (TALENs), and RNA guided Cas9 expand 
the scientific questions one can address. These approaches generate a double-strand break in 
DNA that ultimately results in gene disruption or specific editing. ZFNs and TALENs are protein 
guided nucleases constructed of a DNA binding domain, either a zinc finger protein (ZFP) or a 
transcription activator-like effector (TALE), tethered to a FokI restriction enzyme. FokI is a non-
specific DNA cleavage enzyme so the specificity of target cleavage is governed by the binding 
site of ZFP and TALE domains.173 Even though ZFPs bind GC-rich 3-bp DNA sites, the need of 
ZFNs to function as adjacently bound dimers, within 5-7 base pairs, results in an available target 
site present on average every 100 bases within the genome.174  Alternatively, TALENs target 
repetitive DNA sequences and can be designed to target almost any sequence of DNA. Because 
of the nature of TALEN DNA targeting using complementary binding to repetitive structures, 
these proteins are more difficult to synthesize due the inappropriate annealing of synthetic 
oligomers within the repetitive DNA binding domain.175 RNA-guided nucleases use a common 
nuclease that exerts its nuclease activity after interacting with a guide RNA bound to 
complementary DNA. The limitation of RNA-guide nuclease targeting is requirement of a 
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defined three nucleotide sequence specific to each version of nuclease, at the end of the target 
sequence. Cas9, the first and most extensively studied RNA guided nuclease, scans the genome 
using a NGG sequence, known as the protospacer adjacent motif (PAM site), where N can be 
any nucleotide and the GG dinucleotide occurs approximately every 8 bases in the double 
stranded genome. An alternative RNA-guided nuclease, Cpf1, was recently identified that uses 
different PAM sequences of NTT that generates more targeting options in T-rich intronic regions 
of the genome.176 The major advantage of RNA-guide nucleases is the simple cloning required to 
modify the guide RNA sequences and by using RNA targeting, multiplex editing is easily 
achievable.  
 The three discussed approaches target specific DNA sequences to induce double-strand 
breaks. The preferred mode of double-strand break repair in eukaryotic cells is error prone non-
homologous end joining (NHEJ) that creates insertion/deletion mutations.177 NHEJ can be used 
to disrupt a gene in order to generate knockout models through random generation of 
frameshifting insertions/deletions. Concurrent delivery of the nuclease with a repair template 
leads to homology-directed repair (HDR) to specifically edit the genome to modify single 
nucleotides or insert larger sections of DNA.178,179 The HDR approach in patient-specific iPSCs 
is a tractable approach to study the functional implications of singe nucleotide variants. 
Genome editing of patient-specific cells generates isogenic control lines that are 
genetically identical except for the edited site. Even though the utilization of these techniques 
has become increasingly commonplace since 2013, few studies generate isogenic controls to 
isolate effects driven by genetic variations. Since 2010, more than 60 publications have studied 
inherited arrhythmia conditions using iPSC-CM models.180 In the majority of those publications, 
the disease lines are compared to control lines generated from healthy control volunteers from 
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the general population, and therefore failing to appreciate the effect of genetic variation on the 
phenotype of interest. Less than 12% of iPSC-CM arrhythmia models use isogenic controls. 
Genome editing in patient-derived iPSCs provides definitive testing of the pathogenicity of rare 
variants identified in congenital arrhythmia syndromes. 
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Objective 
The purpose of this dissertation is to advance the understanding and utilization of genome 
science for the application to inherited heart disease. First, in order to utilize next-generation 
sequencing to guide clinical practice, it is imperative to understand the limitations of this 
technology. Using a Long QT syndrome phenotype that is very suggestive of an underlying 
genetic cause of compound heterozygous KCNQ1 variants, we sought to identify a genetic lesion 
not identified by NGS (see Chapter II). Second, while the ability to sequence large portions of 
the genome exists, a significant challenge remaining is how to best interpret the data in order to 
understand the implications of the findings on disease risk. Each person’s genome has 300-600 
rare coding variants.181 While many of the variants identified using NGS and GWAS approaches 
can be rationalized based on the known or associated biology, statistical or functional evidence is 
required to establish causality. Presented here are two approaches to functionally establish 
causation and define the molecular and transcriptional mechanisms of novel variants identified in 
human channelopathies: heterologous expression and stem cell-derived cardiomyocyte models. 
In Chapter III, I characterized the biophysical properties of rare variants in a voltage-gated 
potassium channel identified in epileptic encephalopathy compared to wild-type protein. In 
Chapter IV, genome editing in patient-specific stem cell-derived cardiomyocytes was used to 
study a rare variant in a cardiac transcription factor identified in the Brugada Syndrome.
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CHAPTER II 
IDENTIFICATION OF GENETIC VARIATION: A PARTIAL DUPLICATION AND 
POLY(A) INSERTION IN KCNQ1 NOT DETECTED BY NEXT-GENERATION 
SEQUENCING IN JERVELL AND LANGE-NIELSEN SYNDROME* 
 
 
ABSTRACT 
 
Purpose: The Jervell and Lange-Nielsen syndrome (JLNS) is an autosomal recessive disease 
(caused by loss of function variants in KCNQ1 or KCNE1) defined by congenital deafness, 
markedly prolonged QT interval, and high risk for sudden cardiac death. Variant negative cases 
provide an opportunity to define new types of causative lesions. 
 
Methods and results: Next generation sequencing (NGS) was undertaken in a woman with 
congenital deafness, severe QT prolongation, and polymorphic ventricular tachycardia. 
However, only a single heterozygous mutation in KCNQ1 resulting in a premature stop codon, 
R518X, was identified. Convinced by the clinical phenotype that a second variant was present, 
Sanger sequencing was used to identify a 52-base pair (bp) insertion comprised of a 36-bp poly-
adenine tract and partial exonic duplication, consistent with a truncated Alu element. The two 
variants were present in trans, establishing KCNQ1 compound heterozygosity as the etiology for 
JLNS in this case. 
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Conclusion: Short reads used by NGS can miss complex genetic variations including 
intermediate size indels which have not previously been reported in the congenital long QT 
syndromes. Thus, this result raises the possibility that other cases of genotype-negative 
congenital long QT syndrome can be caused by this kind of genetic variant.  
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INTRODUCTION 
 
Genetic information has become increasingly important to the practice of medicine and 
the effort to understand mechanisms of disease through basic science. Next generation 
sequencing (NGS), a technique that maps short reads to a reference sequence, has emerged as a 
powerful tool for identifying genetic variation. While current NGS algorithms detect single 
nucleotide variants (SNVs) with high confidence, insertion/deletion variants (indels) are not as 
sensitively detected.182 Detection of indels by NGS is inconsistent. Small indels (2-10 bases) and 
large indels (exonic or larger) are readily identified, but intermediate sized indels (10-200 bases) 
are still a significant challenge, and insertions are more challenging to detect than deletions.183,184  
Prolongation of the rate-corrected QT interval (QTc) on the surface electrocardiogram 
(ECG) is a key feature of the congenital long QT syndromes (LQTS). This family of inherited 
syndromes predisposes to the morphologically distinctive polymorphic ventricular 
tachyarrhythmia torsades de pointes, syncope, and sudden cardiac death. The underlying 
mechanism is delayed repolarization in cardiomyocytes through either reduced repolarizing 
potassium current or enhanced depolarizing current through calcium or sodium channels.34 
Genetic evaluation of affected individuals and families has associated variants in at least 15 
genes with the syndrome;33 SNVs, very short indels, altered splicing, and occasionally large 
deletions (e.g. entire exons) have been reported. Type 1 LQTS (LQT1), the most common form, 
accounts for >50% of cases and is caused by heterozygous loss of function variants in KCNQ1, 
the gene encoding the pore forming subunit that, with an accessory subunit encoded by KCNE1, 
generates the slow delayed rectifying repolarizing potassium current (IKs).36,37 Heterozygous loss 
of function variants in KCNE1 result in type 5 LQTS.185 
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Most LQTS is inherited in an autosomal dominant fashion. However, an especially severe 
form is the Jervell and Lange-Nielsen Syndrome (JLNS), an autosomal recessive form of the 
disease defined by a markedly prolonged QT interval and congenital sensorineural deafness. 
Homozygous or compound heterozygous variants in KCNQ1 or KCNE1 cause JLNS.38,40 
Sympathetic activation by emotional or exertional stress is a common trigger for arrhythmia in 
LQT1 and in JLNS. 
We present a clinical case of JLNS with high susceptibility to exercise-induced 
arrhythmia. However, evaluation by NGS only identified a single loss of function variant in 
KCNQ1. Because the clinical presentation and the known genetics of JLNS strongly suggested 
that a second mutation must be present, we used conventional Sanger sequencing to identify a 
complex ~50 bp indel undetected by NGS. This report not only describes a new type of variant 
causing LQTS but also highlights current limitations in the use of short NGS reads for diagnosis 
of genetic diseases.  
 
  
	 45	
MATERIALS AND METHODS 
 
Patient Enrollment: This study was reviewed and approved by the Institutional Review Board 
at Vanderbilt University Medical Center (Nashville, TN). All participants provided written 
informed consent. 
 
Genomic DNA Acquisition: After informed consent, DNA was extracted from peripheral blood 
using Puregene Chemistry on the Autopure LS robotic system according to manufacturer’s 
recommendations (Qiagen, product number 9001340).  
 
GeneDx Next-generation Sequencing: Using genomic DNA from the submitted specimen, the 
coding regions and splice junctions of 12 arrhythmia-associated genes were enriched using a 
proprietary targeted capture system developed by GeneDx (Gaithersburg, Maryland). These 
targeted regions (read length ~50 bp) were sequenced simultaneously by massively parallel 
(NextGen) sequencing on an Illumina platform with paired-end reads. Bi-directional sequence 
was assembled, aligned to reference gene sequences based on human genome build 
GRCh37/UCSC hg19, and analyzed for sequence variants. Capillary sequencing was used to 
confirm all potentially pathogenic variants and to obtain sequence for regions where fewer than 
15 reads were achieved by NextGen sequencing.  
 
GeneDx Exon Array Evaluation: Concurrent deletion/duplication testing was performed for the 
genes in the panel using exon-level oligo array CGH (ExonArrayDx). Data analysis was 
performed using gene-specific filtering. Probe sequences and locations were based on human 
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genome build GRCh37/UCSC hg19. Sequence and array CGH alterations were reported 
according to the Human Genome Variation Society (HGVS) or International System for Human 
Cytogenetic Nomenclature (ISCN) guidelines, respectively. 
 
KCNQ1 Sanger Sequencing Evaluation: Amplicons of each exon of KCNQ1 were generated by 
RT-PCR using the primer sets listed in table 2. The amplification was performed using Applied 
Biosystems Veriti 96-well thermal cycler with a melting temperature of 95oC, annealing temp 
listed next to each primer set in table S1, and extended at 72oC. Each reaction used 30 cycles for 
amplification. 
 
KCNQ1 Allele-specific Analysis: PCR amplicons were placed in an expression vector using 
polyA cloning according to manufacturer’s protocol (Promega, catalog # A1360). DH5α 
competent E. coli were transformed and 10 individual clones were expanded for plasmid 
isolation and subsequent Sanger sequencing. 
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RESULTS 
 
Case Report 
A 47 year old female with a history of congenital deafness and severe QT prolongation 
was referred for management. She had her first episode of syncope at 6 years of age, was 
reported to have marked QT prolongation, and was placed on beta-blocker therapy at that time. 
Shortly thereafter, she was lost to follow-up. She had no siblings and further family history was 
not available. At age 40, she had an episode of syncope while working outdoors in the heat, and 
beta-blocker (propranolol at that time) was continued although she admitted to incomplete 
compliance due to fatigue. At age 46, she had another syncopal episode. She was switched to 
metoprolol 100 mg daily and referred for further evaluation. Her baseline ECG (Fig 8A) showed 
broad symmetric T waves with a rate-corrected QT (QTc) of 580 msec (normal <480), and a 
Holter monitor showed QT intervals after an ectopic atrial beat as long as 800 msec (Fig 8B). An 
implantable cardioverter-defibrillator was recommended but she declined. An exercise test was 
performed to assess the adequacy of beta-blockade. At a heart rate of 101 at 5 minutes, 50 
seconds of exercise on a standard Bruce Protocol, she developed marked T wave lability 
followed by a 40-second, self-terminating episode of torsades de pointes, during which she 
transiently lost consciousness (Fig 9A-F).  
Causative Mutation Identification 
Proband DNA was submitted for commercial (GeneDx Inc, Gaithersburg, Maryland) 
next-generation sequencing (NGS). A single heterozygous nonsense variant (R518X) was 
identified in exon 12 of KCNQ1, and array testing revealed no large deletions or insertions in the  
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Figure 8. Marked QT prolongation at baseline. (A) Resting 12-lead ECG showed a baseline 
QT interval of 600msec (QTc 580msec). (B) Holter monitoring revealed a QT interval of 
800msec on a post-PAC complex (indicated by black arrow). PAC: premature atrial contraction.  
  
Figure	8.	Marked	QT	prolongation	at	baseline. (A)	Resting	12-lead	ECG	showed	a	baseline	QT	interval	of	
600msec	(QTc 580msec).	(B)	Holter monitoring	revealed	a	QT	interval	of	800msec	on	a	post-PAC	complex.	
PAC:	premature	atrial	contraction.	
A
B
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Figure 9. Exercise stress test. (A) Pre-exercise rhythm strip showed normal sinus rhythm with 
broad, symmetric T waves with corrected QT interval (QTc) 580 msec. (B) At 5 minutes, 50 
seconds of exercise, the ECG exhibited a heart rate of 101 bpm with biphasic T waves and 
corrected QT interval (QTc) 908 msec. (C) Thirty seconds later, the patient felt lightheaded, and 
exercise was stopped. The ECG showed deep T wave inversions with periodic T wave 
accentuation (in a non-alternans fashion) and ventricular trigeminy. Torsades de Pointes then 
developed (D), persisting for 40 seconds (E) before self-terminating (F).  
  
5:50
End-exercise: 6:20
15 sec recovery
30 sec recovery
45 seconds into recovery
1 minute recovery
Baseline
3 minutes recovery
Figure	2.	Exercise	stress	test.	(A)	Pre-exercise	rhythm	strip	showed	normal	sinus	rhythm	with	broad,	
symmetric	T	waves	with	corrected	QT	interval	(QTc)	580	msec.	(B)	At	5	minutes,	50	seconds	of	exercise,	the	
ECG	exhibited	a	heart	rate	of	101	bpm with	biphasic	T	waves	and	corrected	QT	interval	(QTc)	908	msec.	(C)	
Thirty	seconds	later,	the	patient	felt	lightheaded,	and	exercise	was	stopped.	The	ECG	showed	deep	T	wave	
inversions	with	periodic	T	wave	accentuation	(in	a	non-alternans fashion)	and	ventricular	trigeminy.	
Torsades de	Pointes	then	developed	(D),	persisting	for	40	seconds	(E)	before	self-terminating	(F).	
A
B
C
D
E
F
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gene. KCNQ1-R518X has been reported in LQTS previously, and functional testing has shown 
absent potassium current when KCNQ1-R518X is expressed in oocytes.186 The clinical picture of 
severe QT prolongation and torsades de pointes, onset at an early age, and congenital deafness, 
strongly suggested that a second KCNQ1 variant was present but undetected by NGS. To test this 
hypothesis, we performed PCR amplification of each exon and approximately 50 base pairs (bp) 
of flanking intronic sequence for Sanger sequencing analysis (primer sets are presented in Table 
2). Sanger sequencing of exon 12 confirmed the heterozygous nonsense variant R518X in the 
JLNS proband (Fig 10A), and analysis of parental DNA showed the R518X allele was paternally 
inherited. PCR amplification of exon 15 in the proband produced two products, one at the 
anticipated size of 500 bp and a second larger product, ~550 bp (Fig 10B). Sequencing of the 
500 bp product showed no variation compared to the reference sequence (NM_000218; Fig 
10C). Sequencing of the larger product identified a frame-shifting 52-bp insertion comprised of a 
partial duplication of the 5’ end of exon 15 and an insertion of 36 adenines followed by 
uninterrupted exon 15 sequence (Fig 10D). The indel is predicted to change the coding sequence 
beginning at amino acid 583 with a truncation occurring after amino acid 667 (Fig 11). The 
unique 52-bp insertion was a de novo event as targeted sequencing of exon 15 in parental DNA 
did not detect the insertion. There were no indels or non-synonymous SNPs identified in exons 
1-4, 6-14, and 16. Parental relationships were confirmed by genetic fingerprinting.  
The Two KCNQ1 Variants are Located in Trans  
For the two identified mutations to be the genetic cause of JLNS in this patient, the two variants 
must be located in trans (on separate alleles) to one another. Since R518X was located on the 
paternal allele and the 52-bp insertion was a de novo event, we sought to establish that the 
insertion was on the maternal allele. To test this idea, we used common SNVs (rs163149,  
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Table 2. KCNQ1 primers used for Sanger sequencing 
Exon Primer direction 5' -> 3' sequence 
Annealing 
temperature (oC) 
1 
Forward TCGCCTTCGCTGCAGCTC 
60 Reverse TCCCCCACACCAGCTCTCAG 
2 
Forward ATGGGCAGAGGCCGTGATGCTGAC 
60 Reverse ATCCAGCCATGCCCTCAGATGC 
3 
Forward GTTCAAACAGGTTGCAGGGTCTGA 
62 Reverse CTTCCTGGTCTGGAAACCTGG 
4 
Forward CCCTTCCCCAGACGAGAGCA 
58 
Reverse CTCCACCCATCCCAGCACAT 
5 
Forward TCTGGGGACTGAGGGAATCTGGAGGTA 
60 
Reverse CCGGGTCCTTGATTTGCCTGGGTTTTT 
6 
Forward TCGCTGGGACTCGCTGCCTT 
64 
Reverse TGTCCTGCCCACTCCTCAGCCT 
7 
Forward TGGCTGACCACTGTCCCTCT 
60 
Reverse CCCCAGGACCCCAGCTGTCCAA 
8 
Forward GCTGGCAGTGGCCTGTGTGGA 
58 
Reverse AACAGTGACCAAAATGACAGTGAC 
9 
Forward TGGCTCAGCAGGTGACAGC 
58 
Reverse TGGTGGCAGGTGGGCTACT 	 	
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Table 2 continued. KCNQ1 primers used for Sanger sequencing. 
10 
Forward GCCTGGCAGACGATGTCCA 
58 
Reverse CAACTGCCTGAGGGGTTCT 
11 
Forward CTGTCCCCACACTTTCTCCT 
60 
Reverse TGAGCTCCAGTCCCCTCCAG 
12 
Forward TGGCCACTCACAATCTCCT 
58 
Reverse GCCTTGACACCCTCCACTA 
13 
Forward GGCACAGGGAGGAGAAGTG 
60 
Reverse CGGCACCGCTGATCATGCA 
14 
Forward CGGGCACGTCAAGCTGTCTGTC 
58 
Reverse CTCCCCTTACTCCCTGGCTTTCA 
15 
Forward GGCCCTGATTTGGGTGTTTTA 
58 
Reverse CACAGGGAGGTGCCTGCT 
16 
Forward CGACCGAGGGCCTTGCAGACATAG 
60 
Reverse CCCCCACACCGGCCAGGAAGAGG 
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Figure 10. Compound heterozygous variation in KCNQ1 identified by Sanger sequencing. 
(A) KCNQ1 p.R518X is present in exon 12 of proband and paternal DNA and is absent in 
maternal DNA. (B) PCR amplification of exon 15 visualized with ethidium bromide results in 
two distinct products in the proband that is absent in parental DNA. (C) Allele specific Sanger 
sequencing of smaller product, which shows normal (reference) sequence. (D) Allele-specific 
Sanger sequencing of larger PCR product identifies a 52-bp insertion comprised of a 15-bp 
partial duplication of exon 15 and insertion of a 36-adenine tract.  
 
  
KCNQ1 Exon	12
MaternalPaternalProband
100 bp
500 bp
1,000 bp
Exon 15 PCR 500 bp Exon 15 Sanger sequencing
540 bp Exon 15 Sanger sequencing
Exon 15Exon 15 duplication
Figure	10.	Compound	heterozygous	variation	in	KCNQ1	identified	by	Sanger	sequencing.	(A)	KCNQ1	
R518X	is	present	in	exon	12	of	proband and	paternal	DNA	and	is	absent	in	maternal	DNA.	(B)	PCR	
amplification	of	exon	15	visualized	with	ethidium bromide	results	in	two	distinct	products	in	the	proband
that	is	absent	in	parental	DNA.	(C)	Allele	specific	Sanger	sequencing	of	smaller	product,	which	shows	
normal	(reference)	sequence.	(D) Allele-specific	Sanger	sequencing	of	larger	PCR	product	identifies	a	52-bp	
insertion	comprised	of	a	15-bp	partial	duplication	of	exon	15	a d	insertion	of	a	36-adenine	tract.	
A
B
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Figure 11. Predicted KCNQ1 amino acid sequence resulting from frameshifting exon 15 
insertion. Black text indicates the wild-type KCNQ1 amino acid sequence. Red text indicates 
insertion sequence. Underlined text highlights the amino acid changes resulting from the 
frameshifting insertion. 
 
 
  
1 
61 
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661
MAAASSPPRA ERKRWGWGRL PGARRGSAGL AKKCPFSLEL AEGGPAGGAL YAPIAPGAPG
PAPPASPAAP AAPPVASDLG PRPPVSLDPR VSIYSTRRPV LARTHVQGRV YNFLERPTGW
KCFVYHFAVF LIVLVCLIFS VLSTIEQYAA LATGTLFWME IVLVVFFGTE YVVRLWSAGC
RSKYVGLWGR LRFARKPISI IDLIVVVASM VVLCVGSKGQ VFATSAIRGI RFLQILRMLH
VDRQGGTWRL LGSVVFIHRQ ELITTLYIGF LGLIFSSYFV YLAEKDAVNE SGRVEFGSYA
DALWWGVVTV TTIGYGDKVP QTWVGKTIAS CFSVFAISFF ALPAGILGSG FALKVQQKQR
QKHFNRQIPA AASLIQTAWR CYAAENPDSS TWKIYIRKAP RSHTLLSPSP KPKKSVVVKK
KKFKLDKDNG VTPGEKMLTV PHITCDPPEE RRLDHFSVDG YDSSVRKSPT LLEVSMPHFM
RTNSFAEDLD LEGETLLTPI THISQLREHH RATIKVIRRM QYFVAKKKFQ QARKPYDVRD
VIEQYSQGHL NLMVRIKELQ RRLDQSIGKP SLFISVSEKS KDRGSNTIGA RLNRVEDKVT
QLDQRLALIT DMLHQLLSLH GGSTPGSGGP PREGGAHITQ PCGSGGSVDP ELFLPSNTLP
TYEQLTVPRR GPDEGS
MAAASSPPRA ERKRWGWGRL PGARRGSAGL AKKCPFSLEL AEGGPAGGAL YAPIAPGAPG
PAPPASPAAP AAPPVASDLG PRPPVSLDPR VSIYSTRRPV LARTHVQGRV YNFLERPTGW
KCFVYHFAVF LIVLVCLIFS VLSTIEQYAA LATGTLFWME IVLVVFFGTE YVVRLWSAGC
RSKYVGLWGR LRFARKPISI IDLIVVVASM VVLCVGSKGQ VFATSAIRGI RFLQILRMLH
VDRQGGTWRL LGSVVFIHRQ ELITTLYIGF LGLIFSSYFV YLAEKDAVNE SGRVEFGSYA
DALWWGVVTV TTIGYGDKVP QTWVGKTIAS CFSVFAISFF ALPAGILGSG FALKVQQKQR
QKHFNRQIPA AASLIQTAWR CYAAENPDSS TWKIYIRKAP RSHTLLSPSP KPKKSVVVKK
KKFKLDKDNG VTPGEKMLTV PHITCDPPEE RRLDHFSVDG YDSSVRKSPT LLEVSMPHFM
RTNSFAEDLD LEGETLLTPI THISQLREHH RATIKVIRRM QYFVAKKKFQ QARKPYDVRD
VIEQYSQGHL NLMVRIKELQ RRLDQSIGKP SLFISVSEKS KDQKKKKKKK KKKKRKEQGS
RQQHDRRPPE PSRRQGDAAG PEAGTHHRHA SPAALLARWQ HPRQRRPPQR GRGPHHPALR
QWRLRRP
Figure	5.	Predicted	KCNQ1	amino	acid	sequence	resulti g	from	
frameshifting exon	15	insertion.	Black	text	indicates	the	wild-type	
KCNQ1	amino	acid	sequence.	Red	text	indicates	insertion	sequence.	
Underlined	text	highlights	the	amino	acid	changes	resulting	from	the	
frameshifting insertion.
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rs163150, and rs1057128; Fig 12) located within 2,500 nucleotides upstream of exon 15 at which 
the father’s genotype was homozygous for the reference allele and the genotype in the mother 
and the proband were heterozygous for the SNVs (Fig 13A and Table 3). Allele-specific 
sequencing demonstrated that the maternal common CNVs were on the same allele as the 
duplication/insertion (Fig 13B rs163149 shown as an example). Thus, the proband inherited the 
variant encoding KCNQ1-R518X from the father and the poly(A) insertion-partial exon 15 
duplication is a de novo event that occurred on the maternally-inherited allele (Fig 13C).  
Re-evaluation of NGS Data 
After we identified the unique 52-bp insertion, the original reads were re-examined at 
GeneDx. During the original assessment using 50-bp reads and repeat attempts using 2X100-bp 
reads, a small number of reads that contained the poly-adenine signal at the 5’ or 3’ edge 
(meaning only one copy of 5’ exon 15 sequence) mapped to the reference sequence. 
Intermediate-sized indels are known to be challenging to identify by NGS.184 There was a drop-
off in read depth at the insertion site, supporting the idea that the algorithm analyzing the NGS 
clipped and then discarded reads containing the insertion near their center due to misalignment 
with the reference sequence. When the 52-bp duplication-insertion was included in a modified 
reference sequence, the insertion-containing variant reads mapped with high confidence to the 
modified reference while reads from the paternal allele failed to map leading to a drop off in read 
depth (Fig 14). 
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Figure 12. Screening of the proband for common SNVs located between exons 12 and 15. 
Sanger sequencing results for SNVs with a MAF >10%. Red boxes indicate CNVs found to be 
heterozygous in the proband. 
rs28730759
rs163149
rs163150
rs1057128
rs233435
rs11024045
rs35993725
rs336982
rs147551585
rs56182401
rs79969904
rs80305020
rs233436
rs233438
rs163152
rs12420943
rs12419355
rs2237882
Figure	6 Screening	of	the	proband for	common	SNVs	located	between	
exons	12	and	15. Sanger	sequencing	results	for	SNVs	with	a	MAF	>10%.	
Red	boxes	indicate	CNVs	found	to	be	heterozygous	in	the	proband.
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Figure 13. Compound heterozygous variants in KCNQ1 located on separate alleles.  
(A) Proband and maternal DNA possess common SNV rs163149 located 1,772 bp upstream of 
exon 15. PCR amplification was performed using Roche expand long template PCR system with 
forward primer 5’-CGTGTCTTTTTGTCCCGCAG-3’ and reverse primer 5’- 
CACAGGGAGGTGCCTGCT -3’ (B) Allele specific sequencing demonstrates the de novo 
insertion is present on the maternally inherited allele. (C) Schematic representation of the 
compound heterozygous variants being located in trans to one another. SNV: single nucleotide 
variant. 
rs163149 (KCNQ1 Intron	14-15)
MaternalPaternalProband
rs163149
Proband:	paternally-inherited	allele
Proband:	maternally-inherited	allele
Exon    12 Exon    15G
R518X
Exon    12 Exon    15C
*
(paternally inherited)
rs163149
(maternally inherited)
de novo
partial duplication 
and poly(A) insertion
…
…
A
B
C
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Figure 14. Next generating sequencing confirms complex 52-bp insertion by ad hoc 
alignment. Alignment of the next generation sequencing reads to a reference sequence modified 
to include the identified insertion (modified ref seq) confirms its presence. Grey horizontal bars 
indicate perfect sequence alignment. Note the decrease in read depth (top) at the insertion site, 
consistent with the rejection of reads that include the paternal allele. 
 
  
Read	depth
Modified	
ref	seq
Figure	7.	Next	generating	sequencing	confirms	complex	52-bp	insertion	by	ad	hoc	alignment.	Alignment	
of	the	next	generation	sequencing	reads	to	a	reference	sequence	modified	to	include	the	identified	
insertion	(modified	ref	seq)	confirms	its	presence.	Grey	horizontal	bars	indicate	perfect	sequence	
alignment.	Note	the	decrease	in	read	depth	(top)	at	the	insertion	site,	consistent	with	the	rejection	of	reads	
that	include	the	paternal	allele.
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Table 3. Common SNVs in KCNQ1 used to determine maternally-inherited allele.  
SNP rs# 
position Reference Alternate 
MAF 
Genotype 
GRCh38 Allele Allele Proband Maternal Paternal 
rs163149 11:2776200 C G 0.459 C/G C/G G/G 
rs163150 11:2776090 G A 0.333 G/A G/A A/A 
rs1057128 11:2776007 G A 0.200 G/A G/A A/A 
 
MAF = minor allele frequency. 
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DISCUSSION 
 
We report here compound heterozygous variants in KCNQ1 resulting in a severe clinical 
presentation of JLNS with exercise-induced arrhythmias despite beta-blocker therapy. Next-
generation sequencing identified a previously reported LQT1-associated KCNQ1 mutation 
(R518X) but failed to recognize an unusual and complex 52-bp duplication-insertion.187 This 
type of variant has not been previously reported in LQTS. While NGS is currently the most 
commonly used method for genetic diagnosis in this disease, initial studies for 15+ years after 
the first disease genes were identified in 1995 did not report this type of variant, either because it 
is rare or not recognized in conventional testing.  
JLNS is a severe autosomal recessive form of long QT syndrome that has the additional 
clinical feature of congenital sensorineural deafness, thought to arise because of altered 
endolymph maintenance in the developing cochlea. This results in collapse of Reissner’s 
membrane, a critical cochlear structure, and loss of hair cells.188 JLNS has only two known 
genetic associations, compound heterozygous or homozygous variation in KCNQ1 (JLNS1) or 
KCNE1 (JLNS2) resulting in near-total loss of IKs. Patients with JLNS typically have a markedly 
prolonged QT interval and have a high incidence of sudden cardiac death in childhood.189 
Cardiac events in JLNS, like LQT1, arise during times of sympathetic activation such as exercise 
or emotional stress.190  
There are several especially unusual features in this case. First, the patient exhibited 
marked T wave instability but in a trigeminal and then a non-alternans fashion during exercise. 
This less common variant of T wave instability has been described previously as an unusual 
manifestation of LQTS thought to reflect temporal variability in repolarization with sympathetic 
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activation.189,191,192 Another unusual feature is that the patient has survived to age 47 with only 
intermittent medical therapy and without experiencing sudden death. While her survival could be 
attributed to a milder phenotype of disease, the extremely long QT intervals and T wave 
instability during exercise would seem to contradict this.  
Missense variants account for the majority of LQTS1 genetic associations but 
pathogenicity may be difficult to predict.191,192 In heterologous expression systems, KCNQ1-
R518X is a complete loss of function variant that does not traffic to the membrane and is trapped 
in the ER.186,193 Additionally, like other variants that result in a truncated C-terminus, R518X 
does not interact with wild-type KCNQ1, consistent with the non-dominant effect of this mutant 
protein.190 These truncating variants terminate the protein prior to a proposed coil-coil domain in 
the C-terminus; evidence that this domain mediates assembly and cell surface expression 
includes extensive mutagenesis experiments194 and the inability of KCNQ1-R594Q to interact 
with wild-type protein.195,196 The same mechanism is speculated to occur in frameshifting 
variants, such as the novel 52-bp insertion identified in this report and a previously reported 
1008delC.195,197  
The severe clinical features of this case provided robust evidence for the diagnosis; 
having identified a single variant in KCNQ1 (R518X), we performed additional genetic 
evaluation to find what we were convinced was a second variant in KCNQ1. Genetic testing in 
cases with clear LQTS identifies a likely causative variant in 80% of cases.34 In LQT1 single 
nucleotide variants, short indels, and large deletions (exonic or larger) have all been 
described.198,199 It is possible that a portion of the remaining 20% of cases without known genetic 
causes could result from intermediate sized indels like the one described here. Alternatively, 
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undiscovered JLNS-associated genes or deep intronic or regulatory variants that disrupt KCNQ1 
expression or transcript processing may also contribute. 
Clinical re-sequencing in LQTS has turned increasingly toward NGS approaches to aid in 
diagnostics and patient/family counseling. NGS has evolved as a low cost, efficient method to 
generate data on a large number of genes in parallel to screen a targeted panel of arrhythmia 
susceptibility genes in patients diagnosed with LQTS. The current NGS algorithms align short 
reads to a reference sequence and have successfully identified SNVs, copy number variants, and 
large exonic deletions in LQT1.199 Algorithms have been designed to better detect indels in NGS 
data sets by utilizing split read and dropped read depth signatures. These approaches have a 
validation rate between 56-80% of indels reported in the 1,000 genomes project.183,200-202 While 
there is a low false negative rate in most approaches, there is discordance between algorithms 
suggesting a high false positive rate.182,184,203 Speaking specifically to the insertion identified in 
this study, it is likely that the 15-bp duplication complicated indel detection by NGS alignment 
approaches that allow for split read alignment such as PINDEL and PRISM.200,204 In addition to 
improvements to NGS analysis algorithms, increasing read length beyond the current 2X100 
approach is another method that may increase the sensitivity of detection for intermediate-sized 
indels. Inclusion of a drop in read depth as an indel signature used by the program inGAP-sv is 
not an approach commonly utilized due to false discovery resulting from poor quality of read 
amplicon generation.205 De novo sequence assembly can be generated and subsequently 
compared to a reference sequence as a complement to mapping based approaches to improve 
indel detection.  
The partial duplication and poly(A) insertion is an unusual de novo variant. The poly(A) 
portion on this variant could result from DNA polymerase slippage.206 However, we consider 
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DNA polymerase slippage unlikely to be the mechanism of the insertion identified because it 
cannot account for the partial duplication. Rather, this variant is most likely a 5’-truncated Alu 
element. Insertions of these short interspersed elements (SINEs) result from DNA nicking by L1 
endonuclease activity at defined target sequences that opens the genome for insertion of an RNA 
intermediate Alu element, a poly(A) insertion, and a DNA target site duplication (TSD).207 The 
duplicated portion of exon 15 in KCNQ1 contains a 5’ GAAAAG target sequence making it 
likely to be the resultant TSD.208 Approximately 85% of Alu elements found in the human 
genome are full length containing the ~290 bps encoding the Alu plus a variable length poly(A) 
tail.209 Significantly truncated versions of Alu elements have been observed throughout the 
genome and comprise ~8% of Alu elements identified.209,210 Truncation of the Alu can result 
from microdomain-mediated end joining (MMEJ) where the Alu RNA sequence can align with 
the 3’ overhang of the cut genomic DNA.210 The 3’ end of the TSD in this case has a 
microdomain of TC, the terminal 3’ nucleotides of all five modern human Alu subfamilies.211 
The single stranded template is then filled by DNA polymerases and joined by DNA ligase as 
part of a DNA repair process.  
Alu elements have been implicated in other diseases through inducing large deletions, 
misregulating transcription when inserted in introns, or disrupting the coding sequence when 
inserted within exons.212 The first described de novo Alu element insertion resulting in disease 
was described in NF1 in 1998 causing neurofibromatosis.213 Since then more than 36 identified 
diseases have been associated with Alu element-mediated variation due to a multitude of 
mechanisms.214 In 2007, two families affected by cystic fibrosis with no identified variation in 
CFTR were found to contain considerably truncated Alu elements located within the gene.210 
NF1 appears to be an Alu insert hotspot as 18 additional cases of neurofibromatosis have been 
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explained by Alu element insertions, including one proposed 5’-truncated element comprised of 
a 120-bp poly(T) flanked by TSDs, very similar to the insertion we identified.215 This is the first 
report of Alu element insertion in an ion channel gene associated with a cardiac arrhythmia 
susceptibility syndrome. 
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CONCLUSION 
 
This chapter highlights that current NGS approaches to variant identification is limited 
for complex insertions. Approaches that provide precise and sensitive interrogation of the 
genome are a necessity as molecular diagnostics increasingly influence clinical practice. 
Algorithms that specifically search for Alu elements, such as Mobster, could be run in patients in 
which genetic evaluation has returned “no variants identified.”216 Additionally, methods to 
identify intermediate-sized indels, such as Sanger sequencing or de novo construction of an 
individual’s genetic code, should be included when the clinical picture strongly implicates 
known disease-associated genes. Further, complex insertions like the truncated Alu element 
described here may comprise a portion of LQT1 cases.
*	Modified from Torkamani, Bersell, and Jorge et. al. Annals of Neurology. (2014). 66	
CHAPTER III 
DE NOVO KCNB1 VARIANTS IN EPILEPTIC ENCEPHALOPATHY* 
 
 
ABSTRACT 
 
Background: Numerous studies have demonstrated increased load of de novo copy number 
variants (CNVs) or single nucleotide variants (SNVs) in individuals with neurodevelopmental 
disorders, including epileptic encephalopathies, intellectual disability and autism.  
 
Materials and Methods: We searched for de novo mutations in a family quartet with a sporadic 
case of epileptic encephalopathy with no known etiology to determine the underlying cause 
using high coverage whole exome sequencing (WES) and lower coverage whole genome 
sequencing (WGS). Mutations in additional patients were identified by WES. The effect of 
mutations on protein function was assessed in a heterologous expression system. 
 
Results: We identified a de novo missense mutation in KCNB1 that encodes the KV2.1 voltage-
gated potassium channel. Functional studies demonstrated a deleterious effect of the mutation on 
KV2.1 function leading to a loss of ion selectivity and gain of a depolarizing inward cation 
conductance. Subsequently, we identified two additional patients with epileptic encephalopathy 
and de novo KCNB1 missense mutations that cause a similar pattern of KV2.1 dysfunction. 
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Conclusion: Our genetic and functional evidence demonstrate that KCNB1 mutation can result 
in early onset epileptic encephalopathy. This expands the locus heterogeneity associated with 
epileptic encephalopathies and suggests that clinical WES may be useful for diagnosis of 
epileptic encephalopathies of unknown etiology. 
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INTRODUCTION 
 
Epileptic encephalopathies are a heterogeneous group of severe childhood-onset 
epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor 
prognosis.217 The developmental trajectory is normal prior to seizure onset, after which cognitive 
and motor delays become apparent. Ongoing epileptiform activity adversely affects development 
and contributes to functional decline. Therefore, early diagnosis and intervention may improve 
long term outcomes.218-220 
Recently, there has been significant progress in identifying genes responsible for epileptic 
encephalopathies and de novo mutations have been reported in approximately a dozen genes, 
including SCN1A, SCN2A, SCN8A, KCNQ2, HCN1, GABRA1, GABRB3, STXBP1, CDKL5, 
CHD2, SYNGAP1, and ALG13.221-225 The majority of mutations reported are in genes encoding 
voltage-gated ion channels, neurotransmitter receptors and synaptic proteins. There is significant 
phenotype heterogeneity, with mutations in the same gene resulting in different clinical 
presentations, as well as locus heterogeneity, with mutations in different genes resulting in the 
same syndrome. Further, epileptic encephalopathy genes have substantial overlap with genes 
responsible for other neurodevelopmental disorders, including autism and intellectual 
disability.226-228 
Due to the considerable phenotype and locus heterogeneity, it is difficult to predict 
appropriate candidate genes for testing in a particular patient. Therefore hypothesis-free 
approaches such as whole exome sequencing (WES) or whole genome sequencing (WGS) may 
be useful for uncovering causative variations in epileptic encephalopathies of unknown etiology. 
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We aimed to identify the underlying genetic cause of epileptic encephalopathy in the proband by 
WES and WGS of a family quartet. 
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MATERIALS AND METHODS 
 
Study Subjects. Study participants included ID9, parents ID9F and ID9M, and an unaffected 
sister ID9S. Adults provided written informed consent, with additional assent by ID9 and ID9S, 
under a protocol approved by the Scripps institutional review board. Consent for release of 
medical information for individual 2 was obtained from the parents. Clinical details are below 
and summarized in Table 7. 
 
Individual ID9 is a 9-year-old female with epileptic encephalopathy, hypotonia, developmental 
delays, cognitive impairment, and intermittent agitation. Pre- and perinatal histories were 
unremarkable, although hypotonia and excessive somnolence were noted early. Motor milestones 
were delayed, with sitting at 9 months, walking at 20 months, and persistent clumsiness. 
Language acquisition was delayed with regression at age 18 months. Motor, language and 
behavior have fluctuated but overall there has been forward developmental progress. Onset of 
generalized tonic-clonic seizures (GTCS) was at 4·75 years of age, although behavioral 
manifestations likely representing other seizure types were present earlier. Multiple seizure 
semiologies were reported including rare GTCS, head drops, and more common facial twitching 
with drooling, eye fluttering, gagging, vomiting and stiffening. Rare GTCS are controlled with 
levetiracetam and clonazepam, but other seizure types have been poorly controlled with multiple 
therapies that were ineffective or limited by side effects (Table 7). In addition, the patient 
experiences sumatriptan-responsive migrainous episodes consisting of headache, abdominal 
discomfort, photophobia and lethargy. 
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Brain MRI showed subtle asymmetric volume loss in left hippocampus. Seven day video-
EEG monitoring revealed mild diffuse slowing and abundant bi-hemispheric multifocal 
epileptiform discharges more prominent in right temporal and midparietal regions. 
Electroclinical seizures began in the left hemisphere, with two in centro-parietal areas and one 
without clear localization. Magnetoencephalography showed frequent epileptiform spikes during 
sleep (648 spikes observed over 50 minutes), with frequent trains of spikes. Source modeling 
showed epileptiform spike activity arising from bilateral posterior perisylvian regions. The first 
cluster of spikes (~55%) originated from the anterior-inferior aspect of the left parietal lobe, 
extending to the left superior temporal gyrus. The second cluster of spikes (~45%) originated 
from the right temporal-parietal junction. No propagations were observed.  
Muscle biopsy showed type 1 fiber predominance with mild generalized hypertrophy. 
There was slight elevation of plasma guanidinoacetate 2·5 (0.3-2.1 µM) but not in the range 
typically associated with disease. There was mild elevation of cerebrospinal fluid (CSF) pyruvate 
with normal lactate [2.06 (0.5-2.2 mM)/147 (0-75 µM)]. CSF 5-methyltetrahydrofolate was 
mildly reduced 36 (40-128 nM). Folinic acid therapy has had unclear impact. Extensive 
additional work-up was normal and included: karyotype, fragile X and Angelman syndrome 
testing, CGH Oligo-SNP Array, mitochondrial DNA Southern blot and mitochondrial DNA 
sequencing, plasma acylcarnitine, CPK, uric acid, biotinidase, ammonia, Vitamin B12, folate, 
homocysteine, folate receptor antibodies, lymphocyte pyruvate dehydrogenase activity, urine 
organic acids, urine creatine and guanidinoacetate, CSF glucose, protein, amino acids, 
neurotransmitter metabolite levels and pterins, muscle carnitine, CoQ10, and electron transport 
chain complex analysis. 
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Individual 2 presented as a 2-yr-10-month male with poor seizure control, developmental delay, 
absent speech, stereotyped handwringing movements, and progressive in-turning of feet 
requiring orthotic support. Prenatal and perinatal histories were normal. Development plateaued 
at 6 months and seizures began at 8 months of age, with hypoarrythmic EEG for which he was 
treated with ACTH. Although seizures were resistant to conventional treatment (Table 7), a 
gluten/casein/sugar/starch-free diet begun at 2.5 years of age resulted in seizure reduction to 
3/day despite marked spike activity demonstrable on EEG. At 4 years of age, seizures worsened 
and L-carnitine was added with subsequent amelioration. At 5 years of age, EEG was 
persistently abnormal with epileptiform discharges of multifocal origin including bursts of 
diffuse polyspikes, diffuse polyspike-wave, right temporal spike and wave, left occipital spikes 
and diffuse polyspike bursts lasting up to 4 minutes. Brain MRI studies at 9 months did not show 
structural, neuronal migration, or white matter abnormalities. He began walking at 2.5 years, and 
became interactive socially, though nonverbal. Extensive additional work-up was normal (Table 
7). Genetic testing for mutations associated with SCN1A, MECP2, CDKL5, FOXG1, ARX, 
Fragile X, Pitt-Hopkins and Angelman syndromes were negative. Tests for plasma and 
cerebrospinal fluid (CSF) amino acid concentrations, urine organic acid levels, CSF 
neurotransmitter levels, lysosomal enzymes, very long chain fatty acids (VLCFA), neuronal 
ceroid lipofuscinosis (NCL) 1 & 2, urine sulfocysteine, congenital disorders of glycosylation 
(CDG), and oligo array were all normal. Clinical WES was performed by GeneDx (Gaithersburg, 
MD) and reported variants were confirmed by Sanger sequencing. 
 
Individual 3 (Coriell ND27062) was ascertained by the Epilepsy Phenome/Genome Project229 as 
part of a patient cohort with infantile spasms and/or Lennox-Gastaut syndrome.5 Seizure onset 
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occurred during the first year of life and seizure types include tonic-clonic, atypical absence, 
atonic, infantile spasms and focal dyscognitive (Table 7). EEG findings were unspecified, while 
imaging studies were reported as normal. 
 
Whole Exome, Whole Genome Sequencing, Variant Calling, and Filtration. Genomic DNA 
was extracted from blood using the QiaAmp system (Qiagen, Valencia, CA). Enriched exome 
libraries were prepared using the SureSelect XT enrichment system (Agilent, Santa Clara, CA). 
WES was performed on an Illumina HiSeq2500 instrument with indexed, 100-bp, paired-end 
sequencing. Reads were mapped to the hg19 reference genome using BWA,230 variant calling 
and quality filtration was performed using GATK best practices variant quality score 
recalibration.202,231,232 Mean coverage of 97 to 124-fold was achieved for each subject with 94-
95% of the target exome covered by >10 reads (Table 4). Libraries for low-pass WGS were 
prepared using the NEBNext DNA Library Prep System (New England Biolabs, Ipswich, MA). 
WGS was performed on an Illumina HiSeq2500 with 100-bp indexed, paired-end sequencing. 
Mean coverage of 4 to 7-fold was achieved for each subject with ~64.3% of the genome covered 
by >5 reads (Table 4). Copy number variants (CNVs) were identified by CNVNator.233 
Variant annotation was performed using the Scripps Genome Annotation and Distributed 
Variant Interpretation Server (SG-ADVISER) (http://genomics.scripps.edu/ADVISER/) as 
previously described.234 A series of filters were applied to derive a set of candidate disease-
causing variants (Table 5): (1) population-based filtration removed variants present at >1% allele 
frequency in the HapMap235 or 1,000 Genomes,236 NHLBI Exome Sequencing Project 
(http://evs.gs.washington.edu/EVS/), or Scripps Wellderly populations (individuals over the age 
of 80 with no common chronic conditions sequenced on the Complete Genomics platform); (2) 
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annotation-based filtration removed variants in segmental duplication regions that are prone to 
produce false positive variant calls due to mapping errors;237 (3) functional impact-based 
filtration retained only variants that are non-synonymous, frameshift, nonsense, or affect 
canonical splice-site donor/acceptor sites, and (4) inheritance-based filters removed variants not 
present in the trio in a manner consistent with affectation status. Following filtering, retained 
variants were confirmed by Sanger sequencing. 
 
Locus Specific Mutation Rate Estimate. The KCNB1 locus specific mutation rate was 
determined as described.238 Human and chimpanzee alignments of the protein coding portion of 
exons and intronic essential splice sites were considered. The KCNB1 mutation rate per site is 
2.71x10-3 differences per bp of aligned sequence. Assuming a divergence time of 12 million 
years between chimpanzee and human and a 25 year average generation time, the KCNB1 locus 
specific mutation rate per site per generation is 5.65x10-9. The probability of observing de novo 
mutation events was estimated using the Poisson distribution: 
 ! "; 	% = 	 [()*+)(%-)]/"! 
where X is the number of de novo events observed and µ is the average number of de 
novo events based on the locus specific mutation rate. 
 
Plasmids and Cell Transfection. Mutations were introduced into full-length human KV2.1 
cDNA engineered in plasmid pIRES2-Ds-Red-MST24 by QuikChange mutagenesis (Agilent). 
Wildtype human KV2.1 cDNA was subcloned into the pIRES2-smGFP expression vector. 
Expression of wildtype and mutant KV2.1 in CHO-K1 cells was achieved by transient 
transfection using FUGENE-6 (Roche) and 0.5 µg of total cDNA (1:1 mass ratio). Expression of 
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wildtype alone was achieved by transfection with pIRES2-smGFP-WT-KV2.1 plus empty 
pIRES2-DsRed-MST, while expression of mutant alone was performed with pIRES2-DsRed-
MST-mutant-KV2.1 and empty pIRES2-smGFP. Co-expression of mutant and wildtype was 
achieved by co-transfection with pIRES2-smGFP-WT-KV2.1 and pIRES2-DsRed-MST-mutant-
KV2.1 or pIRES2-dsRed-MST-WT-KV2.1. Following transfection cells were incubated for 48 
hours before use in experiments. 
 
Cell Surface Biotinylation. Proteins on the surface of CHO-K1 cells transfected with wildtype 
and/or mutant KV2.1 were labeled with cell membrane-impermeable Sulfo-NHS-Biotin (Thermo 
Scientific). Following quenching with 100 mM glycine, cells were lysed and centrifuged. 
Supernatant was collected and an aliquot was retained as the total protein fraction. Biotinylated 
surface proteins (100 µg per sample) were recovered from the remaining supernatant by 
incubation with streptavidin-agarose beads (ThermoScientific) and eluted in Laemmli sample 
buffer. Total (1 µg per lane) and surface fractions were analyzed by Western blotting using 
mouse anti-KV2.1 (1:500; NeuroMab, clone K89/34), mouse anti-transferrin receptor (1:500; 
Invitrogen, #13-6800), rabbit anti-calnexin (H70)(1:250; Santa Cruz, sc-11397) primary 
antibodies, and peroxidase-conjugated mouse anti-rabbit IgG (1:100,000 Jackson 
ImmunoResearch) and goat anti-mouse IgG (1:50,000, Jackson ImmunoResearch) secondary 
antibodies. Blots were probed for each protein in succession, stripping in between with Restore 
Western Blot Stripping Buffer (Pierce). Western blot analysis was performed in triplicate on 
samples from three independent transfections. The order of anti-Kv2.1 and anti-transferrin 
receptor antibodies was alternated, with transferrin receptor probed first in two of three 
experiments. Selectivity of biotin labeling for cell surface was confirmed by probing with 
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calnexin following detection of KV2.1 and transferrin receptor. Calnexin signal was consistently 
present in total protein lanes and absent in surface fraction lanes. Densitometry was performed 
using NIH ImageJ software. To control for protein loading, KV2.1 bands were normalized to the 
corresponding transferrin receptor band. For each genotype, the normalized values were then 
expressed as a ratio of surface:total expression. Normalized total, surface and surface:total ratios 
were compared between genotypes using one-way ANOVA.  
 
Electrophysiology. Whole cell patch-clamp recordings were performed as described,239 except 
recording solutions were altered to achieve appropriate voltage-control. The external solution 
contained (in mM): 132 XCl [where X is Na+ except when molar substitution for K+, Rb+ or N-
methyl-D-glucamine (NMDG+) is indicated in the figure], 4.8 KCl, 1.2 MgCl2, 2 CaCl2, 10 
glucose, and 10 HEPES, pH 7.4. The internal solution contained (in mM): 20 K-aspartate, 90 
NMDG-Cl, 1 MgCl2, 1 CaCl2, 11 EGTA, 10 HEPES, and 5 K2ATP, pH 7·3. When cells 
expressing mutant channels alone or co-expressed with wildtype Kv2.1 (Kv2.1-WT) were held at 
-80 mV, they exhibited large currents that prevented adequate voltage control. Therefore, a 
holding potential of -30 mV was used for experiments. Whole cell currents were measured from 
-80 to +60 mV (in 10 mV, 500 msec long steps) from a holding potential of -30 mV followed by 
a 500 msec step to 0 mV (tail currents). Voltage-dependence of activation was evaluated from 
tail currents measured 10 msec after stepping to 0 mV from -40mV to +30mV and fit to the 
Boltzmann equation. Kinetic analysis of activation rate was performed by exponential fit of the 
first 50 msec of current induced after a voltage step from the holding potential.  
For cation selectivity experiments, recording solutions were altered as follows: sucrose 
dilution was performed by adding 300 mM sucrose solution 10:1 (v/v) to the external solution 
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described above. For determining permeability ratios, the internal solution was modified to 
contain (in mM): 110 K-aspartate, 1 MgCl2, 1 CaCl2, 11 EGTA, 10 HEPES, and 5 K2ATP, pH 
7.3 and equimolar replacement of extracellular sodium with the monovalent cations K+, Rb+ and 
NMDG+. The permeability ratio (PX/PNa) was calculated from measured reversal potentials (Erev) 
according to the following equation:240 
Erev = (RT/F) ln(Px[X+]o / PK+[Na+]i 
where R is the gas constant, T is absolute temperature, F is Faraday’s constant, X+ is the 
monovalent cation in the extracellular solution, and PX is permeability of the X+ cation.  
Data for each experimental condition were collected from ≥3 transient transfections, and 
analyzed and plotted using Clampfit (Molecular Devices) and Graphpad Prism5 (Graphpad 
Software). Currents were normalized for membrane capacitance and shown as mean ± SEM, and 
number of cells used for each experimental condition is listed in Table 8. Statistical significance 
was determined using unpaired Student’s t test (Graphpad). P values are provided in the figures 
or figure legends. 
  
 78	
RESULTS 
 
Genome-wide evaluation identifies de novo variants in a case of epileptic encephalopathy 
We employed WES (~100X coverage) and WGS (~5X coverage) of the proband (ID9), 
unaffected father (ID9F), unaffected mother (ID9M), and unaffected sister (ID9S) to identify the 
molecular cause of an epileptic encephalopathy. Filtering of WES variants was done under the 
assumption that disease in ID9 was the result of a heterozygous de novo mutation, but we also 
considered simple and compound recessive models. Variants discovered by WES were processed 
through a series of population-, variant annotation-, functional-impact-, and inheritance-based 
filters, to identify a set of candidate disease-causing variants (Table 4). Sequence coverage and 
detailed variant data are presented in Table 5. CNVs were also interrogated by WGS, however, 
no CNVs consistent with disease segregation were identified. This process identified de novo 
missense variants in 2 candidate genes, KCNB1 and MLST8 (Table 5). Under other genetic 
models, we identified a homozygous missense variant in HRNBP3 and compound heterozygous 
variants in NLRP1 and BAHCC1. Of all the identified variants, the KCNB1 variant was deemed 
the most likely candidate based on the de novo inheritance pattern, the function of KCNB1 and 
its relationship to other epilepsy genes, and the predicted deleterious consequence on protein 
function by multiple algorithms (Table 6). KCNB1 encodes the alpha subunit of the KV2.1 
voltage-gated potassium channel, a delayed rectifier potassium channel that is an important 
regulator of neuronal excitability. The S347R variant is located in the pore domain that is 
necessary for ion selectivity and gating (Fig 15). 
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Table 4. Whole exome sequencing variant filtration for individual ID9 
 
Variant Type # in Family 
Total Variants 101,797 
  Rare Variants (<1% allele frequency) 18,475 
    Not in Segmental Duplication 13,463 
      Nonsynonymous, Truncating, or Splice Site 1,053 
        De Novo Inheritance 2 
        Homozygous or Compound Heterozygous Inheritance 3 
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Table 5. Whole exome and whole genome sequencing coverage 
 
  Whole Exome Sequencing Whole Genome Sequencing 
Sample Coverage (Mean) 
% Target 
Exome with at 
least 10 Reads 
Coverage 
(Mean) 
% Genome 
Redundancy of 
5 Reads 
ID9 – Proband 109 94.5% 4.1 37.9% 
ID9F – Father 109 94.6% 6.0 66.7% 
ID9M – Mother 124 94.9% 6.9 75.2% 
ID9M – Sister 97 94.2% 7.2 77.4% 
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Table 6. Inheritance of validated candidate variants in individual ID9.  
 
Gene ID1 Status 
Amino 
Acid 
Change 
WES Genotype Predicted Consequence 
ID9 ID9F ID9M ID9S Provean SIFT Polyphen 2 
KCNB1 de-novo S347R 01 00 00 00 deleterious (-4.996) 
damaging 
(0.003) 
probably damaging 
(0.995) 
MLST8 de-novo Q302R 01 00 00 00 neutral (-2.12) 
tolerated 
(0.203) 
benign 
(0.114) 
HRNBP3 homozygous Y5H 11 01 01 00 deleterious (-3.54) 
damaging 
(0.000) 
benign 
(0.446) 
NLRP1 compound heterozygous 
V939M 01 00 01 01 neutral (-2.08) 
damaging 
(0.006) 
probably damaging 
(0.982) 
R834C 10 01 00 00 neutral 
(-0.46) 
tolerated 
(0.216) 
benign 
(0.000) 
BAHCC1 compound heterozygous 
A941T 01 00 01 01 neutral 
(-1.38) 
tolerated 
(0.215) 
benign 
(0.009) 
E1990K 10 01 00 00 neutral 
(-0.91) 
tolerated 
(0.168) 
possibly damaging 
(0.900) 
 
Genotypes: 0 – reference allele, 1 – alternate allele  
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Additional unrelated cases with rare missense KCNB1 variants 
We identified two additional unrelated patients with epileptic encephalopathy and de 
novo missense variants in KCNB1 discovered by WES. Individual 2 presented with a sporadic 
epileptic encephalopathy of unknown cause (Table 7). After a series of negative genetic and 
metabolic tests, he was referred for clinical WES. From that analysis it was determined that he 
had a single de novo missense variant in KCNB1. The variant G379R, located in the selectivity 
filter of KV2.1, was predicted to be deleterious by functional impact algorithms (Fig 15; Table 
7). Additional inherited variants included a heterozygous splice site mutation in the NPC2 gene 
(IVS4+1 G>A) inherited from his unaffected father and a variant of unknown significance in 
GRIN2A (A1276G) inherited from his unaffected mother. Neither of these transmitted variants 
was thought to be causative for principal phenotypes of individual 2, although they may 
contribute by modifying overall expression the clinical phenotype. Inheritance of NPC type 2 is 
generally recessive and the clinical phenotype of individual 2 was not consistent with NPC type 
2. The GRIN2A A1276G variant is a known SNV that was inherited from the unaffected mother 
and exists in the general population (0.1% MAF in European Americans). A1276G is a 
conservative substitution in an alternatively spliced portion of the GRIN2A gene at a position that 
does not show a high degree of evolutionary conservation and was predicted to be benign by 
multiple functional impact algorithms (Provean: neutral (-0.78); SIFT: tolerated (0.284; 
Polyphen2: benign (0.376)). 
Individual 3 was recently reported as part of an epileptic encephalopathy exome 
sequencing study by the Epi4K consortium.5 She presented with early-onset epileptic 
encephalopathy and cerebral palsy (Table 7). A de novo missense variant in KCNB1 was 
reported for individual 3, with no additional de novo variants reported.5 The variant T374I is 
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located in the pore domain of KV2.1 and was predicted to be deleterious by functional impact 
algorithms (Fig 15; Table 7). Given the locus-specific mutation rate of KCNB1 (5.65x10-9 
mutation rate/base/generation), the probability of identifying three independent mutations is low 
(P<1·1x10-13), providing statistical evidence that these variants may be pathogenic. The altered 
residues show a very high degree of evolutionary conservation (Fig 15A), with T374 and G379 
being invariant through the ancestral KcsA bacterial potassium channel. Further, all three 
KCNB1 variants are located in the functionally important pore domain of the KV2.1 channel 
protein. Serine 347 is located in the pre-pore transmembrane segment and threonine 374 is 
located in the pore helix. Glycine 379 is part of the critical “GYG” motif that defines the 
potassium selectivity filter (Fig 15A and 15B).  
Missense variants in pore region of KV2.1 alter channel function 
Effects of the KCNB1 variants on KV2.1 channel function were evaluated following 
transient expression in CHO-K1 cells. Expression of each mutant in CHO-K1 cells resulted in 
total and cell surface expression similar to the wildtype channel, with no significant genotype-
dependent differences in total (F3,8=1.767, p=0.213), surface (F3,8=0.017, p=0.997) and 
surface:total (F3,8=0.266, p=0.848) expression of Kv2.1. This indicates that the mutations do not 
interfere with protein expression or trafficking of channels to the cell surface (Fig 15C). 
Expression of KV2.1-WT resulted in large voltage-dependent potassium currents with 
characteristic outward rectification and late inactivation (Fig 16B and 16C). In contrast, 
expression of each of the three mutants yielded small currents with linear current-voltage 
relationships (Fig 16B and 16C). These aberrant currents were blocked by gadolinium (Gd3+), 
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Table 7. Clinical features in three individuals with epileptic encephalopathy and KCNB1 missense mutations. 
Individual Age of onset 
Seizure 
types 
Seizure control 
with anti-
epileptics? 
(treatments) 
Developmental 
Delay 
Brain 
MRI EEG Other 
Presumed 
causal 
variant 
Amino Acid 
Change 
Predicted 
Consequence 
Provean (score) 
SIFT (score) 
Polyphen2 (score) 
ID9 4 yrs Tonic-clonic; 
Tonic; 
Atonic;  
Focal;  
Focal with 
secondary 
generalizatio
n 
No 
(Topiramate, 
clobazam, 
levetiracetam, 
Depakote, 
carbamazepine, 
trileptal, 
lacosamide, 
clonazepam, 
oxcarbazepine) 
Yes (motor and 
language) 
Subtle 
volume 
loss in left 
hippocam
pus 
Mild diffuse 
slowing and 
abundant bi-
hemispheric 
multifocal 
epileptiform 
discharges 
Hypotonia;  
Strabismus; 
Migraine;  
 
Chr20: 
47991056 
G/T 
S347R Deleterious                       
(-4.996) 
Damaging                
(0.003) 
Probably Damaging 
(0.995) 
 
2 8 
months 
 
Tonic-clonic; 
Atonic; 
Focal; 
Infantile 
spasms 
No 
(ACTH, 
Topiramate, 
Depakote, 
pyridoxine; 
ketogenic diet) 
Yes (motor and 
language) 
normal Hypsarrhythmia; 
diffuse polyspikes, 
diffuse polyspike-
wave, right 
temporal spike and 
wave, left occipital 
spikes and series 
of bursts of diffuse 
polyspikes 
Hypotonia 
Strabismus; 
Tremulousness; 
Non-verbal; 
Stereotyped 
handwringing 
movements; 
In-turning of 
feet 
 
Chr20: 
47990962  
C/T 
 
G379R Deleterious                      
(-7.926) 
Damaging                    
(0.000) 
Probably Damaging 
(1.000) 
 
3 
(Coriell 
ND27062) 
0 years Tonic-clonic; 
Atonic;  
Focal 
dyscognitive 
Atypical 
absence; 
Infantile 
spasms;  
unknown Yes 
(unspecified) 
normal unspecified Cerebral palsy Chr20: 
47990976 
G/A 
T374I Deleterious                       
(-5.945) 
Damaging                  
(0.000) 
Probably Damaging 
(0.999) 
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Figure 15. KV2.1 mutations identified in three individuals with epileptic encephalopathy. 
(A) Evolutionary conservation of KV2.1. Multiple alignment of KV2.1 species orthologs (Clustal 
Omega241). Mutated amino acids are shaded and functional sub-domains of the pore region are 
indicated. (B) Location of mutations mapped onto the crystal structure of a KV2.1/KV1.2 chimera 
(PDB 29R9).242 The left panel shows a channel tetramer from the extracellular side. S347 (green) 
lies at the interface between the voltage sensor (blue) and pore (white) domains. T374 (teal) lies 
adjacent to the selectivity filter, while G379 (red) lies in the selectivity filter. (C) Mutant KV2.1 
proteins are expressed and trafficked to the cell surface. Cell surface expression was measured 
using cell surface biotinylation of CHO-K1 cells transfected with wildtype or mutant KV2.1. 
Total and surface fractions of KV2.1 were detected with anti-KV2.1 antibody. Endogenous 
transferrin receptor levels were measured as a loading control.  
 
  
Figure	15.	KV2.1	mutations	identified	in	three	individuals	with	epileptic	
encephalopathy.	(a)	Evolutionary	conservation	of	KV2.1.	Multiple	
alignment	of	KV2.1	species	orthologs (Clustal Omega38).	Mutated	amino	
acids	are	shaded	and	functional	sub-domains	of	the	pore	region	are	
indicated.	(b)	Location	 f	mutations	mapped	onto	the	crystal	structure	
of	a	KV2.1/KV1.2	chimera	(PDB	29R9).39 The	left	panel	shows	a	channel	
tetramer	from	the	extracellular	side.	S347	(green)	lies	at	the	interface	
between	the	voltage	sensor	(blue)	and	pore	( hite)	 omains.	T374	
(teal)	lies	adj ce t	to	the	selectivity	filter,	while	G379	(red)	lies	in	the	
selectivity	filter.	(c)	Mutant	KV2.1	proteins	are	expressed	and	trafficked	
to	the	cell	surface.	Cell	surface	expression	was	measured	using	cell	
surface	biotinylation of	CHO-K1	cells	transfected	with	wildtype or	
mutant	KV2.1.	Total	and	surface	fractions	of	KV2.1	were	detected	with	
anti-KV2.1	antibody.	Endogenous	transferrin	receptor	levels	were	
measured	as	a	loading	control.	
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Figure 16. Functional consequence of KV2.1 mutations. (a) CHO-K1 cells were held at -
30mV and whole cell currents were recorded from -80 to +60 mV in 10 mV steps for 500 msec 
followed by a 500ms step to 0mV to record tail currents. (b) Average whole-cell current traces 
recorded from non-transfected CHO-K1 cells and CHO-K1 cells transiently expressing wild-type 
or mutant (G379R, S347R, T374I) KV2.1 channels, or co-expressing wild-type plus mutant 
channels. (c) Current density–voltage relationships measured from CHO-K1 cells expressing 
mutant, wild-type, or co-expressing wild-type and mutant KV2.1 channels. Currents were 
normalized to cell capacitance (pF). (d) Voltage dependence of steady-state activation. Tail 
currents were normalized to peak amplitude and fit with Boltzmann function. Biophysical 
parameters of voltage-dependence are detailed in Table 8. (e) The time constant of activation 
was determined from exponential fit of individual current traces.  
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Figure 17. GdCl3 block of mutant KV2.1 channels. Representative traces of control and Gd+3 
block at +60 mV of wild-type (86±2.1%, n=5) or mutant channels (S347R (94±3.7%, n=3), 
G379R (79±4.2%, n=4), T374I (94±2.5%, n=3)). 
  
Figure	15.	GdCl3 block	of	mutant	KV2.1	channels.	Representative	traces	
of	control	and	Gd+3	block	at	+60	mV	of	wild-type	(86±2.1%,	n=5)	or	
mutant	channels	(S347R	(94±3.7%,	n=3),	G379R	(79±4.2%,	n=4),	T374I	
(94±2.5%,	n=3)).
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strongly suggesting that the currents are pore-mediated (Fig 17). Based upon the external and 
internal K+ concentrations used in these experiments, the theoretical reversal potential (Erev) for 
K+-selective currents is -47 mV. Expression of the mutant channels produced currents with 
depolarized Erev (S347R: -23·2±4·8 mV; G379R -14·0±4·5 mV; T374I -16·5±5·5 mV) 
indicating that the mutations affect ion selectivity. To test ion selectivity, the external solution 
was diluted 1:10 with 300 mM sucrose. Under these conditions, a depolarizing shift in Erev would 
indicate anion selectivity, while a hyperpolarizing shift would indicate cation selectivity. 
Dilution of the extracellular solution produced a hyperpolarizing shift in Erev confirming the 
current conducted was cation-selective (Fig 18). Changes in cation selectivity were determined 
by measuring changes in Erev following molar replacement of extracellular sodium with 
monovalent cations. All three mutants exhibited loss of K+ selectivity, with K+/Na+ permeability 
ratios of 0.9 (Fig 18; Table 8) compared to the reported 14:1 ratio for Kv2.1-WT.243 
To investigate the effects of the mutant channels in a heterozygous background, we co-
expressed each mutant with Kv2.1-WT channel and compared to the wildtype channel expressed 
alone. Co-expression of KV2.1-WT with T374I, S347R, or G379R resulted in reduced current 
measured at test potentials ranging from 0 to +60 mV (Fig 14C), depolarizing shifts in the 
voltage-dependence of steady-state activation (Fig 16D and 20; Table 8), and greater time 
constants of activation (τ) measured from +30 to +60 mV test potentials (Fig 16E and 20). The 
observed changes in kinetic parameters suggest that the mutant and wild-type subunits can form 
heterotetrameric channels. 
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Figure 18. Extracellular cations are conducted through mutant KV2.1 channels. Current-
voltage plots in control bath and after bath was diluted 10-fold in 300mM sucrose solution in (a) 
KV2.1-S347R (b) KV2.1-G379R and (c) KV2.1-T374I. (d) Reversal potentials were determined 
by linear fit to y=mx+b in control bath and after bath was diluted 10-fold in 300mM sucrose 
solution. 
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Figure	16. Extracellular	cations	are	conducted	through	mutant	KV2.1	
channels. Reversal	potentials	were	determined	by	linear	fit	to	y=mx+b
in	control	bath	and	after	bath	was	diluted	10-fold	in	300mM	sucrose	
solution	in	(a) KV2.1-S347R (b)	KV2.1-G379R	and	(c)	KV2.1-T374I.	(d)	
Change	in	reversal	potential	after	equimolar	substitution	of	
extracellular	monovalent	Na+.
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Figure 19. Ion selectivity of mutant KV2.1 channels. Reversal potentials were determined by 
linear fit to y=mx+b in control bath and after bath solution change with equimolar substitution of 
extracellular monovalent Na+ in (a) KV2.1-S347R (b) KV2.1-G379R and (c) KV2.1-T374I. (d) 
Change in reversal potential after equimolar substitution of extracellular monovalent Na+. 
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Figure	17.	Ion	selectivity	of	mutant	KV2.1	channels. Reversal	potentials	
were	determined	by	linear	fit	to	y=mx+b in	control	bath	and	after	bath	
solution	change	with	equimolar	substitution	of	extracellular	
monovalent	Na+ in	(a)	KV2.1-G379R	(b)	KV2.1-S347R	and	(c)	KV2.1-T374I.	
(d)	Change	in	reversal	potential	after	equimolar	substitution	of	
extracellular	monovalent	Na+.
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Figure 20. Expanded view of whole-cell current traces for evaluation of activation kinetics 
of wild-type KV2.1 channel alone or co-expressed with mutant channels. Expanded view of 
the first 50 msec of whole-cell currents following voltage change from -80mV to +60mV and 
normalized to peak current recorded from CHO-K1 cells transiently expressing KV2.1-WT (a) or 
co-expressing wild-type and mutant KV2.1 channels ((b) G379R, (c) S347R, (d) T374I). 
  
Figure	18.	Expanded	view	of	whole-cell	current	traces	for	evaluation	of	
activation	kinetics	of	wild-type	KV2.1	channel	alone	or	co-expressed	
with	mutant	channels.	Expanded	view	of	the	first	50	msec of	whole-cell	
currents	following	voltage	change	from	-80mV	to	+60mV	and	
normalized	to	peak	current	recorded	from	CHO-K1	cells	transiently	
expressing	KV2.1-WT	(a)	or	co-expressing	wild-type	and	mutant	KV2.1	
channels	((b)	G379R,	(c)	S347R,	(d)	T374I).
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Table 8. Biophysical properties of voltage-dependence of activation for wild-type and 
mutant KV2.1 channels. 
 
 Mean V1/2 ± S.E.M. Slope factor ± S.E.M. n 
Kv2.1-WT -4·1 ± 1·5 4·4 ± 0·4 12 
Kv2.1-WT + G379R 1·3 ± 2·0 * 5·2 ± 0·6 8 
Kv2.1-WT + S347R 2·8 ± 1·6 * 5·9 ± 0·5 8 
Kv2.1-WT + T374I 1·9 ± 1·5 * 5·7 ± 0·2 7 
 
* P < 0.05 
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DISCUSSION 	
Co-occurrence of de novo variants in KCNB1 in three independent patients with 
overlapping clinical phenotypes that include epileptic encephalopathy with associated cognitive 
and motor dysfunction provides strong genetic evidence that the KCNB1 variants are likely 
pathogenic. Further evidence for a pathogenic effect of the KCNB1 mutations comes from 
functional studies of mutant KV2.1 channels. All three mutations, located within the pore domain 
of KV2.1, resulted in channels with similar dysfunctional features. 
Previous studies demonstrated that mutations in the pore region can result in altered ion 
selectivity.244-247 Consistent with this, each KV2.1 mutant exhibited voltage-independent, non-
selective cation currents. When co-expressed with wildtype channels, all Kv2.1 mutants induced 
depolarizing shifts in the voltage-dependence of activation and reduced current density at more 
depolarized voltages. Further, co-expression of the Kv2.1 mutants with wildtype channels 
resulted in inward currents in the voltage range where KV2.1 channels are normally closed, as 
evidenced by large inward currents observed when using a holding potential of -80 mV. These 
gain-of-function and dominant-negative functional defects are predicted to result in depolarized 
resting membrane potential and impaired membrane repolarization, with increased cellular 
excitability as a net consequence. 
KV2.1 is the main contributor to delayed rectifier potassium current in pyramidal neurons 
of the hippocampus and cortex.248-252 Delayed rectifier potassium current is critical for 
membrane repolarization under conditions of repetitive stimulation and acts to dampen high 
frequency firing. Reduction of delayed rectifier potassium current by Kcnb1 deletion in mice 
results in reduced thresholds to induced seizures, but not spontaneous seizures.253 This suggests 
that loss of KV2.1 function predisposes neuronal networks to hyperactivity, resulting in a modest 
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increase in seizure risk. In contrast, our results demonstrate that gain-of-function and dominant-
negative effects result in epileptic encephalopathy. A similar phenomenon is observed with 
KCNQ2 wherein heterozygous loss-of-function mutations result in benign familial neonatal 
seizures, while mutations with dominant-negative effects result in epileptic encephalopathy.254 
This suggests that variable functional defects resulting from different mutations in the same gene 
contribute to the pleiotropic effects observed for genes associated with neurodevelopmental 
disorders. 
In summary, our genetic and functional evidence identify mutation of KCNB1 as a cause 
of epileptic encephalopathy. This expands the considerable locus heterogeneity associated with 
epileptic encephalopathies, suggesting that clinical exome sequencing may be useful for 
molecular diagnosis. Rapid genetic diagnosis is beneficial for appropriate disease management 
and may improve long-term outcomes in epileptic encephalopathies. 
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CONCLUSIONS 
 
 Based on the data presented here, KCNB1 is a novel genetic cause of epileptic 
encephalopathy. Heterologous expression studies that I performed of wild-type or mutant KV2.1 
elucidated a combined loss- and gain-of-function mechanism associated with epileptic 
encephalopathy. Disruption of the selectivity filter in this neuronal voltage-gated potassium 
channel not only loses the repolarizing outward potassium current, but also renders the channel 
insensitive to voltage control and allows passage of large monovalent cations through the pore. 
These biophysical changes suggest the variants described here result in enhanced neuronal 
excitability through combined loss- and gain-of-function mechanisms.  
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CHAPTER IV 
FUNCTIONAL AND TRANSCRIPTIONAL MECHANISMS OF RARE 
MISSENSE TBX5 VARIANT CAUSING THE BRUGADA SYNDROME 
 
 
ABSTRACT 
 
 
Background. Loss of function variants in SCN5A, the gene encoding the cardiac sodium 
channel, are the only major monogenic cause of the Brugada Syndrome (BrS) but account for 
only 20% of cases. Rare, predicted protein altering variants in multiple other genes have been 
implicated, but evidence supporting their role in BrS pathogenesis has been weak.  Our 
laboratory identified a rare variant, resulting in the substitution of glycine (G) for arginine (R) at 
amino acid position 145 (G145R), in the cardiac transcription factor TBX5 in an SCN5A-
negative BrS family.  TBX5 is a candidate BrS gene because it is known to modulate SCN5A 
expression and a common BrS-associated variant disrupts a putative TBX5 binding site in an 
SCN5A enhancer. However, approaches to establish that variants in transcription factor genes 
cause congenital arrhythmia syndromes have not been developed.  
 
Materials and Methods. We compared in vitro DNA binding and transcriptional activity of 
wild-type TBX5, BrS-identified G145R, and Holt-Oram syndrome-associated G80R as a control 
loss-of-function mutation.  We generated induced pluripotent stem cells (iPSCs) from family 
members with BrS and from population controls. Using CRISPR/Cas9, we generated other TBX5 
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variants, and also corrected the G145R variant to create isogenic control lines. We differentiated 
the iPSCs to cardiomyocytes (iPSC-CMs) for functional and transcriptional assessments, 
including electrophysiologic studies and RNA sequencing.   
 
Results. In vitro, TBX5-G145R displayed markedly reduced (-63%) transcriptional activity and 
(-97%) binding to TBX5 target sequences compared to wild-type.   SCN5A expression and peak 
sodium current were reduced ~50% in TBX5G145R/WT iPSC-CMs. Correction of the TBX5 variant 
restored SCN5A expression to levels detected in population control lines. Unexpectedly, TBX5-
G145R also caused increased late sodium current and action potential duration lability. The 
heterogeneity in action potential duration was inhibited with pharmacologic blockade of the late 
sodium current and with genome editing to correct the missense variant. Genes with altered 
expression in TBX5-G145R relative to TBX5 heterozygous knockout and wild-type myocytes 
included members of the PI3 kinase pathway, a known modulator of late sodium current.  
 
Conclusion. Using genome editing in patient-derived cardiomyocytes, we were able to 
demonstrate that TBX5-G145R reduces cardiac sodium current, the hallmark of BrS. Missense 
variants in transcription factors can result in discrete alterations in gene expression resulting in 
pleiotropic or variable expressivity of clinical presentations due to unique variants in a common 
gene. Genome editing in patient-derived cells is a powerful approach to directly establish the role 
of DNA variants in human disease.   
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INTRODUCTION 
 
The Brugada syndrome (BrS) is an inherited arrhythmia condition that increases risk of 
ventricular tachyarrhythmia and sudden cardiac death.52,255 The most common genetic cause of 
BrS, accounting for 20% of cases, is loss of function variants in SCN5A46,75 but approximately 
70% of cases of BrS are due to genetically undefined etiology. Genotype-phenotype studies have 
identified decreased peak sodium current due to abnormal gating or reduced cell surface 
expression as the cellular electrophysiologic hallmark of BrS.68,69 We have recently described a 
missense variant in the cardiac transcription factor TBX5 that is predicted to be deleterious to 
protein function in a case of BrS.107 This is variant is not reported in the Exome Aggregation 
Server, indicating that it is very rare. 
Altered gene expression is an appreciated causative or modulatory mechanism in inherited 
arrhythmia syndromes. Missense variants in TBX5 (gain of function mutation),115 and other 
transcription factors GATA4 (loss of function mutations)116-118 and NKX2.5 (loss of function 
mutations)119 have been identified in cases of familial atrial fibrillation, supporting transcriptional 
misregulation as a mechanism of arrhythmia conditions.107 Common variants located near TBX5 
are associated with prolonged QRS duration, a feature observed in BrS.114 TBX5 is implicated in 
BrS pathogenesis through a previously described BrS-associated common SCN10A variant 
(rs6801957) that is located in a putative TBX5 binding motif of an SCN5A enhancer, causing lower 
levels of SCN5A expression in human myocardium.103,109 Therefore, TBX5-G145R is a reasonable 
causal candidate variant in familial BrS.  The conventional approach to functionally characterizing 
candidate variants in ion channelopathies is to compare electrophysiologic properties of reference 
and mutant sequences using electrophysiologic assays in heterologous expression systems.  
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However, this approach cannot be used to assess the functional properties of variants in upstream 
pathways such as regulators of transcription.   
TBX5 is a T-box containing transcription factor critical to mammalian tissue patterning 
and cellular differentiation during development of the upper extremities and the heart. TBX5 
variants that result in TBX5 haploinsufficiency (nonsense, frameshifting indels, and splice site 
variants) or severe alterations in DNA binding (missense and intragenic duplications) cause the 
human condition Holt-Oram syndrome (HOS).120 HOS is a rare developmental syndrome affecting 
1:100,000 live births with abnormal development of the upper limbs and the heart. In the heart, 
common pathology includes isolated septal defects and conduction defects.121 Haploinsufficiency 
of Tbx5 in murine models results in diminished cardiac expression of gap junction proteins, atrial 
natriuretic peptide, and the cardiac sodium channel.140,143 Models (animal or cellular) of specific 
missense variants in TBX5 under endogenous expression have not been studied in order to define 
the resultant transcriptional mechanism underlying disease.  
Differentiation of cardiomyocytes from stem cells derived from somatic cell origin has 
provided a human model of heart disease. Inherited256-263 and drug-induced264,265 arrhythmia 
conditions have been recapitulated in induced pluripotent stem cell-derived cardiomyocytes 
(iPSC-CMs). Accurate models of sodium channel dysfunction have been established in human 
iPSC-CMs containing genetic lesions in SCN5A that cause BrS and Long QT syndrome 
(LQTS).172,266 Integrating genome editing approaches (TALENs, ZFNs, and CRISPR/Cas9) with 
iPSC-CMs provides an advanced model for testing causation of genetic variants on cellular 
phenotypes and a way to account for the confounding effect of genetic background. This 
approach has been validated by editing variants in known Mendelian disease genes, such as 
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KCNH2 in LQTS267 and phospholamban in dilated cardiomyopathy,268 and is primed for the 
application of test the causality of novel genetic associations. 
We generated iPSC-CMs from patients carrying TBX5-G145R, and demonstrated 
decreased sodium channel expression and current, consistent with the BrS phenotype. However, 
this experiment did not establish the contribution of the G145R variant to the phenotype.  
Generation of isogenic control iPSC-CMs through RNA-guided nuclease-mediated homology-
directed repair reversed the functional defect, thereby proving that TBX5-G145R causes BrS in 
this family. By generating this human model, we also identified a previously unappreciated role 
for TBX5 in modulating late sodium current and action potential duration lability leading to 
arrhythmia activity. Treatment of TBX5-G145R containing iPSC-CMs with the late sodium 
channel blocker ranolazine prevented the observed arrhythmogenic features. Our findings 
advance molecular diagnostics to progress from variant identification to causation with 
mechanistic understanding of disease pathogenesis. 
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MATERIALS AND METHODS 
 
 
Patient enrollment: This study was reviewed and approved by the Institutional Review Board at 
Vanderbilt University Medical Center (Nashville, TN). All participants provided written 
informed consent. 
Genotyping: After informed consent, DNA was extracted from peripheral blood using Puregene 
Chemistry on the Autopure LS robotic system according to manufacturer’s recommendations 
(Qiagen, product number 9001340). Amplicons of containing each SNV of interest were 
generated by RT-PCR using the primer sets listed in table 9. The amplification was performed 
using Applied Biosystems Veriti 96-well thermal cycler with a melting temperature of 95oC, 
annealing temp listed next to each primer set in table 9, and extended at 72oC. Each reaction used 
30 cycles for amplification. 
 
TBX5 structural modeling: The G145R variant of TBX5 was modeled into the Tbx5-DNA 
complex (PDBID: 2X6V) using PyMOL (Schrodinger; NY, NY). Energy minimized analysis of 
10 iterative side-chain repacking and gradient-based minimization with a ramping repulsive 
potential (relax) was performed on 1,000 models. Wild-type structures were also subjected to 
this minimization protocol to generate a total of 100 structures. The best scoring 10 models of 
WT and G145R were compared by Rosetta energy score to estimate energy well depth.  
 
Human TBX5 expression vectors: An expression vector containing full-length human TBX5 
cDNA under control of the CMV promoter was purchased from Origene (catalog # RC216520).  
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Table 9. Primers for Sanger sequencing to genotype rare and common BrS SNVs. 
Target Primer direction 5' -> 3' sequence 
Annealing temperature 
(oC) 
TBX5 
c.G433A 
Forward TCCCAGCTACTACTCAACAACCC 
58 Reverse GCGACGAAAGTGGGGGAAAATG 
rs6801957 
Forward CTCAGGGCATTCACCTCTGC 
60 Reverse GTAGGGAACTTGGCCACCTG 
rs9388451 
Forward TGAACGGAGTTGGGCCACTA 
60 Reverse AGGGAGCGAGGAGAATACCA 
rs10428132 
Forward ATTCAGATGGTTATAAACAAATG 
58 
Reverse GTAGGGTACACAGTTTATATCTG 
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Site-direct mutagenesis introduced single missense variants c.433G>A (p.Gly145Arg) or 
c.238G>A (p.Gly80Arg, a known HOS-associated mutation) into the expression vector using the 
QuikChange system (Stratagene).  
 
In vitro transcription/translation: TBX5 (reference or mutant) was synthesized using in vitro 
transcription/translation with rabbit reticulocyte lysate using the T7 RNA polymerase TNT 
system (Promega). 
 
Electrophoretic mobility shift assays: A well described TBX5 binding site in the NPPA 
promoter was generated by annealing the 22-mer oligonucleotide 5’–
TTACTCTTCTCACACCTTTGAAGTGG – 3’ to the complementary sequence. After annealing, 
the DNA target was radiolabeled with γ-32ATP using T4 polynucleotide kinase (NEB) and 
purified with a Sephadex G-50 gravity column. In vitro translated TBX5 was incubated with 
radiolabeled DNA target site in binding buffer (20 mM HEPES, 20% glycerol, 50 mM NaCl, 5 
mM MgCl2, 0.5 mM EDTA, 2 mM DTT, 1 µg/mL BSA, and 1 µg dI-dC) at room temperature 
for 20 min. DNA-TBX5 complex was separated from unbound DNA by electrophoresis. 
Afterwards the gel was dried for 45 mins onto DE-81 paper and visualized using overnight 
exposure to a K-screen.   
 
Luciferase assay: The NPPA promoter (-337 to 0 position from the transcription start site as 
previously reported138) was inserted into the pGL3 basic reporter construct multiple cloning site 
using SacI and NheI. Human embryonic kidney cells (HEKs) were grown and maintained in 
Dulbecco’s minimum essential medium supplemented with 10 fetal bovine serum, 1% 
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penicillin/streptomycin, and 1X non-essential amino acids. 20,000 cells per well were plated in a 
96 well plate and transfected 24-hours later using FuGene6. Each well received 4 ng of renilla, 
30 ng of NPPA-luciferase reporter construct, and 30 ng of TBX5 construct. Luciferase assays 
were performed according to Promega Dual Luciferase Assay Kit. The renilla signal was used to 
normalize for transfection efficiency among wells. Experiments were performed in triplicate for 
each condition and results presented are averages from three independent experiments. 
 
Human induced pluripotent stem cell (iPSC) reprograming: Dermal fibroblasts were isolated 
from a 2-mm dermal punch biopsy from consented participants. Fibroblasts from the second 
passage were reprogrammed into iPSCs using electroporation delivery (Neon system) of non-
integrating episomal vectors (Epi5™ Episomal iPSC Reprogramming Kit (ThermoFisher)). After 
episomal delivery, fibroblasts were plated on a standard cell culture grade 10-cm plate. iPSC-like 
colonies were manually moved to hES-grade matrigel (Corning) coated 24-well plates between 
day 14-30 post-electroporation.  Individual colonies were expanded for validation and line 
maintenance. 
 
Human iPSC "stemness" validation: Human iPSC were validated for the presence of stem cell 
associated markers via immunofluorescent detection of OCT4 (Cell Signaling, #2750), SSEA4 
(DSHB, MC-813-70), SSEA3 (Millipore, MAB4303), Tra-1-60 (Millipore, MAB4360). The 
presence of stem cell-associated alkaline phosphatase were detected by commercially available 
colorimetric assay (Stemgent, 00-0055).  
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Human iPSC pluripotency validation: Human iPSCs were grown in suspension on low 
adherence plates in DMEM/F12 w/ GlutamaX (Invitrogen, 10565) supplemented with 20% 
knockout serum replacement (Invitrogen , 10828-028), 1% non-essential amino acids (Sigma, 
M7145), 1% penicillin/streptomycin (MediaTech,15140122). The media was supplemented with 
10 µM Rho kinase inhibitor (Y-27632 , CalBiochem) on day 0 to promote the formation of 
embryoid bodies (EBs). EBs were pelleted by gravity for 10 minutes and media were exchanged 
every 2 days. On day 7 of differentiation, individual EBs were replated on growth factor reduced 
matrigel (Corning) coated glass coverslips for 7-14 days in media listed above. The presence of 
cells in the endoderm, mesoderm, and ectoderm lineages was visualized by immunofluorescent 
detection of proteins associated with each of the three germ layers: GATA4 (Abcam, ab84593) 
for endoderm, α-smooth muscle actin (Abcam, ab7817) for mesoderm, and βIII-tubulin 
(Millipore, MAB1637f) for ectoderm. 
 
Human iPSC chromosomal assessment: Twenty iPSCs were screened for large chromosomal 
abnormalities by commercial karyotype analysis (Genetics Associates, Nashville, TN). 
 
Human iPSC maintenance: Human iPSCs were maintained on growth factor-reduced Matrigel 
(Corning) coated plates (1:200 dilution, DMEM/F12) in mTeSR1 medium (Stemcell 
Technologies). Cells were passaged every 4-5 days using 0.5 mM EDTA (Life Technologies) in 
D-PBS without CaCl2 or MgCl2 (Life Technologies). 10 µM Rho kinase inhibitor (Y-27632, 
CalBiochem) was added for the first 24 hours after passaging. Cells were maintained at 37oC, 
with 5 % CO2 and 20% O2. 
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CRISPR/Cas9 expression vector construction: Guide RNAs (gRNA) were designed using the 
Zhang lab CRISPR design tool (http://crispr.mit.edu/). gRNAs 20 nucleotides in length with a 
low number of predicted coding region off-target sites were selected for insertion into Px459269 
expression system (Addgene). Px459 is an expression vector containing a U6 promoter driven 
gRNA (crRNA tethered to a tracrRNA sequence) and a CMV promoter driven human optimized 
S. pyogenes Cas9. Elements for specific genomic targeting were constructed by the following 
methods. A 25mer oligonucleotide containing the gRNA targeting exon 5 of TBX5 and BbsI 
compatible 5’ overhangs (Forward sequence 5’ – CACCGCCACCCGGGGCGATTGGATG – 
3’; Reverse sequence 5- AAACCATCCAATGCGCCCCGGTGGCC – 3’) was annealed and 
subsequently phosphorylated with T4 polynucleotide kinase. Px459 was linearized using BbsI 
and ligated to the phosphoannealed oligomers in a single reaction. The plasmid was transformed 
in competent cells lines and isolated from bacterial cultures using MAXI preparations. The 
gRNA insertion was confirmed by Sanger sequencing. 
 
Genome modification in patient-derived iPSCs: iPSCs were singularized using 0.5 mM EDTA 
in PBS without CaCl2 and MgCl2 and passed through a 30 micron filter. Ten micrograms of 
gRNA inserted Px459 plasmid and 10 µmoles of 150 base pair single-stranded repair template 
were delivered to 2X106 iPSCs via electroporation (Neon system, ThermoFisher). Post-delivery 
iPSCs were plated on matrigel GFR coated 10-cm plates for expansion of individual clones. 
Clonal colonies were manually passaged to matrigel-coated 24-well plates for expansion. Each 
colony was passaged using 0.5 mM EDTA for line maintenance and DNA extraction. DNA was 
isolated using QuickExtract solution (EpiCentre) for PCR amplification of exon 5 of TBX5. 
Screening of the specific edit was done by NciI digestion as wild-type sequence is selectively cut 
	 107	
by this enzyme and TBX5 c.G433A is not. The editing event in all clones that were screened 
positive by restriction digest was confirmed by Sanger sequencing. 
 
Cas9 off-target analysis: Predicted off-target sites (determined by http://crispr.mit.edu/) were 
amplified by PCR and evaluated by Sanger sequencing. The genomic location, nearest gene, and 
primers used for amplification are presented in Table 10.  
 
Cardiomyocyte differentiation: Human iPSCs were cultured in mTeSR media and split at 1:12-
20 ratios. Cells were grown for 4-5 days to achieve ~80% confluency. This is referred to as day 0 
of differentiation and media was change to cardiac differentiation media supplemented with 6 
µM CHIR99021 (LC Laboratories) for day 0 to day 2. Cardiac differentiation media is comprised 
of RPMI 1640 (11875, Life Technologies), 2% B-27 minus insulin supplement (A1895601, Life 
Technologies), and 1% Pen-Strep (Life Technologies). On day 2 medium was changed to cardiac 
differentiation medium. On day 3 medium was changed to cardiac differentiation medium 
supplemented with 5 µM IWR-1 (Sigma). Cardiac differentiation media was replenished every 
other day. On days 13, 15, and 17 the medium was switch to metabolic selection medium 
consisting of RPMI1640 without glucose (11879, Life Technologies), 2% B-27 minus insulin 
supplement (A1895601, Life Technologies), and 1% Pen-Strep (Life Technologies). On day 19, 
the media was switched to cardiomyocyte media consisting of RPMI 1640 (11875, Life 
Technologies), 2% B-27 supplement (17504, Life Technologies), and 1% Pen-Strep (Life 
Technologies). Cardiomyocyte medium was exchanged every other day until dissociation, 
generally at day 30-35 in these experiments. 
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Cardiomyocyte dissociation: Human iPSC-derived cardiomyocytes (iPSC-CMs) were 
incubated with TrypLE Express (Life Technologies) for 13 min at room temperature to 
dissociate cells. Cardiomyocytes were passed through a 100 micron filter to remove non-
dissociated aggregates and either used immediately for experiments or cryopreserved in 10% 
DMSO, 90% FBS and stored in liquid nitrogen. Human iPSC-CMs were thawed and plated at 
high density on Matrigel growth factor-reduced coated dishes in cardiomyocyte media. Human 
iPSC-CMs were maintained at 5% CO2 and 21% O2 for 4-5 days prior to performing 
experiments.  
 
mRNA Quantification: Total RNA was isolated from iPSC-CM on day 32-35 of differentiation 
using the RNAeasy Mini Kit with DNAse treatment (Qiagen). cDNA was synthesized from 2 µg 
of the RNA by use of the Transcriptor First Strand cDNA Synthesis Kit with random hexamer 
primers (Roche Applied Science, Indianapolis, IL) and used as a template. To generate a 
standard curve for absolute quantification, SCN5A subcloned into the pGEM-T vector (Clontech, 
Mountain View, CA) was used. cDNA and 5 different dilutions of the SCN5A vector were 
prepared with predesigned 6-carboxyfluorescein-labeled fluorogenic TaqMan probe and primers 
(Applied Biosystems) for SCN5A (Hs00165693.m1), TBX5 (Hs01052562) or RPL19 
(Hs02338565.qh) in triplicate in the same 96-well plate for real-time polymerase chain reaction 
amplification. Real-time quantitative RT-PCR was conducted with a 7900HT Real-Time 
Instrument (Applied Biosystems). Data were collected with instrument spectral compensation 
and analyzed by use of absolute quantification and a standard curve with SDS 2.2 software 
(Applied Biosystems). Each value was normalized to that for RPL19. 
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Cell Surface Biotinylation: On day 35 of differentiation iPSC-CMs were washed with room 
temperature PBS without calcium and magnesium and then treated with PBS containing 1.5 
mg/ml sulfo-NHS-LC-biotin (Pierce) at 4 °C for 1 hour. Excess biotin was inactivated and 
removed by a 20-min incubation in 10 mM glycine/PBS at 4 °C and three washes in PBS. The 
cells were lysed in lysis buffer containing (in mM) 10 Tris (pH 7.3), 150 NaCl, 1 EDTA, 1% 
Triton X-100, and 1% sodium deoxycholate and a mixture of mammalian protease inhibitors 
(Roche). Cell lysates were spun at 13,000 × g for 20 min, and the supernatants were incubated 
with streptavidin-coated beads (Pierce) for 1 hour at room temperature. Beads were washed four 
times with lysis buffer and resuspended in Laemelli buffer, boiled, and analyzed by Western 
blot. 
 
Western Blot Analysis: Whole-cell lysates or biotinylated membrane fractions were prepared 
from iPSC-CMs on day 35 of differentiation. Lysates were centrifuged at 10,000g for 5 min, and 
protein content was analyzed with a bicinchoninic acid assay (Pierce Biochemicals, Rockford, 
IL). Proteins (40 to 100 µg) were separated by running the sample on a NuPage 4-20% Tris-HCl 
gel (Invitrogen, Carlsbad, CA). The protein was transferred to PVDF membranes (BioRad, 0.45 
um pore), blocked for 1 hour with 5% nonfat dry milk in 0.1% Tween-20 Tris-buffered saline 
(TTBS) plus at room temperature and then incubated overnight with antibodies targeting SCN5A 
(anti-pan NaV polyclonal antibody, 1:250; Alomone Labs, Israel), βIII-tubulin (1:1,000; Abcam), 
or calnexin (polyclonal antibody, 1:1000, Stressgen Bioreagents, Belgium) at 4oC. Membranes 
were washed 9 times with TTBS for 10-30 min each and incubated with secondary anti-mouse 
and anti-rabbit horseradish peroxidase-linked antibodies (Amersham Biosciences) in TTBS at 
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room temperature for 1hr. The blots were then washed 6 times for 10-30 min each in TTBS, and 
antibody interactions were visualized with the ECL system (Amersham Biosciences). 
 
Whole cell voltage clamp sodium current measurements: Whole-cell voltage clamp 
experiments were conducted at room temperature (22-23°C). To record sodium currents, the 
external solution contained (in mM) NaCl 135, KCl 4.0, MgCl2 1.0, CaCl2 1.8, glucose 10, and 
HEPES 10; the pH was 7.4, adjusted with NaOH. The pipette (intracellular) solution contained 
(mM) NaF 5, CsF 110, CsCl 20, EGTA 10, and HEPES 10; the pH was 7.4, adjusted with CsOH. 
To eliminate L- and T-type inward calcium currents as well as outward potassium currents, 1 
µmol/L nisoldipine, 200 µmol/L NiCl2, and 500 µmol/L 4-aminopyride (4-AP) were added into 
the bath solution. Glass microelectrodes were heat polished to tip resistances of 0.5-2 MΩ. To 
measure sodium current densities, cells were held at -100 mV, and sodium current was elicited 
with a single 50-ms pulse from -100 to +60 mV in 20 mV increments. To measure late sodium 
current, current was averaged in a 3 ms time window (195-198 ms after the pulse) before the 
capacity transient at the end of a 200 ms depolarizing pulse of -30mV from a resting voltage of -
100 mV. Data acquisition was carried out using an Axopatch 200B patch-clamp amplifier and 
pCLAMP version 9.2 software (MDS Inc., Mississauga, Ontario, Canada). Currents were filtered 
at 5 kHz (−3 dB, four-pole Bessel filter) and digitized using an analog-to-digital interface 
(DigiData 1322A, MDS Inc.). To minimize capacitive transients, capacitance and series 
resistance were corrected ~80%. Current magnitudes were normalized to cell size, generated 
from the cell capacitance calculated by Membrane Test (OUT 0) in pClamp 9.2. Clamp protocols 
used are shown on the figures. Electrophysiological data were analyzed using pCLAMP version 
9.2 software and the figures were prepared by using GraphPad Prism6.  
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Whole cell current clamp: In whole cell rupture patch current-clamp mode, action potentials 
from isolated human iPSC-CMs on day 30-35 of differentiation were elicited by injection of a 
brief stimulus current (1–2 nA, 2–6 ms, variable stimulation frequencies). The bath 
(extracellular) solution contained (in mM): NaCl 135, KCl 4.0 , CaCl2 1.8, and MgCl2 1, HEPES 
5, glucose 10, with a pH of 7.4 (adjusted by NaOH). The pipette (intracellular) solution 
contained (in mM): 120 Aspartate-K, 25 KCl, 4 ATP-Na2, 1 MgCl2, 2 Phosphocreatine-Na2, 2 
GTP-Na, 1 CaCl2, 10 EGTA, and 5 HEPES, with a pH of 7.3 (adjusted by KOH). 
Microelectrodes with tip resistances of 3-5 mΩ were used. Twenty successive traces were 
averaged for analysis of action potential durations at 50 and 90% repolarization (APD50 and 
APD90). The short term variability (STV) was calculated using ∑(|APDi+1-APDi|)/[nbeat√2] and 
long term variability (LTV) using ∑(|APDi+1+APDi - (2*APDmean)|)/[nbeat√2].270 The scatter area 
of each cell was calculated assuming the shape of an ellipse using # ∗ STV ∗ LTV.270  
 
Calcium handling: Human iPSC-CMs were incubated with 2 µM Fura-2 AM for 8 minutes at 
room temperature to load the indicator in the cytosol. CMs were washed twice for 10 minutes 
with Tyrode’s solution containing 250 µM probenecid to retain the indicator in the cytosol. A 
minimum of 30 min were allowed for de-esterification before imaging the cells. Fura-2 AM 
loaded Ca transients were recorded during spontaneous beating or 0.2 Hz field stimulation in 2 
mM Ca+2 Tyrode’s solution. For experiments assessing sarcoplasmic reticulum calcium content, 
10 mM caffeine was introduced for 5 seconds. Ca+2 transients were recorded and analyzed using 
commercially available data analysis software (IonOptix, IonWizardTM Milton, MA). For each 
cell and each experimental condition, tau (τ), amplitude and baseline values were averaged. All 
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experiments were conducted at room temperature. Tyrode’s solution containing (in mM): CaCl2 
5, NaCl 134, KCl 5.4, MgCl2 1, glucose 10, and HEPES 10, pH adjusted to 7.4 with NaOH. 
 
Human iPSC-CM monolayer extracellular field potential: Day 30 iPSC-CMs were plated at 
65,000 cells/well on 1:100 Matrigel coated 96-well plates. After 5 days of acclimation, plates were loaded 
on a CardioExcyte-96 (Nanion) for acquisition of extracellular field potential. Measurements were 
acquired at 37⁰C, 80% humidity, and 5% CO2 at a sampling rate of 1ms. Data were exported and 
converted to text files for compatibility on LabChart 6 (ADI). Utilizing the peak analysis tool, peak 
detection threshold was set to identify duration of beat rate as well as field potential duration (FPDmax). 
Beat rate was calculated by identifying duration of interspike intervals as defined by time between 
adjacent sodium spikes. FPDmax was calculated by measuring the duration between the most positive 
deflection of the sodium spike to the peak of the repolarization wave. Analyses were performed on 30 
seconds of EFP recordings to produce ~40 measurements per well for both parameters. Measurements 
were averaged and denoted as FPDmax. 
 
RNA-sequencing: Total RNA was isolated from iPSC-CM on day 32-35 of differentiation using 
the RNAeasy Mini Kit with DNAse treatment (Qiagen). Total RNA quality was assessed using 
the 2100 Bioanalyzer (Agilent). rRNA-depleted libraries were generated using TruSeq Total 
RNA sample kits with indexed adaptors (Illumina). Library quality was assessed using the 2100 
Bioanalyzer (Agilent) and libraries were quantitated using KAPA Library Quantification Kits 
(KAPA Biosystems). Pooled libraries were subjected to 75 bp paired-end sequencing according 
to the manufacturer’s protocol (Illumina HiSeq3000). Bcl2fastq2 Conversion Software 
(Illumina) was used to generate de-multiplexed Fastq files. The short-read sequence files 
generated by Illumina's CASAVA pipeline were processed by FastQC 
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(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  Low mean base-call quality scores 
well below pred-like values of 30 in the first 5 and last 4 positions of all samples prompted hard 
trimming of the reads.   The sequence files were then aligned to human assembly build GRCh38 
using the Tophat2 splice junction mapper (http://ccb.jhu.edu/software/tophat/index.shtml).  
Transcripts were assembled by and differential expression analysis was performed with 
Cufflinks (http://cole-trapnell-lab.github.io/cufflinks/) using the bias-correction.  All non-coding 
RNA features were masked and RefSeq gene annotation was provided to the algorithm to allow 
for quantification of known transcript isoforms.  Cuffdiff was run twice to test for pairwise 
differential expression between all individual samples as well as between sample groups.  Gene 
level expression tests flagged as “NOTEST” or “HIDATA” were excluded from further 
analysis.  Normalized expression values were databased and plotted using CummeRbund 
(http://compbio.mit.edu/cummeRbund/). For variant calling of RNA-seq data, short reads were 
aligned using the 2-pass method from the STAR RNA-seq aligner 
(http://bioinformatics.oxfordjournals.org/content/early/2012/10/25/bioinformatics.bts635).  
Duplicate reads were flagged, and alignments with CIGAR strings containing “N” were 
split and trimmed of intronic overlaps.  GATK was then used for base-call quality score 
recalibration, variant calling, and hard filtering using the following thresholds: 3+ SNP clusters in 
35bp windows; FS>30; QD<2.0.  
 
Statistical analyses: Data are mean ± SEM unless otherwise indicated. Statistical differences 
among two groups were tested with two-tailed Student’s t test or Whitney Manning test for 
nonparametric comparisons. Statistical differences among more than two groups were assessed 
using one-way ANOVA followed by post-hoc Bonferroni correction. Results were considered 
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statistically significant if the p-value was less than 0.05. Statistical analysis was performed using 
GraphPad Prism 6. Please refer to RNA-seq methods for statistics related this experimental 
approach.  
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RESULTS 
 
Clinical presentation of Brugada syndrome and TBX5 genotyping 
A male patient was diagnosed with Brugada syndrome during evaluation for a near 
syncopal episode at the age of 12 based on a characteristic ECG pattern of ST elevation in the 
right precordial leads (Fig 21A). Sequencing of the coding and flanking intronic regions of 
known BrS-associated genes failed to find rare non-synonymous variants. Through a 
collaborative effort, a novel and rare missense variant in the gene encoding the cardiac 
transcription factor TBX5 (c.G433A; p.G145R) was identified in the proband and predicted to be 
deleterious by the consensus classifier PredictSNP.107,153 Subsequent genotyping and clinical 
screening for the Brugada syndrome identified multiple family members who harbor the TBX5 
variant and were later diagnosed with BrS due to a type I ECG patterns present at baseline or 
after flecainide challenge (Fig 21B and 21C). All individuals in this pedigree diagnosed with 
BrS carry the TBX5 variant while a single individual is a phenotypically-normal carrier. 
Accordingly, we hypothesized that TBX5G145R/WT causes BrS in this family. 
TBX5-G145R decreases DNA binding and transcriptional activation 
Modeling based on the crystal structure of wild-type TBX5 (TBX5-WT) bound to the 
NPPA promoter126 predicts TBX5-G145R is a destabilizing variant likely to alter protein 
function (Fig 22A), consistent with the PredictSNP prediction.153 To evaluate if the identified 
TBX5 variant impacts protein function, we tested the impact of the glycine to arginine amino acid 
change at amino acid position 145 on DNA binding and transcriptional activation. Expression of 
TBX5 was not impacted by presence of missense variants as determined by Western blot  
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Figure 21 Familial Brugada syndrome-associated TBX5 variant. (A) Representative Type I 
Brugada syndrome ECG pattern of affected family member. Red arrows highlight ST segment 
elevation in right precordial leads. (B) Sanger sequencing confirmation of hypothesized risk 
allele TBX5 c.G433A (C) Genotype of TBX5 variant listed below individuals in pedigree. Red 
letters signify risk allele. Arrow indicates proband. Filled shapes indicate clinically diagnosed 
BrS. Asterisk indicates iPSC participant. (D) X-ray evaluation of hand pathology found 
hypoplastic thenar musculature. Prior surgical scaphotrapezial fusion of the right wrist was also 
evident. White arrows highlight hypoplastic musculature. PA = posteroanterior view. 
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approaches (Fig 2B). We performed an electrophoretic mobility shift assay (ESMA) to test DNA 
binding capacity using the previously described TBX5 binding site present in the NPPA 
promoter.115,137,138 In EMSA experiments, incubation of in vitro translated TBX5-G145R from 
rabbit reticulocyte lysate with radiolabeled NPPA promoter sequence resulted in 2.3±0.4% (n=3 
experiments) of the amount of shifted complex compared to wild-type protein (Fig 22C). TBX5-
G80R is a known complete loss of function mutation at a position critical for TBX5 binding the 
major groove of DNA.122,126,271 While TBX5-G145R maintained some capacity to bind specific 
DNA targets; TBX5-G80R generated no detectable complex formation in EMSAs (Fig 22C). 
We assessed the functional impact of TBX5-G145R on transcriptional activation using a NPPA-
luciferase reporter assay. TBX5 (wild-type, G145R, or G80R) was co-transfected with the 
reporter construct in human embryonic kidney cells (HEKs). Cells transfected with TBX5-
G145R had 37% the luciferase activity of wild-type TBX5 while TBX5-G80R had similar 
activity to a no TBX5 control condition (Fig 22D). Based on these biochemical assays of DNA 
binding and transcriptional activation, TBX5-G145R is a partial loss of function variant. 
TBX5-G145R causes subtle features of Holt-Oram syndrome 
Loss of function variants in TBX5 commonly cause the human condition Holt-Oram 
syndrome (HOS) defined by upper limb abnormalities and, in a subset of patients, heart 
pathology. While malformation of the upper extremities in the individual is required for the 
diagnosis of HOS, the heart involvement can either be present in the individual and/or through 
family history of heart malformations or cardiac conduction disease.272 After determining TBX5-
G145R is a partial loss of function variant, we evaluated the TBX5 c.G433A carriers for HOS 
clinical phenotypes of structural abnormalities of the hands and heart by X-ray and 
echocardiography, respectively. No evaluated family members had structural alterations in the 
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Figure 22. TBX5-G145R impairs DNA binding and transcriptional regulation. (A) Rosetta 
modeling predicted TBX5-G145R destabilizes protein-DNA interactions. Grey indicates 
published wild-type TBX5 bound to NPPA promoter. Yellow indicates predicted TBX5-G145R 
structure. Modeling done in collaboration with Brett Kroncke, PhD. (B) Wild-type and mutant 
TBX5 (65 kDa) are expressed at similar levels (n=3 experiments). kDa = kiloDaltons. (C) 
Electrophoretic mobility shift assay demonstrated TBX5-G145R has reduced DNA binding 
capacity compared to wild-type protein. TBX5-G80R included as loss of function control 
variant. (D) TBX5-G145R had reduced luciferase activity compared to WT.  
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heart, although the family reports atrial and ventricular septal defects in the extended family.    
X-ray analysis of one family member identified bilateral hypoplasia of the thenar musculature 
confirming a diagnosis of HOS. Also observed on X-ray was prior surgical fusion along the 
radial aspect of the right wrist, performed for treatment of scaphotrapezial arthritis, and all other 
bones of the hand were evaluated as normal (Fig 21D). It is unknown if the scaphotrapezial 
fusion was related to mal-development of the hand or an unrelated pathology. Thenar muscular 
hypoplasia has been reported as a variable manifestation of HOS.273 The extent of reduced DNA 
binding and transcriptional activation of TBX5-G145R is consistent with other TBX5 variants 
identified in HOS274 but the family pedigree presented here is the first implication of TBX5 in 
BrS pathogenesis.  
Generation of a human iPSC-CM model of BrS 
In order to study TBX5-G145R in the context of a human cardiomyocyte, dermal 
fibroblasts were isolated from a 26-year old woman from the described family diagnosed with 
BrS who carries the TBX5 variant (asterisk in Fig 21C). Using non-integrating episomal 
expression vectors to transiently express reprogramming factors, we established multiple induced 
pluripotent stem cell (iPSC) clones. Each line expressed stem cell-associated proteins OCT4, 
SSEA3, and alkaline phosphatase (Fig 23A). Non-directed differentiation of iPSCs using 
embryoid body protocols generated cells of each of the three germ layers, establishing 
pluripotency characteristics (Fig 23B). All reprogrammed and validated lines tested were capable 
of differentiation through chemical modulation of Wnt signaling to cardiomyocyte lineage (Fig 
23C). Lastly, the cells that acquired large chromosomal abnormalities during the process of 
reprograming from dermal fibroblasts to iPSCs were excluded from further studies (Fig 23D and 
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Figure 23. iPSC generation and validation. (A) iPSC colony express stem cell-associated 
proteins (B) Embryoid body differentiation to three germ layers demonstrates iPSC pluripotency: 
endoderm (GATA4), mesoderm (α-SMA), ectoderm (β3-tubulin). Scale bars = 50 microns. (C) 
All lines studied efficiently differentiate to cardiomyocytes (marked by α-actinin). (D) Multiple 
iPSC clones were identified that maintained a normal karyotype from each donor. (E) iPSC 
clones determined to have abnormal karyotypes were removed from the study. Black arrowheads 
indicate representative abnormalities.  
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23E). iPSCs were also generated and validated from somatic cells obtained from four population 
control donors. 
TBX5 variant correction in patient-derived iPSCs 
To directly test if TBX5-G145R caused the BrS phenotype, we edited the TBX5 c.G433A 
missense variant back to the reference sequence using the RNA-guided Cas9 nuclease system. 
Genome targeting occurs through gRNA binding through complementation to specific DNA 
sequences.275 The Cas9 protein scans the genome by pausing at defined trinucleotide sequences, 
known as the PAM, and, when adjacent to gRNA-DNA, hybridizes to induce a conformation 
change in Cas9 exposing the active nuclease domains.276,277 Cas9 derived from S. pyogenes uses 
a PAM sequence of NGG, where N can be any nucleotide. The Cas9 conformational change 
leads to the generation of a double strand break five base pairs away from the PAM site. Specific 
modifications to the genome can be achieved when active Cas9 is delivered in the presence of 
excess repair template to promote homology-directed repair (HDR; Fig 24A). This approach was 
carried out in patient-derived iPSCs and plated for clonal screening. PCR amplicons of genomic 
DNA containing the wild-type sequence of TBX5 is selectively digested with the restriction 
enzyme NciI and this difference in restriction site between wildtype and G145R was utilized to 
screen for edited cells. Targeting exon5 of TBX5 with CRISPR/Cas9 repaired the missense 
variant present in familial BrS with HDR efficiency of 30% (Fig 24B). Initial efforts used a 
template that attempted to generate a single nucleotide change to correct only TBX5 c.G433A but 
all clones that screened positive by restriction digest contained secondary insertion/deletion 
(indel) variants due to repeat targeting of Cas9. As long as Cas9 is expressed and gRNA is 
present, the nuclease activity remains active due to the maintained presence of the PAM site. 
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Figure 24. TBX5 variant correction in patient-derived iPSCs. (A) Schematic of genome 
editing approach using CRISPR/Cas9 in patient-derived iPSCs. Risk single nucleotide variant 
indicated as red text. Purple letters indicate nucleotide changes in repair template. Arrow head 
indicates cut site by Cas9. The black box indicates the protospacer adjacent motif (PAM). (B) 
NciI restriction digest of 400 bp TBX5 PCR product. The NciI cut site is present in wild-type 
sequence but not c.G433A. A yellow star indicates TBX5 edited to homozygous wild-type 
sequence. Unlabeled lanes indicate iPSCs heterozygous for G145R. (C) Sanger sequencing of 
PCR amplified exon 5 of TBX5 unedited (upper panel) and edited to reference sequence (lower 
panel). Red box indicates c.433 and the purple box indicates c.449.   
 	  
Figure 22 TBX5 variant correction in patient-derived iPSCs.
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Therefore, repeat efforts introduced two nucleotide alterations in the repair template, correction 
of the TBX5 variant and a silent SNV that disrupted the PAM sequence. This approach 
successfully prevented retargeting by Cas9 to generate multiple subclones with the two 
nucleotide changes that repair TBX5 c.G433A (p.G145R) and disrupt the PAM site (c.G449A; 
p.R150R) (Fig 24A and 24C). Nonspecific genomic changes due to off-target Cas9 activity were 
evaluated by Sanger sequencing of in silico determined potential off-target sequences (Table 
10). 
TBX5-G145R containing iPSC-CMs recapitulate the BrS phenotype of reduced sodium 
channel expression and current  
Reduced sodium current is the most common mechanism of inherited BrS due to reduced 
channel expression or loss of function variants in SCN5A or genes encoding NaV1.5-associated 
proteins. We first tested the hypothesis that TBX5-G145R causes reduced sodium channel 
expression and thus the BrS phenotype in the study family. Population controls were used to 
define “normal” levels of sodium channel transcript and protein. Isogenic controls generated by 
genome editing with Cas9 directly tested the changes in sodium channel expression compared to 
TBX5G145R/WT iPSC-CMs. TBX5G145R/WT iPSC-CMs have significantly reduced levels of SCN5A 
transcript while expression of TBX5 is unchanged compared to both population and isogenic 
controls (P<0.05; Fig 25A). Expression of SCN5A or TBX5 is not significantly different between 
population and isogenic control groups. To confirm the mRNA quantification reflects the actual 
amount of sodium channel at the cell surface, we performed biotinylation experiments to semi-
quantitatively compare the amount of voltage-gated sodium channel present in each group.  
Similar to the transcript level analysis, TBX5G145R/WT iPSC-CMs have approximately half of the 
amount of NaV1.5 protein in whole-cell lysate and membrane-associated fraction (Fig 25B). 
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Table 10. In silico predicted CRISPR/Cas9 off-target sites. 
Potential off-target complementation 
Number of 
mismatches 
[variable nucleotide] 
Genomic 
position Forward sequencing primer Reverse sequencing primer 
CCACTGGTGCACATTGGATGCGG 3MMs [5:8:11] chr16:-30100319 GAGGCCCGCTACTTGTTTCT GGTGAGCTTGACACGATGGA 
CCCCGGGGAGGCATTGGATGGGG 4MMs [3:5:9:10] chr11:+119599131 CAGCTGACCTGGATCCTTCG CAAGCCGTGACCCAACTTTT 
CCACAGGCGCACCTTGGATGTGG 4MMs [5:8:11:13] chr17:-72345473 AACGTCTCCTACCACATCGC AAGGTGGGGTTGGGAAATCG 
CCCCGGGGGCTCATGGGATGTGG 4MMs [3:5:11:15] chr1:-203830934 TCAGGACTAGGAGGTTCGGG GTCCATTCCTGCATTCCCCA 
CCAAGGGCGCGCAGTGGATGAAG 4MMs [4:5:8:14] chr22:+19751765 ACAGGGTGTCCAGTTCCTTG TTCTACAGGCCTCTTAGGGACA 
CCACTGGGGCCTATTGGATTTGG 4MMs [5:11:12:20] chr2:-31412447 GCAGATGACCTAACCCGTCT ACCCTGAGGACGAACTCTGA 
CCGCCGGCGCTCATTGGCTGGGG 4MMs [3:8:11:18] chr11:-134201815 CTGCAGGCGCGGAGC AGCTCCCAGAAAGAAGCAGC 
CCACAGGAGCCCACTGGATGCGG 4MMs [5:8:11:14] chr17:+59544934 GGTGGGACCAGCAGCTATTT CCCGGAGTGGATTCTCCCTA 
CCACCGTAGCACATTGGTTGTAG 4MMs [7:8:11:18] chr11:+14901717 TGGATTGGCATCCTGCCTTT TATACTTGGCTGGCATCGCA 
CCACGGGGGCACATTGGCAGGGG 4MMs [5:11:18:19] chr16:-89265840 GGATGAAGGTTGGACCCTGG AGGGTACTCACGAGCCAGAT 
CCACCGGGGTGGCGTGGATGGGG 4MMs [10:12:13:14] chr7:+134931463 GACTGGCAGCGGGATCATTA CTGCACCTCCAACCTGCTAA 
CCACCGTGGCACATGGGGTGAGG 4MMs [7:11:15:18] chr7:+5519995 GACATCCTCCTGGCATCTGAG GCAAGGAGCTGCTGAAAACC 
CCACCTGGGCGCGCTGGGTGAGG 4MMs [6:13:14:18] chr16:-30596717 TCTCCCGAGGAGTGGGAATG ACGGGAGGGGAGAATGAGAC 
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To evaluate the effect of reduced sodium channel expression on the generation of sodium 
current, we performed whole cell voltage-clamp experiments after 35 days of differentiation. The 
result paralleled the mRNA result in that TBX5G145R/WT iPSC-CMs displayed ~50% reduced 
peak sodium current (-97±35 pA/pF) compared to the control groups (population: -211±36; 
isogenic: -213±38) for a test voltage of -30mV (P<0.05; Fig 25C and 25D). TBX5-G145R cells 
demonstrate the electrophysiologic hallmark of BrS, reduced sodium current, and in this instance 
the reduction is attributable to reduced SCN5A expression without altering the kinetics of 
channel activation, consistent with murine heterozygous germline Scn5a knockout models (Fig 
25E).73,74 However, the comparison of population controls and TBX5-G145R cells did not 
establish that the mutation causes the phenotype.  It is the result of the genomic editing 
experiment, showing reversal of the transcriptional and electrophysiologic defect, that proves 
that TBX5-G145R is the cause of the functional defect, and thus the BrS phenotype, in this 
family.   
Unexpected arrhythmogenic late sodium current and APD lability in patient-derived iPSC-
CMs are caused by TBX5-G145R 
SCN5A-associated Long QT Syndrome mutations generate a persistent (“late”) sodium 
current (INa-L) usually through defective fast inactivation.46 Some SCN5A mutations, such as 
E1784K and 1795insD in the cytoplasmic c-terminus, result in overlap BrS and Long QT type 3 
(LQT3) syndromes, characterized by both decreased peak current and increased late 
current.278,279 Interestingly and unexpectedly, TBX5G145R/WT iPSC-CMs had increased INa-L 
measured at the end of a 200-msec test pulse (-30 mV) that was not appreciably measured in any 
of the population control lines studied (Fig 26C and 26D). Treatment of TBX5G145R/WT iPSC-
CMs with 3 µM ranolazine, the late sodium current blocker, completely eliminated INa-L 
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Figure 25. BrS iPSC-CM have reduced sodium channel expression and current density. (A) 
TBX G145R iPSCs have reduced mRNA levels of SCN5A normalized to RPL19 transcript, and 
this is corrected by Cas9-mediated correction of the mutation. (B) Western blot analysis of 
membrane-associated sodium channel demonstrates TBX5-G145 variant causes reduced protein 
expression. (C) Representative whole cell voltage clamp recordings at voltage steps from -100 to 
20 mV in 10 mV increments. (D) BrS iPSC-CMs have decreased sodium current density 
compared population and isogenic controls. (E) Steady-state activation kinetics were unaltered 
by TBX5-G145R. Ctr = control. 	  
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 (Fig 26C and 26D).280 The INa-L phenotype is caused by the heterozygous TBX5-G145R variant 
as it was also abolished with genomic editing of the variant back to the reference sequence.    
A published iPSC-CM model of LQT3 recapitulates the cellular LQTS phenotype of 
prolonged action potential duration (APD) and arrhythmogenic afterdepolarizations.266 
Accordingly, we recorded action potentials in whole-cell current clamp experiments. The 
presence of TBX5-G145R did not alter resting membrane potential or action potential amplitude 
(Fig 27A), but did prolong time to 90% repolarization (APD90) (Fig 27B).281 Early 
afterdepolarizations were observed in TBX5G145R/WT iPSC-CMs (12% of cells) but were not 
found in any cell studied from either control group or after exposure to 3 µM ranolazine (Fig 
27C).  
In healthy stem cell-derived cardiomyocytes, the APD from beat-to-beat is largely 
consistent (Fig 27D).282 As demonstrated by superimposing 20 action potentials recorded from a 
single iPSC-CM, iPSC-CMs containing the TBX5 variant have significant APD heterogeneity 
that is completely resolved by pharmacologic blockade of INa-L with ranolazine or with genomic 
correction of TBX5-G145R (Fig 27D). Poincaré plots, the duration of one action potential 
(APDn) plotted against the APD of the subsequent beat (APDn+1), provide a graphical 
representation of APD variability and permit quantitative assessment of short term variability 
(STV), long term variability (LTV), and the area of plotted points for a single cell.283 STV and 
LTV terms were similar between population and isogenic controls and significantly increased in 
TBX5G145R/WT iPSC-CMs (Table 11).  Block of INa-L with ranolazine prevented APD variability 
in myocytes containing TBX5-G145R supporting late sodium current as a mechanism of APD 
lability. Other studies have demonstrated that chemical enhancement of INa-L with ATX-II or 
veratridine in canine ventricular cardiomyocytes increased STV and APD90.284 Our findings 
	 128	
 
 
Figure 26. BrS iPSC-CM have increased late sodium current. (A) Representative sodium 
current recordings highlighting late current. (B) Increased late current is caused by TBX5 
c.G433A and selectively blocked by 3 µM ranolazine (n=7-8 per group). Ctr = control. Data 
collected in collaboration with Tao Yang, PhD. 	  
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Figure 27. Arrhythmogenic changes in cardiac action potential in TBX5-G145R containing 
iPSC-CMs. (A) Population control, isogenic control, and TBX5G145R/WT iPSC-CMs have similar 
resting membrane potential (RMP) and action potential amplitude (APA) (B) TBX5-G145R 
containing iPSC-CM have prolonged APD90 but not APD50. (C) Early afterdepolarizations were 
observed in TBX5-G145R containing iPSC-CM but not in population or isogenic control cells. 
(D) Superimposed action potentials demonstrate APD variability caused by TBX5-G145R. (E) 
Representative Poincaré plots comparing the APD of each beat (APDN) to subsequent beat APD 
(APDN+1). See table 11 for summative data. All recorded action potential were stimulated at 1 
Hz. Ctr = control. Data collected in collaboration with Tao Yang, PhD. 
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provide further evidence that inward sodium current is a driving ionic mechanism of APD 
variability. 
Calcium handling is not impacted by TBX5-G145R 
 An alternative mechanism of afterdepolarization generation is inappropriate calcium 
release from the sarcoplasmic reticulum. We used the calcium indicator dye Fura-2AM to 
interrogate the impact of TBX5-G145R on calcium handling properties of cardiomyocytes. 
TBX5G145R/WT iPSC-CMs have similar levels of diastolic calcium levels compared to control 
groups (Table 12). When pacing at 0.2 Hz, TBX5 variant containing myocytes were capable of 
capturing pacing stimuli in 43% of cells studied compared to 78% across multiple control lines 
analyzed, consistent with descriptions of decreased cardiomyocyte excitability due to reduced 
sodium current.285 Of cells that were capable of stimulus capture, the amount of calcium released 
during each beat, determined by peak height, and kinetics of calcium removal from the 
cytoplasm was unchanged in TBX5G145R/WT iPSC-CMs (Fig 28A and Table 12). Total 
sarcoplasmic reticulum (SR) calcium was evaluated by perfusing 10 mM caffeine over the cell to 
fully unload the SR. This showed that calcium loading into the SR was not impacted by TBX5-
G145R based on peak height after caffeine exposure (Table 12). The calcium imaging 
experiments also highlighted the arrhythmogenic nature of TBX5G145R/WT iPSC-CMs as triggered  
beats were observed in 8.3% of cells studied during the repolarization phase of the excitation-
contraction cycle and at times degenerated into a tachycardic pattern (Fig 28B). 
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Table 11. Poincaré analysis of single iPSC-CM APD. 
Group STV LTV STV:LTV Scatter area (msec2) 
Population control 3.21±0.65 4.22±0.82 0.78±0.08 50.85±15.36 
TBX5G145R/WT 16.42±3.0* 27.93±5.71* 0.71±0.13 1567.0±377.3* 
TBX5G145R/WT +ranolazine  2.81±0.78 3.09±1.04 1.0±0.11 45.59±24.37 
Isogenic control 8.05±1.83 8.35±1.98 0.97±0.09 276.0±123.4 
 *		P<0.05	compared	to	all	other	groups	studied.	 	
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Figure 28. TBX5-G145R iPSC-CMs reduced capture efficiency and arrhythmia activity by 
calcium evaluation. (A) Representative calcium transients of iPSC-CM with 1:1 capture 
recorded at 0.2Hz pacing rate. See Table 12 for summative data. (B) TBX5-G145R containing 
iPSC-CMs display single (red asterisks) and multiple afterdepolarizations (red line). Data 
collected in collaboration with Kyunsoo Kim, PhD and Bjorn Knollmann, MD, PhD. 	  
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Table 12. Calcium handling properties in TBX5G145R/WT iPSC-CMs. 
 Population ctr TBX5G145R/WT Isogenic ctr 
n 30 12 8 
Calcium transient height (Fratio) 1.19 ± 0.02 1.11 ± 0.10 0.76 ± 0.10 
Calcium transient t10 (s) 0.21  ± 0.02 0.17 ± 0.2 0.26 ± 0.05 
Calcium transient t50 (s) 0.95 ± 0.06 0.85 ± 0.7 1.06 ± 0.13 
Calcium transient t90 (s) 2.60 ± 0.11 2.46 ± 0.15 2.82 ± 0.27 
Calcium transient decay rate (s) 1.52 ± 0.11 1.21 ± 0.07 1.55 ± 0.22 
SR calcium content (Fratio) 1.21 ± 0.08 1.17 ± 0.09 1.46 ± 0.19 
 
Ctr = control 
SR = sarcoplasmic reticulum 
No significant difference among groups for all parameters. Data analyzed using one-way 
ANOVA with Bonferroni post-test. 
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Tissue-level model of TBX5-G145R containing cardiomyocytes exhibit arrhythmogenic 
features observed in single-cell assays 
The arrhythmogenic features of increased INa-L and APD variability caused by TBX5-
G145R were observed in assays evaluating function of single cardiomyocytes. APD variability is 
reduced in the tissue context of the whole heart or cardiomyocyte monolayers.286 Therefore, to 
probe the impact of the single-cell arrhythmogenic phenotype in a tissue context, we assayed the 
electrical properties of spontaneously beating monolayers of iPSC-CMs using extracellular field 
potentials (EFPs; Nanion technologies). Endogenous beat rate, beat-to-beat variability, and 
detection of arrhythmogenic afterdepolarizations can be evaluated using EFP analysis.287 
Population and isogenic controls groups had rapid beat rates of 100 beats/min that occurred at 
regular intervals (Fig 29A). Poincaré plots displayed similar findings to single cell assays of 
manual patch-clamp experiments as TBX5G145R/WT iPSC-CM monolayers had larger STV and 
APD variability, both of which were significantly reduced by 3 µM ranolazine (Fig 29C and 
Table 13). Additionally, monolayers of TBX5G145R/WT iPSC-CMs also exhibited arrhythmic 
behaviors of triggered afterdepolarizations (Fig 29B). This monolayer assay evaluated the 
cumulative alteration in electrical behavior in 65,000 iPSC-CMs and dampened the inherent 
limitation of cell-to-cell heterogeneity frequently described in iPSC-CMs.  
Discrete transcriptional changes in TBX5-G145R relative to iPSC-CMs with TBX5 
heterozygous deletion 
Genomic editing in patient-derived iPSCs provided strong evidence that TBX5-G145R 
causes reduced sodium channel expression and current in this family. Further, by generating and 
modifying these lines, we found that TBX5-G145R unexpectedly resulted in arrhythmogenic  
 
	 135	
 
Figure 29. TBX5-G145R containing iPSC-CM monolayers have arrhythmogenic features 
observed at single-cell level. (A) Representative extracellular field potentials recorded from 
isogenic controls and TBX5G145R/WT iPSC-CM monolayers. (B) TBX5G145R/WT iPSC-CM 
monolayers display afterdepolarizations (red asterisks). (C) Representative Poincaré plots 
comparing the FPD of each beat to the FPD of the subsequent beat. See Table 13 for summative 
data. All recordings are of spontaneous activity. Data collected in collaboration with Shan Parikh 
and Bjorn Knollmann, MD, PhD. 
 
Figure 29 TBX5- 45R containing iPSC-CM monolayers have
arrhythmogenic features observed at single-cell level. (a)
Representative extracellular field potential of iPSC-CM isogenic and
TBX5G145R/WT iPSC-CMs. (b) TBX5-G145R conta ing iPSC-CMs display
afterdep larizations (red asterisks). (c) Representative Poincare plots
comparing the FPD of each beat to the FPD of the subsequent beat. See
table 13 for summative data. All recordings are of spontaneous activity.
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Table 13. Poincaré analysis of iPSC-CM monolayer FPD. 
 
Group STV LTV STV:LTV Scatter area (msec2) 
Population control 4.04±0.77 4.40±1.02 0.99±0.06 96.3±46.8 
TBX5G145R/WT 11.25±2.13* 12.86±2.78* 0.91±0.06 640±229* 
TBX5G145R/WT +ranolazine  4.66±0.71 5.29±0.65 0.87±0.73 82.7±22.0 
Isogenic control 6.51±0.69 6.04±0.66 1.10±0.06 141±31.6 
 
*  P<0.05 compared to all other groups studied. 	  
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features (increased INa-L and APD variability). TBX5 loss of function variants, mostly nonsense 
or frameshifting indel mutations that lead to haploinsufficiency, typically cause Holt-Oram 
syndrome, with severe cardiac and upper limb structural birth defects,272 but the arrhythmogenic 
features caused by TBX5-G145R are not described in HOS.  One question raised by these 
findings is why does TBX-G145R, unlike usual HOS variants, lead to a prominent arrhythmia 
phenotype with a structurally normal heart? One possibility is that the missense variant causes a 
mild, or perhaps even subclinical, manifestation of Holt-Oram syndrome (e.g. the thenar 
abnormality seen in Fig 21D) and overt Brugada syndrome compared to other TBX5 variants that 
cause more typical HOS presentations. This hypothesis would predict that the transcriptional 
consequences of the TBX5-G145R variant diverge from those with a more typical HOS variant. 
RNA transcription in a cell is highly regulated and genetic variation that alters 
transcription factor function can have a large impact on the transcriptome. To compare the 
transcriptional consequences of TBX5-G145R to a more typical HOS variant, we took advantage 
of the error prone mode of double-stranded DNA break repair, non-homologous end joining 
(NHEJ)288 to generate TBX5 heterozygous knockout lines.  We transiently expressed Cas9 and a 
gRNA targeting exon 5 of TBX5 without a repair template in 2X106 iPSCs. We sequenced and 
identified three clones containing unique heterozygous frameshifting indels in isogenic controls 
(TBX5-/ WT; Fig 30A-C). The three clones have either a deletion of 16-bp, a deletion of 22-bp, or 
an insertion of 1-bp. These TBX5-/ WT lines change the amino acid sequence between position 
144 and 148 with all clones having a resultant premature stop codon between amino acid 166 and 
182 (Fig 31). A similar one base pair deletion has been described in HOS altering the amino acid 
sequence beginning at position 138 and a premature stop codon at position 148.289 We have 
generated the first HOS iPSC-CM model allowing us to compare changes in transcription in the  
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Figure 30. iPSC model of Holt-Oram syndrome. (A) Allele-specific sequencing of frame-
shifting heterozygous 16-bp deletion. (B) Allele-specific sequencing of frame-shifting 
heterozygous 22-bp deletion. (C) Allele-specific sequencing of frame-shifting heterozygous 1-bp 
insertion. 	  
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Figure 28 iPSC model of Holt-Oram syndrome. (a) Allele-specific
sequencing of frame-shifting heterozygous 16-bp deletion (b) Allele-
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Figure 31. Predicted amino acid sequence in TBX5 heterozygous deletion model.   
  
1     MADADEGFGLAHTPLEPDAKDLPCDSKPESALGAPSKSPSSPQAAFTQQGMEGIKVFLHE
1     MADADEGFGLAHTPLEPDAKDLPCDSKPESALGAPSKSPSSPQAAFTQQGMEGIKVFLHE
1     MADADEGFGLAHTPLEPDAKDLPCDSKPESALGAPSKSPSSPQAAFTQQGMEGIKVFLHE
1     MADADEGFGLAHTPLEPDAKDLPCDSKPESALGAPSKSPSSPQAAFTQQGMEGIKVFLHE
61    RELWLKFHEVGTEMIITKAGRRMFPSYKVKVTGLNPKTKYILLMDIVPADDHRYKFADNK
61    RELWLKFHEVGTEMIITKAGRRMFPSYKVKVTGLNPKTKYILLMDIVPADDHRYKFADNK
61    RELWLKFHEVGTEMIITKAGRRMFPSYKVKVTGLNPKTKYILLMDIVPADDHRYKFADNK
61    RELWLKFHEVGTEMIITKAGRRMFPSYKVKVTGLNPKTKYILLMDIVPADDHRYKFADNK
121   WSVTGKAEPAMPGRLYVHPDSPATGAHWMRQLVSFQKLKLTNNHLDPFGHIILNSMHKYQ
121   WSVTGKAEPAMPGRLYVHPDSPATGAHWPSRNSSSPTTTWTHLGILF-------------
121   WSVTGKAEPAMPGRLYVHPDSPATSSPSRNSSSPTTTWTHLGILF---------------
121   WSVTGKAEPAMPGRLYVHPDSPATGAHWDEAARLLPETQAHQQPPGPIWAYYSKFHAQIP
181   PRLHIVKADENNGFGSKNTAFCTHVFPETAFIAVTSYQNHKITQLKIENNPFAKGF....512
181   --------------------------------------------------------
181   --------------------------------------------------------
181 P-------------------------------------------------------
Wild-type amino acid sequence
16-bp deletion amino acid sequence
22-bp deletion amino acid sequence
1-bp insertion amino acid sequence
Change in amino acid sequence from wild-type
Figure	31.	Predicted	amino	acid	sequence	in	TBX5	heteroygous deletion	model		
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 G145R missense variant found in BrS compared to TBX5 heterozygous knockout.  
In mice, homozygous germline deletion of Tbx5 is embryonic lethal.143 Through the 
generation of the iPSC lines with heterozygous deletion of TBX5, we also created lines with 
homozygous indels in the gene. It was our observation that homozygous indels in TBX5 render 
human iPSCs incapable of differentiation into cardiomyocytes. This is in contrast to a recent 
report using a mouse ESC-CM model possessing a homozygous deletion of Tbx5.290 As an 
additional comparison group, we also generated lines that are homozygous for the missense 
variant (TBX5G145R/G145R) using the same HDR targeting approach that created isogenic controls 
(Fig 24). Surprisingly, all TBX5G145R/G145R lines created were capable of differentiation into 
cardiomyocytes, supporting the findings of biochemical assays that TBX5-G145R is a partial 
loss of function variant (Fig 22).  
To determine the transcriptional effects of TBX5 variation in iPSC-CMs, we performed 
RNA-sequencing on population controls, isogenic controls, TBX5G145R/WT (heterozygotes), 
TBX5G145R/G145R (homozygotes), and TBX5-/WT cell lines. We isolated RNA from 2-4 replicates 
per group and generated ribo-depleted Illumina sequencing libraries to generate 46-66 million 
reads per sample. A standard Bowtie/Tophat/Cufflinks read mapping and differential expression 
pipeline identified genes that were differentially expressed between samples. TBX5-/WT iPSC-
CMs had substantially altered gene expression to the other samples with an average of 266 genes 
differentially expressed when compared any other group studied (Range 180-400; Fig 32A). All 
other pairwise group comparisons had between 52-96 genes differentially expressed, again, 
supporting the biochemical evidence that TBX5-G145R is a partial loss of function variant. 
Unsupervised hierarchical clustering verified that TBX5-/WT lines have distinct expression 
patterns compared to all other groups (Fig 32B). TBX5-G145R seemed to result in discrete 
	 141	
transcriptional changes as TBX5G145R/G145R iPSC-CMs clones cluster together and fall under the 
same branch as the heterozygous variant containing myocytes, isogenic controls, and population 
controls (Fig 32B). Of the 51 genes differentially expressed between TBX5G145R/WT and isogenic 
controls, 31 were also differentially expressed when comparing isogenic controls and TBX5-/WT 
(Fig 32C). An additional 189 non-overlapping genes are also differentially expressed between 
comparing isogenic controls and TBX5-/WT.  
A heatmap displaying the top 50 significantly upregulated and downregulated genes in 
TBX5-/WT compared to isogenic controls (sorted by fold change of genes with P<0.00015) 
indicated that all other lines studied are highly dissimilar to iPSC-CMs with a complete loss of 
one TBX5 allele (Fig 33A). We generated a heatmap of expression changes in BrS-associated 
genes, including only genes with defined functional mechanisms,291 to interrogate the effect of 
TBX5 variation on expression of these genes. The heatmap shows that SCN5A expression is 
commonly reduced in myocytes with any type of TBX5 variation, consistent with the qRT-PCR 
data presented in Figure 23. All other genes rarely associated with BrS genes have similar 
expression in all groups, including TBX5 (Fig 33B).  
To investigate the extent of genome wide transcriptional changes that occur in iPSC-CMs 
generated from a BrS patient containing heterozygous TBX5-G145R compared to the Cas9-
mediated generated isogenic controls, we generated a volcano plot (Fig 33C). Plotting the fold-
change between these groups against the significance of differential expression shows modest 
differences in expression profiles. The genes that show a significant difference in expression 
level in this plot likely underlie the reduced sodium channel expression and current observed in 
this variant. As presented in Figure 25, TBX5-G145R caused reduced sodium channel 
expression and the electrophysiologic signature of BrS, reduced sodium current influx. Since 
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Figure 32. RNA sequencing analysis. (A) Pairwise display of number of genes with 
significantly altered differential expression (B) Unsupervised hierarchical clustering of 
differentially expression genes. (C) Venn diagram of genes differentially expressed in 
TBX5G145R/WT and TBX5-/WT relative to isogenic control levels. 
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Figure 33. Differentially expressed genes in iPSC-CMs with TBX5 variants. (A) Heat map of 
top 50 upregulated and downregulated genes in TBX5 heterozygous deletions relative to isogenic 
controls. (B) Heat map of relative expression of BrS-associated genes relative to isogenic 
controls. (C) Volcano plot comparing TBX5G145R/WT to isogenic controls.  	  
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correction of the TBX5-G145R variant completely rescues the phenotype, we postulate that the 
arrhythmogenic INa-L and APD variability are a result of altered TBX5 transcriptional regulation.  
In order to further identify specific genes and pathways underlying the late sodium 
current, we examined a list of candidate genes in which the encoded protein influences INa-L but 
none were differentially expressed. We then analyzed the list of differentially expressed genes by 
pathway analysis of gene ontology (GO terms) for biologic processes using PANTHER.292 When 
comparing TBX5G145R/WT iPSC-CMs to population and isogenic control myocytes, the list of 
genes was significantly enriched for the processes of cardiovascular development and regulation 
of phosphoinositol 3-kinase (PI3K) signaling (Table 14). The PI3K signal was driven by reduced 
expression of genes that encode proteins activating the PI3K pathway (FLT1, DCN, and TEK). 
Excitingly, our lab and others have recently shown that a reduction in PI3K signaling in 
cardiomyocytes enhances late sodium current, suggesting that TBX5 regulation of PI3K as a 
mechanism of the late current in the proband.293-297 Thus, this unbiased gene ontology approach 
highlighted a potential role of PI3K signaling on INa-L and APD variability that would have 
remained unappreciated only using candidate gene analyses.  
Comparison of differential gene expression between TBX5-/WT and control iPSC-CMs 
found enrichment for the processes of heart development and response to growth factor signaling 
(Table 14). These findings are consistent with the development on an in vitro model of HOS. 
However, further functional characterization is required to evaluate if the heterozygous knockout 
lines also contain primary electrophysiologic phenotypes. In contrast, compared to control iPSC-
CMs, TBX5G145R/G145R identified the GO terms ion homeostasis and membrane depolarization 
(Table 14). These pathways analyses suggest the gene network regulated by TBX5 that govern 
heart development is less affected by TBX5-G145R and those that influence cardiac conduction 
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are equally or perhaps more greatly affected compared to heterozygous TBX5 deletion. One open 
question is whether all sites of TBX5 DNA binding are equally altered in TBX5G145R/G145R and 
TBX5-/WT. Future studies that quantitatively compare DNA occupancy between TBX5 variant 
lines could provide insight into the molecular mechanisms driving the observed transcriptional 
differences.
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Table 14. Gene ontology terms enriched in differentially expressed among pairwise comparisons. 
Group1 Group 2 Biologic process % List Enrichment P value 
Control TBX5G145R/WT Regulation of PI3K signaling 4.3 15.23 2.37E-02 
Control TBX5G145R/WT Cardiovascular development 1.5 5.29 1.75E-02 
Control TBX5-/WT Heart development 2.3 5.61 3.52E-02 
Control TBX5-/WT Cardiovascular development 1.7 4.23 4.17E-02 
Population ctr TBX5G145R/G145R Regulation of ventricular membrane depolarization 42.9 >100 6.54E-03 
Population ctr TBX5G145R/G145R Regulation of atrial membrane depolarization 37.5 >100 9.75E-03 
Population ctr TBX5G145R/G145R Regulation of ion homeostasis 3.0 14.75 2.58E-02 
Population ctr TBX5G145R/G145R Cardiac muscle contraction 7.5 36.4 2.33E-03 
TBX5G145R/WT TBX5-/WT organ development 1.6 2.68 2.14E-06 
TBX5G145R/WT TBX5-/WT mesenchymal cell proliferation 30.8 52.46 1.02E-02 
TBX5G145R/WT TBX5-/WT heart morphogenesis 4.2 7.2 4.31E-02 
TBX5G145R/WT TBX5-/WT cardiovascular system development 2.6 4.44 8.70E-05 
TBX5G145R/WT TBX5-/WT anatomical structure morphogenesis 1.8 3.08 2.40E-06 
TBX5G145R/WT TBX5-/WT regulation of cell adhesion 2.5 4.27 9.54E-03 
TBX5G145R/WT TBX5-/WT cell migration 2.2 3.79 2.15E-02 
TBX5G145R/WT TBX5-/WT tissue development 2.1 3.54 3.71E-06 
TBX5G145R/WT TBX5-/WT cell differentiation 1.4 2.37 1.00E-04 
            
All terms biologic processes listed are enriched at statistically significant levels. Control = population controls and isogenic controls. 
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DISCUSSION 
 
Rare variants in more than 45 genes have been identified in cases of BrS, including 
TBX5, with varying strength of evidence related to causality. Our work addresses the causal role 
of a TBX5 variant of previously unknown significance discovered in a patient with BrS. The 
finding of ~50% decrease in SCN5A expression and sodium current in patient-derived iPSC-
CMs validates this cellular model (See Table 1 in Chapter I), but does not establish causation. 
Genome editing of patient derived iPSCs reversed these functional defects and thereby 
established TBX5-G145R as the cause of BrS in this family.  
TBX5-G145R is a novel rare variant that is not present in over 130,000 alleles sequenced 
from more than 65,000 individuals (ExAC database) in which 165 non-synonymous variants 
(164 missense and a single nonsense; minor allele frequency <0.1% for all) were observed in 
TBX5. Nonsense variants in TBX5 often lead to severe maldevelopment of the heart as part of 
the constellation of symptoms described in HOS. Rare missense TBX5 variants have been 
recognized in other forms of heart disease including atrial fibrillation, dilated cardiomyopathy, 
and hypertrophic cardiomyopathy.115,141,150 Often, missense variants are evaluated for alterations 
in DNA binding and transcriptional activation in biochemical assays and heterologous 
expression systems. However, the extent to which a change in transcription activation from a 
single TBX5-responsive luciferase assay in non-cardiomyocytes can be applied to pathogenesis 
remains unestablished.141 Heterologous expression studies fail to provide insight into the 
underlying mechanisms as transcription factor (TF) function is dependent upon the correct 
cellular context, in this case a cardiomyocyte.  
Understanding of TF biology is primarily through the study of animal knockout models 
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that define the global contribution of a particular TF to developmental phenotypes.298 
Heterozygous loss of Tbx5 in mice phenocopies the major features of human HOS: upper limb 
anomalies, impaired cardiac conduction, and septal defects in the heart.120,121,274 TBX5 is also 
critical for homeostatic electrical conduction in the murine heart. Inducible deletion of Tbx5, 
specifically from the conduction system, from the adult mouse heart leads to ventricular 
tachycardia and disrupted fast conduction through reduced expression of Scn5a and Gja5 
(encoding Cx40 a major cardiac connexin in atria and conduction system).148 Missense variants 
of Tbx5 have not been studied in mouse models to date. Gain-of-function mutations in TBX5 
have been associated with atrial fibrillation.115,299 TBX5-G125R is a mutation positioned at the 
TBX5-DNA interface with increased affinity for TBX5 binding sites, presumed because of the 
attraction of the positively charged arginine to negatively charged DNA, leading to increased 
promoter activity of Nppa and Gja5 in heterologous assay driving luciferase activity.115  Gain-of-
function variants localized to the transactivation domain of TBX5 (R355C, G376R, S372L, and 
A428S) increase expression of Gja5 and Nppa without altering expression of structural genes 
also regulated by TBX5 (α-MCH or MLC-2a).299 Like mouse models of missense variants in 
Nkx2.5300 and ARX,301 TBX5-R355C has been studied using overexpression in a zebrafish fish 
model which increases occurrence of atrial fibrillation. TF overexpression leads to an increase in 
target site occupancy when compared to endogenous levels of TF expression which may 
confound animal models of missense TF variants overexpression.302,303 
We provide a human model of missense TF variation studied under expression from the 
endogenous locus in the appropriate cellular context. Genome editing in patient-derived iPSCs is 
a scalable approach to test the impact of individual variants of unknown significance within the 
genetic background of the affected individual. We chose this approach rather than to engineer the 
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variant into a population control line because of the translation potential of testing the impact of 
the variant within cardiomyocytes generated from the patient. Other reports have knocked-in 
missense variants within a defined genetic background when access to the patient was not 
available. However, the influence of the defined background on cellular function is unknown and 
may contribute to phenotypic presentation. There are certainly advantages of knocking in 
variants into a common genetic background when the goal is to directly compare the phenotype 
of iPSC-CMs due to multiple variants in the same gene, for example our comparison of TBX5-
G145R and TBX5 heterozygous knockout.  
Compared to TBX5-/WT, TBX5-G145R results in discrete alterations in gene expression 
relevant to the pathogenesis of BrS. Amino acid position 145 of TBX5 is located in the DNA 
binding domain of the protein but located away from where the protein interfaces with DNA 
targets. The structural modeling predicts that TBX5-G145R changes the orientation of the amino 
acids in direct contact with a canonical T-box family binding site within the NPPA promoter, 
consistent with DNA binding assays presented in Figure 24. There is some flexibility in 
transcription factor target sequence and one possible explanation for the discrete expression 
changes is that our observed reduction in DNA binding is restricted to particular DNA targets. 
To address this possibility, we proposed ChIP-sequencing experiments in isogenic iPSC-CMs 
that are either homozygous for wild-type or mutant (G145R) TBX5. We failed to 
immunoprecipitate endogenous TBX5 using antibodies that were successful in mouse Tbx5-
chromatin immunoprecipitation experiments.290 TBX5-G145R is located near a group of acidic 
amino acids that are critical for interacting with basic side chains of other transcription factors 
that work in synergy with TBX5.126 Probing the effect of missense variants in TBX5 on 
interactions with other cardiac transcription factors may also provide insight into the 
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discrete expression changes observed in RNA-sequencing experiments.  
The genetic basis of BrS was long presumed to be an autosomal dominant disease with 
variable penetrance. A GWAS comparing 312 cases of BrS to 1,115 population controls 
unraveled a strong influence of genetic background on disease risk. Three common variants, one 
of which marks a variant that disrupts TBX5 binding to a cis-regulatory element of SCN5A on 
chromosome 3, can impart an odds ratio of 21.5 if the individual carries 5 or 6 risk alleles. In the 
family pedigree presented here a single individual is a TBX5 cG433A carrier and currently 
unaffected by BrS. We genotyped all TBX5 variant carriers for the common variants associated 
with BrS to look for a potential influence of these variants on disease penetrance. All carriers in 
the family carry 4-5 risk alleles (Table 15) suggesting currently unappreciated genetic 
contributions or environmental influences may alter BrS risk. BrS also has an age-related 
penetrance with the average age at diagnosis of 43 years old which may contribute to the variable 
penetrance observed in this famly.304 The unaffected carrier was 17 years of age at time of 
evaluation. Based on the natural history of BrS and the large effect of TBX5-G145R on SCN5A 
expression in iPSC-CMs, it would be prudent to maintain a screening regimen in this individual. 
Unexpectedly, we observed arrhythmogenic features of increased INa-L and APD lability 
in patient-derived iPSC-CMs that is caused by TBX5-G145R. INa-L can result from gain-of-
function variants in SCN5A or altered gating characteristics mediated by auxiliary subunit 
interactions or post-translational modification (nitrosylation and phosphorylation).305 The 
proband carries no coding variants in SCN5A, therefore ruling out mutations increasing late 
current in NaV1.5 as the underlying INa-L mechanism. We hypothesized that increased INa-L in 
patient derived iPSC-CMs was due to a transcriptional mechanism because editing the missense 
TBX5 variant corrected the phenotype (Fig 26). Acute silencing of SCN2B in dog ventricular 
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Table 15. Genotypes of TBX5-G145R carriers for common variants associated with BrS. 
 
  
TBX5 
c.433G>A rs6801957 rs11708996 rs9388451 
Ancestral allele G G C T 
Risk allele A T G C 
Pt ID   
ALLELE 
1 
ALLELE 
2 
ALLELE 
1 
ALLELE 
2 
ALLELE 
1 
ALLELE 
2 
2994 (proband) G/A A A G G T C 
2997 (mother) G/A A A G C T C 
3651 (iPSC donor) G/A A A G C C C 
6614 (noncarrier 
sibling) G/G A A G C T C 
6615 (carrier sibling) G/A A A G C T C 
MAF (1000 
genomes) 0 0.29 0.09 0.41 
OR N/A 2.55 1.73 1.58 
Gene/biology missense SCN5A EnhA SNP SCN5A intron 17 Hey2 SNP 
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cardiomyocytes increases INa-L while SCN1B silencing decreases peak and late INa, a finding 
confirmed in an independent heterologous expression experiment.43,44 We quantified the beta 
subunit transcripts and they were not differentially expressed in TBX5G145R/WT iPSC-CMs 
compared to isogenic controls. The nitrosylation and phosphorylation state of NaV1.5 alters the 
amount of INa-L as nitrosylation306 and phosphorylation by Ca2+/calmodulin-dependent protein 
kinase II (CaMK)307 and protein kinase C (PKC)308 increases INa-L while it is reduced by PI3K 
activity. While expression of the proteins responsible for direct post-translational modification 
was not affected by the missense TBX5 variant, pathway analysis unveiled regulators of PI3K 
activity were downregulated (Table 14).297 Chronic exposure to tyrosine kinase inhibitors or a 
subset of antiarrhythmic medications inhibit PI3K to increase INa-L that can be reversed by 
intracellular dialysis with 3,4,5-triphosphate (PIP3).293,295 We found a novel association between 
TBX5-G145R and decreased expression of PI3K activators. Further work is required to elucidate 
if the expression changes are a direct result of the TBX5 variant or other (e.g. compensatory) 
mechanisms.  
Experimental models and clinical observations demonstrate that beat-to-beat variability 
in the duration of the cardiac action potential is a strong predictor of arrhythmia susceptibility.309 
In healthy myocardium, cardiomyocytes are resilient to mild alterations in ionic currents as the 
heart rate fluctuates based on the activity of an individual. Situations such as genetic variation or 
medication exposure, where the balance of depolarizing and repolarizing current becomes 
narrow, small alterations in inward or outward cation current can dramatically (and sometimes 
on a beat to beat basis) shift the duration of the action potential. Drugs impacting IKr and INa have 
been shown to have a great impact on APD instability.310 Chemically induced INa-L by exposure 
to either veratridine or ATX-II leads to APD lability in canine ventricular myocytes. The exact 
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mechanisms of INa-L leading to APD lability due to drug exposure or the TBX5G145R/WT iPSC-
CMs studied are currently unknown. One possible explanation is variable activation of signaling 
cascades activated by sodium overload. For example, sodium overload activates the sodium-
calcium exchanger leading to increased diastolic calcium. This activates the CaMKII which 
modifies the behavior of many ion channels, including enhancing INa-L. Computational modeling 
predicts beat-to-beat variation in CaMKII signaling occurs and that could be an important 
modifier of repolarization kinetics.311 Another potential mechanism of APD variability is the 
self-perpetuating effect of the diastolic interval on ion channel behavior. The APD restitution 
curve demonstrates a nonlinear relationship of the diastolic interval influencing the duration of 
the subsequent action potential. Shortening the diastolic intervals decrease the ionic currents 
during the plateau phase of the action potential, resulting in a loss of the phase 2 notch generated 
by Ito and a shortening of the APD.312 A reduction in Ito, ICa-L, and INa after short diastolic 
intervals is supported by computational models.313-316   
This study has multiple translational implications. Based on the reversal of the cellular 
BrS phenotype of decreased sodium current by genome correction of TBX5 c.G433A in patient-
derived iPSCs, we have defined the genetic bases of BrS in this study family. Additionally, 
molecular diagnostics unveiled a previously undiagnosed case of mild HOS. These findings have 
a direct benefit to the study family by providing the knowledge base required for genetic 
counseling of the TBX5-G145R carriers within the family. In the development of the iPSC-CM 
model of BrS, we observed a shared phenotype and anti-arrhythmic response to ranolazine 
treatment among single cell and monolayer evaluation which accentuates the potential of 
screening drug response in populations of iPSC-CMs. Monolayers of stem cell-derived 
cardiomyocytes minimize the limitation of stem cell differentiated cardiomyocytes consisting of 
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heterogeneous populations of cells.317 Testing of drug efficacy in patient-specific iPSC-CM 
monolayers have the potential to guide future clinical decision making based on personalized in 
vitro drug response that can be influenced by the genetic architecture underlying disease. This 
complements the efforts that have validated iPSC-CM models that evaluate drug toxicity, 
particularly for arrhythmia risk.282,318 
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CONCLUSION 
 
 We have developed a new iPSC-CM model of BrS and applied this model to advance our 
understanding of TBX5 biology. Generating isogenic controls by genome editing proved TBX5-
G145R causes BrS through the mechanism of reduced sodium channel expression. Our findings 
establish a regulatory role of TBX5 that influences electrical activity in ventricular 
cardiomyocytes. The missense variant characterized in this report has discrete transcriptional 
alterations that are unique from haploinsufficiency mechanisms. Unexpectedly, TBX5-G145R 
causes increased late sodium current leading to action potential duration lability. By studying a 
missense TBX5 variant in a human cardiomyocyte model, we propose a transcriptional 
mechanism leading to reduced PI3K signaling and increased arrhythmia risk. Lastly, 
incorporating molecular diagnostics with strong clinical phenotyping allowed for detection of a 
subclinical presentation of HOS that may impact future genetic counseling of the presented 
family.  
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
The vision of precision medicine is to tailor health care in order to optimize treatment for 
each and every patient. This requires the understanding and integration of genetic, 
environmental, and lifestyle factors that comprise the individual’s risk for developing disease 
and response to preventative or curative interventions. For precision medicine to reach its full 
potential, we, as a scientific community, must define these unique disease modifying 
characteristics with sensitive detection and accurate interpretation. The objective of this body of 
work was to contribute to the pursuit of precision medicine by advancing the understanding and 
utilization of genome science for application to inherited heart disease. Through the experiments 
described in this dissertation, we have advanced the field of molecular cardiology by addressing 
two important questions: 
(1) What types of variants elude detection by genetic testing? 
(2) Are variants of unknown significance contributory to disease?  
 
Summary of Chapter II 
Some genetic conditions have well-defined genetic architecture which can be explained 
by variation in just a single or few genes. Therefore, the clinical presentation of such conditions 
is highly suggestive of variation in a known associated gene. These types of conditions provide a 
unique opportunity to evaluate the efficacy of broadly used methods in genetic testing for variant 
identification. A classic example of one such medical condition is cystic fibrosis where the only 
genetic cause is homozygous or compound heterozygous variation in CFTR.319,320 We utilized an 
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analogous (in terms of genetic specificity) inherited heart condition called Jervell and Lange-
Nielsen syndrome (JLNS), a severe version of the long QT syndrome with congenital deafness. 
JLNS has only two known genetic causes: homozygous or compound heterozygous mutations in 
either KCNQ1 or KCNE1. KCNQ1 encodes the pore forming α subunit and KCNE1 encodes the 
auxiliary β subunit of the voltage-gated potassium channel that conducts the slow delayed 
rectifying potassium current, IKs. A complete loss of IKs delays cardiac repolarization and 
increases risk of developing polymorphic ventricular tachycardia. Genetic testing using next-
generation sequencing (NGS) approaches was conducted on the patient with JLNS and returned 
a single nonsense variant in KCNQ1. As described in Chapter II, we tested the hypothesis that 
the patient possessed a second variant in KCNQ1 that was not detected by NGS approaches. 
Using conventional Sanger sequencing methods, we found a complex 52-bp insertion comprised 
of a partial duplication of exon 15 and a poly-adenine tract, likely a truncated Alu element. 
Additional filters can be applied to NGS analysis to appropriately identify insertion-type variants 
that are similar to the one we described.  
 
Future directions for Chapter II 
While the cause of long QT syndrome in this patient is well appreciated in loss of IKs, we 
still chose to generate and validate induced pluripotent stem cells (iPSCs) for expression of stem 
cell markers, pluripotency, and a normal karyotype from this individual (Fig 34A and 34B). 
JLNS has previously been modeled using iPSC-CMs.259 A striking finding in this report is the 
severe prolongation of the action potential with a doubling of the APD90. There are multiple 
rationales for creating this model. While it benefits the field to have a second JLNS model due to 
different genetic causation, it also provided an internal positive control for detection of APD  
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Figure 34. JLNS iPSC-CM model preliminary data. (A) JLNS iPSC colonies express stem 
cell-associated proteins. Embryoid body differentiation to three germ layers demonstrates iPSC 
pluripotency: endoderm (GATA4), mesoderm (α-SMA), ectoderm (β3-tubulin). Scale bars = 50 
microns. (B) JLNS iPSC clones maintain a normal karyotype. (C) JLNS iPSC-CMs grown using 
standard 1:200 matrigel plating have prolonged action potential duration (APD) and expected 
response to dofetilide treatment. (D) PCR amplification of KCNQ1 off cDNA template 
demonstrates low expression when using standard 1:200 matrigel iPSC-CM methodology that is 
increased by matrigel mattress (undiluted matrigel) plating as previously described321 that could 
be used in future patch-clamp experiments to elucidate the mechanisms of KCNQ1 contribution 
to repolarization beyond IKs generation. Ctr = population control. 
Figure	32	JLNA	iPSC-CM	model	preliminary	data. (a) iPSC colony 
express stem cell-associated proteins. Embryoid body 
differentiation to three germ layers demonstrates iPSC 
pluripotency: endoderm (GATA4), medoserm (α-SMA), 
ectoderm (β3-tubulin). Scale bars = 50 microns. (b) iPSCs
maintain a normal karyotype. (c) JLNS have prolonged action 
potential duration (APD) and expected response to dofetilide
treatment. (d) PCR amplification of KCNQ1 off cDNA template 
demonstrates low e ression when using st dard iPSC-CM 
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prolongation in iPSC-CMs. We recorded action potentials from population control and JLNS 
iPSC-CMs and confirmed that complete loss of KCNQ1 causes a severe prolongation of APD50 
and APD90 with further APD prolongation with IKr blockade by dofetilide (Fig 34C). This model 
also provides an opportunity to learn new KCNQ1 biology. JLNS iPSC-CMs have twice as long 
action potentials compared to controls even though it is abundant in the literature, and confirmed 
by our evaluation (Fig 34D), that KCNQ1 expression is quite low in iPSC-CMs when using 
standard plating conditions.321 We generated cDNA from mRNA isolated from JLNS iPSC-CMs 
after standard or matrigel mattress321, a condition that increases expression of many cardiac 
genes including KCNQ1, plating for PCR amplification of KCNQ1 transcripts. Adult human left 
ventricle (LV) cDNA was included as a positive control. Amplicons were visible for reactions 
using cDNA template synthesized from adult LV and mattress treated cells while standard iPSC-
CM methods failed to amplify KCNQ1 transcripts. All samples generated amplicons using 
primers specific to GAPDH to control for the quality of template used in PCR reactions. Based 
on the very low expression, I hypothesize that KCNQ1 serves other cellular functions in addition 
to generating IKs. At the protein level, KCNQ1 is reported to interact with Kv11.1, encoded by 
KCNH2 (also known as HERG) and may modulate trafficking322,323 or endocytosis324 of Kv11.1 
channels. iPSC-CMs provide a renewable source of human cardiomyocytes to study the biology 
of these interactions. Genome modification to alter amino acid sequence or introduce tags for 
fluorescence resonance energy transfer (FRET) or biochemical assessment of JLNS iPSC-CMs 
can be used to interrogate the regulatory role of KCNQ1 on other channels at the protein and 
RNA levels.  
During the process of differentiation of JLNS iPSCs into cardiomyocytes, the cells detach 
from the plate during the Wnt inhibition with IWR-1 step (see methods in chapter IV). This 
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occurred during every attempted differentiation. The floating cells lacked pyknotic nuclei and 
membrane blebbing leading me to assess the viability of the floating cells. Using trypan blue 
exclusion >70% of floating cells were still viable. In order to generate cardiomyocytes, I merged 
two differentiation protocols: the matrigel sandwich method325 and the chemical method.167 I 
modified the chemical method of differentiation by including 1:200 dilution of matrigel in the 
media during the first 5 days of differentiation to provide a top layer of extracellular matrix in 
hopes to keep cells attached to the bottom of the plate. This was very successful producing high 
yield differentiations with adequate cardiomyocyte purity.  These observations may implicate a 
role of KCNQ1 in interactions with the extracellular matrix early during development. This 
theory is supported by reports that loss of KCNQ1 increases metastatic potential of cancerous 
cells which requires a change in cell-to-cell and cell-to-matrix adhesion.326 In a mouse model of 
colon cancer, deletion of Kcnq1 upregulates expression of pro-proliferative and metastatic 
genes.327 Another report describes downregulation of Kcnq1 or upregulation of Kcne1 promotes 
invasive behavior in embryonic stem cells.328 The observations in the oncology fields support the 
theory that KCNQ1 and possibly other ion channels serve functions beyond ion conductance. 
 
Summary of Chapter III 
A particular challenging aspect of implementing genomic sequencing into clinical 
practice is accurately assigning a variant as pathogenic or non-contributory to disease. This is 
difficult when only considering large effect rare variants and becomes overwhelming when 
attempting to incorporate common variants that comprise an individual’s unique genetic 
background. In Chapter III, I worked in a collaborative effort to evaluate the functional 
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consequences of a series of rare variants located in or near the selectivity filter of the voltage-
gated potassium channel, KV2.1. Prior to my involvement, a clinical effort identified multiple de 
novo variants in a child afflicted with epileptic encephalopathy not carried by either parent. The 
challenge was to determine variants in which gene caused the child’s condition. A missense 
variant in KCNB1, the gene encoding KV2.1, was the top candidate because the variant occurred 
in a highly conserved region of the protein and this protein contributes to repolarization of a 
neuron. Therefore, the missense variant identified would likely alter neuronal electric 
homeostasis. Mice with germline deletion of Kcnb1 demonstrate increased susceptibility to drug 
induced seizures but have no change in baseline seizure activity.253 While species differences 
may explain why the patient identified had severe epilepsy, it was possible that the identified 
mutation may have different biophysical properties contributing to the severity of the clinical 
phenotype. 
I performed electrophysiologic characterization of wild-type or mutant KV2.1 in Chinese 
hamster ovarian (CHO) cells via heterologous expression. This model allows for direct 
functional testing of KV2.1 without confounding currents since CHO cells do not express 
endogenous potassium channels. Mutations in the selectivity filter of the pore of KV2.1 altered 
two major features of channel function. The channels were no longer voltage-gated and lost 
selectivity. The mutant channels conduct the monovalent cations potassium, sodium, rubidium, 
and the large cation N-methyl-d-glucamine. Therefore, it is possible that the mutant KV2.1 
channels studied not only abolish voltage-gated repolarizing potassium current but directly 
contribute to hyperexcitability, severe seizure burden, and neuron cell death through conduction 
of depolarizing INa. 
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Future directions for Chapter III 
The electrophysiology experiments conducted in Chapter III were done entirely in 
heterologous expression systems. While this model interrogates the impact of missense variants 
on ion channel function, insight into the global effect in the relevant cell type, a neuron, or in a 
whole organism is lacking. A mouse model of the missense Kcnb1 variant is being generated and 
characterized by my collaborator and co-author Dr. Jennifer Kearney. The mouse model will 
compare the seizure burden and response to pro- and anti-epileptic interventions in the mice with 
the missense variant compared to Kcnb1 knockout mice. This study will directly test the 
hypothesis that loss of selectivity results in a gain-of-function mechanism to increase seizure 
burden and neuronal cell death.  
 Mouse models of epilepsy provide whole organism evaluation of epilepsy phenotypes 
and response to therapeutics. It is unrealistic to generate a mouse model for each variant 
discovered. The discovery of iPSCs (as discussed in Chapter I and IV) provide a renewable 
source of human neurons. Complex neuron pathology has been modeled using iPSC-neurons, 
including epilepsy329 and ALS.330 The application of genome-editing and advances in 3-
dimensional culturing systems will improve the validity and utility of iPSC-neuron epilepsy 
models.    
 
Summary of Chapter IV 
Heterologous expression systems permit relatively high-throughput characterization of 
mutant proteins from which causation can be inferred. This approach is particularly effective 
when studying a gene with a strong association to a clinical phenotype. There are examples in 
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which the dysfunction of a protein can only be detected and the mechanisms elucidated in the 
appropriate cellular context, for example, SCN5A-D1275N and its disrupted subcellular 
localization158 or TBX5-G145R, a cardiac transcription factor.107 In Chapter IV, we tested the 
hypothesis that TBX5-G145R caused familial BrS. Through genome editing of patient-derived 
stem cells, we established the genetic basis, functional mechanisms, and transcriptional 
mechanisms of BrS in the study family. The TBX5 variant caused decreased sodium current, the 
electrophysiologic hallmark of BrS.331 Increased late sodium current and action potential 
variability were also identified in iPSC-CMs containing the missense TBX5 variant. These 
arrhythmogenic features were completely abolished by correction of the variant by 
CRISPR/Cas9 methodology or treatment with the late sodium current blocker ranolazine. 
 Relative to the transcriptome of population control and isogenic control iPSC-CMs, the 
TBX5-G145R variant resulted in modest transcriptional alterations compared to TBX5 
heterozygous knockout iPSC-CMs. The genes that were altered by the TBX5-G145R missense 
variant are important for cardiac conduction and regulation of PI3K signaling. TBX5 
heterozygous deletion resulted in global changes in expression of genes associated with cardiac 
defects in the developmental condition HOS. Through the project described in Chapter IV, we 
have established TBX5-G145R as a causative variant in familial BrS and expanded the known 
roles of TBX5 beyond cardiac development to now include human cardiomyocyte homeostasis.  
 
Future directions for Chapter IV 
We have established that TBX5-G145R caused BrS in the study family. A remaining question is 
whether or not this missense variant is sufficient to cause BrS. More specifically, does the 
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genetic background present in the individuals studied provide the summative risk necessary to 
cause BrS. The family studied carries many of the common SNVs identified by GWAS to 
increase BrS risk. The SNVs identified actually mark a region of DNA that contains one 
functional SNV responsible for this increased risk.103 Because the functional SNVs of GWAS 
identified common variants are not known, the genetic background of the study family cannot be 
modified to test the contribution of genetic background on the phenotype. TBX5 c.G433A can 
alternatively be inserted into population control iPSCs that have been genotyped for the common 
SNVs associated to BrS to test if TBX5-G145R is sufficient to cause the cellular phenotype we 
describe (Table 16).  
TBX5-G145R results in discrete transcriptional changes compared to heterozygous 
deletion of TBX5. I hypothesize that TBX5-G145R has preferential disruption of DNA binding 
based on the sequence of the DNA target. This hypothesis can be tested by defining the location 
of TBX5 occupancy within the genome based on the sequence of the DNA target using 
chromatin-immunoprecipitation sequencing (ChIP-seq) evaluation in isogenic (TBX5WT/WT) 
control and TBX5G145R/G145R iPSC-CMs (Fig 35). TBX5 ChIP-seq has only been successfully 
performed to date in mouse cell lines, originally using overexpression of affinity-tagged Tbx5 in 
an immortalized mouse cardiomyocyte cell line332 and recently from endogenous Tbx5 from 
mouse ESC-derived cardiomyocyte progenitors.290 We tested multiple commercially available 
antibodies directed against TBX5, including the antibody successfully applied in endogenous 
mouse Tbx5-ChIP, by Western blot on nuclear lysate from population control iPSC-CMs without 
success. Future efforts could test additional commercial antibodies directed against TBX5 for 
effectiveness in human cardiomyocytes or insertion of affinity tags by homology-directed repair 
after nuclease targeting of the endogenous TBX5 locus. V5 and biotin tags have been  
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Table 16. Genotypes of population control iPSC for common variants associated with BrS. 
 
rs6801957 rs11708996 rs9388451 
Odds Ratio Ancestral allele G C T 
Risk allele T G C 
Pt ID ALLELE 1 ALLELE 2 ALLELE 1 ALLELE 2 ALLELE 1 ALLELE 2  
Population control 1 G T G G T C 8.33 
Population control 2 G T G C G C 4.04 
Population control 4 G T G G C C 4.04 
Population control 6 G G G C T C 1.87 
MAF (1000 genomes) 0.29 0.09 0.41  
OR 2.55 1.73 1.58  
Gene/biology SCN5A EnhA SNP SCN5A intron 17 Hey2 SNP  
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Figure 35. Sanger sequencing of exon 5 of TBX5. Chromatogram of Sanger sequencing 
confirmation of TBX5-G145R homozygous CRISPR/Cas9-mediated edit. 
   
Figure 33 ChIP seq
W
T	
al
le
le
G145
C GC C CA G G G GC C CA A A AT T TG G G GA G C CT G T TC C C T T C CA
c.
G4
33
A
al
le
le
R145
C AC C CA G G G GC C CA A A AT T TG G G GA G C CT G T TC C C T T C CA
	 167	
successfully applied to ChIP techniques to overcome the lack of commercially available ChIP-
grade antibodies for other transcription factors.333  
The analysis of RNA-sequencing datasets by gene ontology revealed decreased 
expression of known PI3K activators as a potential mechanism of late sodium current in iPSC-
CMs containing the missense TBX5-G145R variant. Certain tyrosine kinase inhibitors used in 
the treatment of malignancies result in a common mechanism of reduced PI3K activity and an 
associated side effect of QT prolongation.294 The ionic mechanism of increased late sodium 
current contributes to the prolongation of APD in cardiomyocyte models that can be rescued by  
intracellular dialysis of PIP3. For example, dofetilide was previously thought to increase risk of 
arrhythmia onset by potent IKr block but is it now described to also cause PI3K-mediated 
increased late sodium current.293,296 Intracellular dialysis of PIP3 in TBX5G145R/WT iPSC-CM 
could be tested to prevent late sodium current and APD lability. The activity of PI3K can be 
indirectly tested by relative quantification of the phosphorylation state of known targets (Akt and 
S6) by Western blot comparison using phospho-specific antibodies relative to total protein. This 
would be the first report of a missense variant in a transcription factor altering PI3K activity in 
cardiomyocytes. 
 A goal of precision medicine is to tailor therapy based on the underlying genetics. 
Ongoing efforts are testing the response of genotype specific therapies to treat inherited 
arrhythmia syndromes. These approaches would directly address underlying mechanisms of 
disease. Altering transcription of genes affected directly or indirectly may provide another path 
to the realization of precision medicine. I hypothesize that increasing expression of TBX5 in 
TBX5G145R/WT iPSC-CMs to “functional” normal will ameliorate the reduced sodium current, 
enhanced late sodium current, and APD variability.  
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CRISPR/Cas9 has been modified to generate RNA-guided synthetic transcription factors 
by inactivating the nuclease domains of Cas9 and tethering transactivation domains to the C-
terminus by a short peptide linker (dCas9-activator).334-336 To test the expression hypothesis, I 
began to generate the tools to create a genetically encoded, doxycycline-inducible dCas9-
activator (Fig 36A). Using HDR after Cas9-induced double strand break, I inserted a Flp 
recombinase target site and tet repressor system within intron1-2 of PPP1R12C, an area known 
as a safe harbor site and common target of gene therapy integration (Fig 36B and 36C).337,338 
Transient expression of Flp recombinase in the presence of a donor plasmid containing the 
dCas9-activator and gRNA expression system will generate stable iPSC lines. This system is 
modular in that various gRNA can be inserted into the donor plasmid using simple cloning. This 
approach could also be tested as a proof-of-concept in cell or animal models of other causative 
non-dominant heterozygous variants. 
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Final summary 
The body of work presented in this dissertation has contributed to the field of molecular 
cardiology by providing knowledge that can be approach broadly to genetic variant identification 
and evaluation of variant causality. Specifically, I have identified a class of genetic variation 
missed by next-generation sequencing-based genetic testing (Chapter II). I have defined the 
changes in biophysical properties of mutations in KV2.1 that cause severe seizure burden in cases 
of epileptic encephalopathy (Chapter III). Through genome editing of patient derived induced 
pluripotent stem cells, I have established a novel genetic cause of the Brugada syndrome, a rare 
missense variant in TBX5 (Chapter IV). In studying TBX5-G145R containing stem cell-derived 
cardiomyocytes, I have implicated a role of TBX5 in regulating expression of upstream 
regulators of PI3 kinase and when disrupted results in arrhythmogenic increased late sodium 
current and action potential duration lability. In conclusion, the summation of the presented 
findings participates in the collective goal of advancing scientific knowledge for translation into 
clinical practice. 
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Fig 36. Construction of genetically-encoded doxycycline-inducible dCas9-activator. (A) 
Schematic of genetically encoded doxycycline-inducible expression system in intron 1-2 of 
PPP1R12C. (B) Dual CRISPR/Cas9 and Flp recombinase modulate approach. (C) PCR reaction 
with forward primer specific to CRISPR/Cas9-mediated insertion and reverse primer in the 
genome outside of homologous template. (D) Sanger sequencing chromatogram of amplicon 
depicted in (D).   
Fig 34 Construction of genetically-encoded doxycycline-inducible
dCas9-activator. (a) Schematic of genetically encoded doxycycline-
inducible expression system in intron 1-2 of PPP1R12C. (b) Dual
C ISPR/Cas9 and Flp recombinase modulate ap ro . (c) PCR
reaction with forward primer specific to CRISPR/Cas9-mediated insertion
and reverse primer in the genome outside of homologous template. (d)
Sanger sequencing trace of amplicon presented in (C).
5’	PPP1R12C	
intron	1-2
SV40	promoter	
-Tet repressor
dCas9-
activator
3’	PPP1R12C	
intron	1-2
Hygromycin
resistance
U6	promoter	
- gRNAT2
A
Te
tO
Genomic	sequence
(outside	homology	arm)
A
D
B C
	 171	
REFERENCES 
 
1. Mollova M, Bersell K, Walsh S, Savla J, Das LT, Park SY, Silberstein LE, Dos 
Remedios CG, Graham D, Colan S, Kuhn B. Cardiomyocyte proliferation contributes to heart 
growth in young humans. Proc Natl Acad Sci U S A 2013;110:1446-51. 
2. Raju TN. The Nobel chronicles. 1963: Sir Alan Lloyd Hodgkin (1914-98), Sir Andrew 
Fielding Huxley (b 1917), and Sir John Carew Eccles (1903-97). Lancet 1999;354:263. 
3. Hodgkin AL, Huxley AF. Resting and action potentials in single nerve fibres. J Physiol 
1945;104:176-95. 
4. Neher E. Nobel lecture. Ion channels for communication between and within cells. 
Neuron 1992;8:605-12. 
5. Grant AO. Cardiac ion channels. Circ Arrhythm Electrophysiol 2009;2:185-94. 
6. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 
1993;55:455-72. 
7. Accili EA, Proenza C, Baruscotti M, DiFrancesco D. From funny current to HCN 
channels: 20 years of excitation. News Physiol Sci 2002;17:32-7. 
8. Yang N, Horn R. Evidence for voltage-dependent S4 movement in sodium channels. 
Neuron 1995;15:213-8. 
9. Yang N, George AL, Jr., Horn R. Molecular basis of charge movement in voltage-gated 
sodium channels. Neuron 1996;16:113-22. 
10. Yellen G, Jurman ME, Abramson T, MacKinnon R. Mutations affecting internal TEA 
blockade identify the probable pore-forming region of a K+ channel. Science 1991;251:939-42. 
11. West JW, Patton DE, Scheuer T, Wang Y, Goldin AL, Catterall WA. A cluster of 
hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad 
Sci U S A 1992;89:10910-4. 
12. McPhee JC, Ragsdale DS, Scheuer T, Catterall WA. A critical role for the S4-S5 
intracellular loop in domain IV of the sodium channel alpha-subunit in fast inactivation. J Biol 
Chem 1998;273:1121-9. 
	 172	
13. Torkamani A, Bersell K, Jorge BS, Bjork RL, Jr., Friedman JR, Bloss CS, Cohen J, 
Gupta S, Naidu S, Vanoye CG, George AL, Jr., Kearney JA. De novo KCNB1 mutations in 
epileptic encephalopathy. Ann Neurol 2014;76:529-40. 
14. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: molecular 
defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52:557-94. 
15. Deschenes I, Tomaselli GF. Modulation of Kv4.3 current by accessory subunits. FEBS 
Lett 2002;528:183-8. 
16. Rosati B, Pan Z, Lypen S, Wang HS, Cohen I, Dixon JE, McKinnon D. Regulation of 
KChIP2 potassium channel beta subunit gene expression underlies the gradient of transient 
outward current in canine and human ventricle. J Physiol 2001;533:119-25. 
17. Soltysinska E, Olesen SP, Christ T, Wettwer E, Varro A, Grunnet M, Jespersen T. 
Transmural expression of ion channels and transporters in human nondiseased and end-stage 
failing hearts. Pflugers Arch 2009;459:11-23. 
18. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. 
Pacing Clin Electrophysiol 1998;21:1029-34. 
19. George AL, Jr. Molecular and genetic basis of sudden cardiac death. J Clin Invest 
2013;123:75-83. 
20. Cascio WE, Yang H, Muller-Borer BJ, Johnson TA. Ischemia-induced arrhythmia: the 
role of connexins, gap junctions, and attendant changes in impulse propagation. J Electrocardiol 
2005;38:55-9. 
21. Pierson JB, Berridge BR, Brooks MB, Dreher K, Koerner J, Schultze AE, Sarazan RD, 
Valentin JP, Vargas HM, Pettit SD. A public-private consortium advances cardiac safety 
evaluation: achievements of the HESI Cardiac Safety Technical Committee. J Pharmacol Toxicol 
Methods 2013;68:7-12. 
22. Echt DR, David. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or 
Placebo. The New England Journal of Medicine 1991;324:781-8. 
23. Moss AJ. Long QT Syndrome. Jama 2003;289:2041-4. 
24. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini 
F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, 
Spazzolini C. Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761-7. 
	 173	
25. Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. Curr Probl Cardiol 2008;33:629-
94. 
26. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and 
torsades de pointes. Med Clin North Am 2001;85:321-41. 
27. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, 
Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen 
L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, 
Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-
phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening 
arrhythmias. Circulation 2001;103:89-95. 
28. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, 
Weitkamp L, Vincent GM, Garson A, Jr., et al. The long QT syndrome. Prospective longitudinal 
study of 328 families. Circulation 1991;84:1136-44. 
29. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, 
Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, 
Smith SC, Jr., Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, 
Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, 
Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, 
Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for management of patients with 
ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American 
College of Cardiology/American Heart Association Task Force and the European Society of 
Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for 
Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac 
Death). J Am Coll Cardiol 2006;48:e247-346. 
30. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, 
Hauer RN, Beckmann BM, Spazzolini C, Rordorf R, Rydberg A, Clur SA, Fischer M, van den 
Heuvel F, Kaab S, Blom NA, Ackerman MJ, Schwartz PJ, Wilde AA. Not all beta-blockers are 
equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under 
metoprolol. J Am Coll Cardiol 2012;60:2092-9. 
31. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. 
Am J Med 2002;112:58-66. 
32. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang 
CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, 
Tomaselli G, Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and 
management of patients with inherited primary arrhythmia syndromes: document endorsed by 
HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. 
Heart Rhythm 2013;10:1932-63. 
	 174	
33. Spears DA, Gollob MH. Genetics of inherited primary arrhythmia disorders. Appl Clin 
Genet 2015;8:215-33. 
34. Schwartz PJ, Ackerman MJ, George AL, Jr., Wilde AA. Impact of genetics on the 
clinical management of channelopathies. J Am Coll Cardiol 2013;62:169-80. 
35. Keating M, Dunn C, Atkinson D, Timothy K, Vincent GM, Leppert M. Consistent 
linkage of the long-QT syndrome to the Harvey ras-1 locus on chromosome 11. Am J Hum 
Genet 1991;49:1335-9. 
36. Peroz D, Rodriguez N, Choveau F, Baro I, Merot J, Loussouarn G. Kv7.1 (KCNQ1) 
properties and channelopathies. J Physiol 2008;586:1785-9. 
37. Bezzina CR, Lahrouchi N, Priori SG. Genetics of sudden cardiac death. Circ Res 
2015;116:1919-36. 
38. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hordt 
M, Towbin JA, Borggrefe M, Assmann G, Qu X, Somberg JC, Breithardt G, Oberti C, Funke H. 
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet 1997;17:267-8. 
39. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, 
Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT 
syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-
85. 
40. Giudicessi JR, Ackerman MJ. Prevalence and potential genetic determinants of 
sensorineural deafness in KCNQ1 homozygosity and compound heterozygosity. Circ Cardiovasc 
Genet 2013;6:193-200. 
41. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel 
mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. 
Heart Rhythm 2005;2:507-17. 
42. Zimmer T, Surber R. SCN5A channelopathies--an update on mutations and mechanisms. 
Prog Biophys Mol Biol 2008;98:120-36. 
43. Mishra S, Undrovinas NA, Maltsev VA, Reznikov V, Sabbah HN, Undrovinas A. Post-
transcriptional silencing of SCN1B and SCN2B genes modulates late sodium current in cardiac 
myocytes from normal dogs and dogs with chronic heart failure. Am J Physiol Heart Circ 
Physiol 2011;301:H1596-605. 
44. Maltsev VA, Kyle JW, Undrovinas A. Late Na+ current produced by human cardiac Na+ 
channel isoform Nav1.5 is modulated by its beta1 subunit. J Physiol Sci 2009;59:217-25. 
	 175	
45. Lin X, O'Malley H, Chen C, Auerbach D, Foster M, Shekhar A, Zhang M, Coetzee W, 
Jalife J, Fishman GI, Isom L, Delmar M. Scn1b deletion leads to increased tetrodotoxin-sensitive 
sodium current, altered intracellular calcium homeostasis and arrhythmias in murine hearts. J 
Physiol 2015;593:1389-407. 
46. Kapplinger JD, Giudicessi JR, Ye D, Tester DJ, Callis TE, Valdivia CR, Makielski JC, 
Wilde AA, Ackerman MJ. Enhanced Classification of Brugada Syndrome-Associated and Long-
QT Syndrome-Associated Genetic Variants in the SCN5A-Encoded Na(v)1.5 Cardiac Sodium 
Channel. Circ Cardiovasc Genet 2015;8:582-95. 
47. Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz PJ, Vincent GM, 
Benhorin J, Heilbron EL, Towbin JA, Priori SG, Napolitano C, Zhang L, Medina A, Andrews 
ML, Timothy K. Comparison of clinical and genetic variables of cardiac events associated with 
loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 
1999;84:876-9. 
48. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and 
antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 
2000;35:778-86. 
49. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A 
mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 
2007;116:1137-44. 
50. Kehl HG, Haverkamp W, Rellensmann G, Yelbuz TM, Krasemann T, Vogt J, Schulze-
Bahr E. Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful 
treatment and confirmation of clinically suspected extreme long QT-syndrome-3. Circulation 
2004;109:e205-6. 
51. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine 
shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT 
syndrome. J Cardiovasc Electrophysiol 2008;19:1289-93. 
52. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and 
sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter 
report. J Am Coll Cardiol 1992;20:1391-6. 
53. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, 
Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA. Proposed diagnostic criteria for the 
Brugada syndrome: consensus report. Circulation 2002;106:2514-9. 
54. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation 
in leads V1 through V3: a marker for sudden death in patients without demonstrable structural 
heart disease. Circulation 1998;97:457-60. 
	 176	
55. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada 
syndrome. Circulation 2004;110:1731-7. 
56. Ashino S, Watanabe I, Kofune M, Nagashima K, Ohkubo K, Okumura Y, Mano H, 
Nakai T, Kunimoto S, Kasamaki Y, Hirayama A. Effects of Quinidine on the Action Potential 
Duration Restitution Property in the Right Ventricular Outflow Tract in Patients With Brugada 
Syndrome. Circulation Journal 2011;75:2080-6. 
57. Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl S, Streitner F, 
Kuschyk J, Schimpf R, Haase KK, Borggrefe M. Intravenous drug challenge using flecainide 
and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005;2:254-60. 
58. Keller DI, Rougier JS, Kucera JP, Benammar N, Fressart V, Guicheney P, Madle A, 
Fromer M, Schlapfer J, Abriel H. Brugada syndrome and fever: genetic and molecular 
characterization of patients carrying SCN5A mutations. Cardiovasc Res 2005;67:510-9. 
59. Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, Wichter T, Boisseau P, 
Heinecke A, Breithardt G, Borggrefe M, LeMarec H, Bocker D, Wilde AA. Long-term prognosis 
of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 
2005;111:257-63. 
60. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, 
Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J. Natural history of 
Brugada syndrome: insights for risk stratification and management. Circulation 2002;105:1342-
7. 
61. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan 
HL, Hiraoka M, Brugada J, Wilde AA. Drugs and Brugada syndrome patients: review of the 
literature, recommendations, and an up-to-date website (http://www.brugadadrugs.org/). Heart 
Rhythm 2009;6:1335-41. 
62. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms 
of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660-6. 
63. Antzelevitch C. J wave syndromes: molecular and cellular mechanisms. J Electrocardiol 
2013;46:510-8. 
64. Postema PG, van Dessel PF, Kors JA, Linnenbank AC, van Herpen G, Ritsema van Eck 
HJ, van Geloven N, de Bakker JM, Wilde AA, Tan HL. Local depolarization abnormalities are 
the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a 
study of electrocardiograms, vectorcardiograms, and body surface potential maps during 
ajmaline provocation. J Am Coll Cardiol 2010;55:789-97. 
	 177	
65. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, Sanna T, Bellocci 
F, Russo MA. Cardiac histological substrate in patients with clinical phenotype of Brugada 
syndrome. Circulation 2005;112:3680-7. 
66. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, 
Giustetto C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P, Le Marec H, Wolpert C, 
Wilde AA. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the 
FINGER Brugada Syndrome Registry. Circulation 2010;121:635-43. 
67. Nishii N, Nagase S, Morita H, Kusano KF, Namba T, Miura D, Miyaji K, Hiramatsu S, 
Tada T, Murakami M, Watanabe A, Banba K, Sakai Y, Nakamura K, Oka T, Ohe T. Abnormal 
restitution property of action potential duration and conduction delay in Brugada syndrome: both 
repolarization and depolarization abnormalities. Europace 2010;12:544-52. 
68. Nielsen MW, Holst AG, Olesen SP, Olesen MS. The genetic component of Brugada 
syndrome. Front Physiol 2013;4:179. 
69. Hoshi M, Du XX, Shinlapawittayatorn K, Liu H, Chai S, Wan X, Ficker E, Deschenes I. 
Brugada syndrome disease phenotype explained in apparently benign sodium channel mutations. 
Circ Cardiovasc Genet 2014;7:123-31. 
70. Kyndt F, Probst V, Potet F, Demolombe S, Chevallier JC, Baro I, Moisan JP, Boisseau P, 
Schott JJ, Escande D, Le Marec H. Novel SCN5A Mutation Leading Either to Isolated Cardiac 
Conduction Defect or Brugada Syndrome in a Large French Family. Circulation 2001;104:3081-
6. 
71. Todd SJ, Campbell MJ, Roden DM, Kannankeril PJ. Novel Brugada SCN5A mutation 
causing sudden death in children. Heart Rhythm 2005;2:540-3. 
72. Smits PE, L; Probst, V; Bezzina, CR; Schulze-Bahr, E. Genotype-Phenotype 
Relationship in Brugada Syndrome: Electrocardiographic Features Differentiate SCN5A-Related 
Patients From Non–SCN5A-Related Patients. J Am Coll Cardiol 2002;40. 
73. Martin CA, Zhang Y, Grace AA, Huang CL. In vivo studies of Scn5a+/- mice modeling 
Brugada syndrome demonstrate both conduction and repolarization abnormalities. J 
Electrocardiol 2010;43:433-9. 
74. Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA, Benndorf K, Saumarez 
RC, Trezise AE, Huang CL, Vandenberg JI, Colledge WH, Grace AA. Slowed conduction and 
ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc 
Natl Acad Sci U S A 2002;99:6210-5. 
	 178	
75. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, 
Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schulze-Bahr 
E, Keating MT, Towbin JA, Wang Q. Genetic basis and molecular mechanism for idiopathic 
ventricular fibrillation. Nature 1998;392:293-6. 
76. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC, Pfahnl 
AE, Shang LL, Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R, Ackerman MJ, 
McNamara DM, Weiss R, Dudley SC, Jr. Mutation in glycerol-3-phosphate dehydrogenase 1 
like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 
2007;116:2260-8. 
77. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, 
Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP, Jr., Burashnikov E, Wu 
Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M, Schimpf R, 
Borggrefe M, Wolpert C. Loss-of-function mutations in the cardiac calcium channel underlie a 
new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden 
cardiac death. Circulation 2007;115:442-9. 
78. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpon E, Hu D, Desai M, Borggrefe M, 
Haissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laino R, Marieb M, Nademanee K, 
Nam GB, Robles R, Schimpf R, Stapleton DD, Viskin S, Winters S, Wolpert C, Zimmern S, 
Veltmann C, Antzelevitch C. Mutations in the cardiac L-type calcium channel associated with 
inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010;7:1872-82. 
79. Crotti L, Marcou CA, Tester DJ, Castelletti S, Giudicessi JR, Torchio M, Medeiros-
Domingo A, Simone S, Will ML, Dagradi F, Schwartz PJ, Ackerman MJ. Spectrum and 
prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of 
unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. 
J Am Coll Cardiol 2012;60:1410-8. 
80. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, 
Demolombe S, Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S, Wichmann 
HE, Hasdemir C, Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium channel beta1 subunit 
mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin 
Invest 2008;118:2260-8. 
81. Holst AG, Saber S, Houshmand M, Zaklyazminskaya EV, Wang Y, Jensen HK, 
Refsgaard L, Haunso S, Svendsen JH, Olesen MS, Tfelt-Hansen J. Sodium current and 
potassium transient outward current genes in Brugada syndrome: screening and bioinformatics. 
Can J Cardiol 2012;28:196-200. 
82. Delpon E, Cordeiro JM, Nunez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, 
Kanters JK, Larsen CT, Hofman-Bang J, Burashnikov E, Christiansen M, Antzelevitch C. 
	 179	
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. 
Circ Arrhythm Electrophysiol 2008;1:209-18. 
83. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer R, 
Koopmann TT, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C. A mutation in the 
beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ 
Cardiovasc Genet 2009;2:270-8. 
84. Verkerk AO, Wilders R, Schulze-Bahr E, Beekman L, Bhuiyan ZA, Bertrand J, Eckardt 
L, Lin D, Borggrefe M, Breithardt G, Mannens MM, Tan HL, Wilde AA, Bezzina CR. Role of 
sequence variations in the human ether-a-go-go-related gene (HERG, KCNH2) in the Brugada 
syndrome. Cardiovasc Res 2005;68:441-53. 
85. Medeiros-Domingo A, Tan BH, Crotti L, Tester DJ, Eckhardt L, Cuoretti A, Kroboth SL, 
Song C, Zhou Q, Kopp D, Schwartz PJ, Makielski JC, Ackerman MJ. Gain-of-function mutation 
S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-
wave syndromes. Heart Rhythm 2010;7:1466-71. 
86. Kattygnarath D, Maugenre S, Neyroud N, Balse E, Ichai C, Denjoy I, Dilanian G, 
Martins RP, Fressart V, Berthet M, Schott JJ, Leenhardt A, Probst V, Le Marec H, Hainque B, 
Coulombe A, Hatem SN, Guicheney P. MOG1: a new susceptibility gene for Brugada syndrome. 
Circ Cardiovasc Genet 2011;4:261-8. 
87. Ohno S, Zankov DP, Ding WG, Itoh H, Makiyama T, Doi T, Shizuta S, Hattori T, 
Miyamoto A, Naiki N, Hancox JC, Matsuura H, Horie M. KCNE5 (KCNE1L) variants are novel 
modulators of Brugada syndrome and idiopathic ventricular fibrillation. Circ Arrhythm 
Electrophysiol 2011;4:352-61. 
88. Giudicessi JR, Ye D, Tester DJ, Crotti L, Mugione A, Nesterenko VV, Albertson RM, 
Antzelevitch C, Schwartz PJ, Ackerman MJ. Transient outward current (I(to)) gain-of-function 
mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart 
Rhythm 2011;8:1024-32. 
89. Ishikawa T, Sato A, Marcou CA, Tester DJ, Ackerman MJ, Crotti L, Schwartz PJ, On 
YK, Park JE, Nakamura K, Hiraoka M, Nakazawa K, Sakurada H, Arimura T, Makita N, Kimura 
A. A novel disease gene for Brugada syndrome: sarcolemmal membrane-associated protein gene 
mutations impair intracellular trafficking of hNav1.5. Circ Arrhythm Electrophysiol 
2012;5:1098-107. 
90. Liu H, Chatel S, Simard C, Syam N, Salle L, Probst V, Morel J, Millat G, Lopez M, 
Abriel H, Schott JJ, Guinamard R, Bouvagnet P. Molecular genetics and functional anomalies in 
a series of 248 Brugada cases with 11 mutations in the TRPM4 channel. PLoS one 
2013;8:e54131. 
	 180	
91. Riuro H, Beltran-Alvarez P, Tarradas A, Selga E, Campuzano O, Verges M, Pagans S, 
Iglesias A, Brugada J, Brugada P, Vazquez FM, Perez GJ, Scornik FS, Brugada R. A missense 
mutation in the sodium channel beta2 subunit reveals SCN2B as a new candidate gene for 
Brugada syndrome. Hum Mutat 2013;34:961-6. 
92. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, 
Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes 
GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 
mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23. 
93. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-45. 
94. Hanson B, Tuna N, Bouchard T, Heston L, Eckert E, Lykken D, Segal N, Rich S. Genetic 
factors in the electrocardiogram and heart rate of twins reared apart and together. Am J Cardiol 
1989;63:606-9. 
95. Havlik RJ, Garrison RJ, Fabsitz R, Feinleib M. Variability of heart rate, P-R, QRS and Q-
T durations in twins. J Electrocardiol 1980;13:45-8. 
96. Russell MW, Law I, Sholinsky P, Fabsitz RR. Heritability of ECG measurements in adult 
male twins. J Electrocardiol 1998;30 Suppl:64-8. 
97. Mutikainen S, Ortega-Alonso A, Alen M, Kaprio J, Karjalainen J, Rantanen T, Kujala 
UM. Genetic influences on resting electrocardiographic variables in older women: a twin study. 
Ann Noninvasive Electrocardiol 2009;14:57-64. 
98. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, West K, Kashuk C, 
Akyol M, Perz S, Jalilzadeh S, Illig T, Gieger C, Guo CY, Larson MG, Wichmann HE, Marban 
E, O'Donnell CJ, Hirschhorn JN, Kaab S, Spooner PM, Meitinger T, Chakravarti A. A common 
genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 
2006;38:644-51. 
99. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C, Ehret GB, Orru M, 
Pattaro C, Kottgen A, Perz S, Usala G, Barbalic M, Li M, Putz B, Scuteri A, Prineas RJ, Sinner 
MF, Gieger C, Najjar SS, Kao WH, Muhleisen TW, Dei M, Happle C, Mohlenkamp S, Crisponi 
L, Erbel R, Jockel KH, Naitza S, Steinbeck G, Marroni F, Hicks AA, Lakatta E, Muller-Myhsok 
B, Pramstaller PP, Wichmann HE, Schlessinger D, Boerwinkle E, Meitinger T, Uda M, Coresh J, 
Kaab S, Abecasis GR, Chakravarti A. Common variants at ten loci modulate the QT interval 
duration in the QTSCD Study. Nat Genet 2009;41:407-14. 
100. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, Bis JC, 
Marciante K, Rivadeneira F, Noseworthy PA, Sotoodehnia N, Smith NL, Rotter JI, Kors JA, 
Witteman JC, Hofman A, Heckbert SR, O'Donnell CJ, Uitterlinden AG, Psaty BM, Lumley T, 
	 181	
Larson MG, Stricker BH. Common variants at ten loci influence QT interval duration in the 
QTGEN Study. Nat Genet 2009;41:399-406. 
101. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, 
Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis 
E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson 
G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of 
complex diseases. Nature 2009;461:747-53. 
102. Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, Sotoodehnia 
N, Rossin EJ, Morley M, Wang X, Johnson AD, Lundby A, Gudbjartsson DF, Noseworthy PA, 
Eijgelsheim M, Bradford Y, Tarasov KV, Dorr M, Muller-Nurasyid M, Lahtinen AM, Nolte IM, 
Smith AV, Bis JC, Isaacs A, Newhouse SJ, Evans DS, Post WS, Waggott D, Lyytikainen LP, 
Hicks AA, Eisele L, Ellinghaus D, Hayward C, Navarro P, Ulivi S, Tanaka T, Tester DJ, Chatel 
S, Gustafsson S, Kumari M, Morris RW, Naluai AT, Padmanabhan S, Kluttig A, Strohmer B, 
Panayiotou AG, Torres M, Knoflach M, Hubacek JA, Slowikowski K, Raychaudhuri S, Kumar 
RD, Harris TB, Launer LJ, Shuldiner AR, Alonso A, Bader JS, Ehret G, Huang H, Kao WH, 
Strait JB, Macfarlane PW, Brown M, Caulfield MJ, Samani NJ, Kronenberg F, Willeit J, Smith 
JG, Greiser KH, Meyer Zu Schwabedissen H, Werdan K, Carella M, Zelante L, Heckbert SR, 
Psaty BM, Rotter JI, Kolcic I, Polasek O, Wright AF, Griffin M, Daly MJ, Arnar DO, Holm H, 
Thorsteinsdottir U, Denny JC, Roden DM, Zuvich RL, Emilsson V, Plump AS, Larson MG, 
O'Donnell CJ, Yin X, Bobbo M, D'Adamo AP, Iorio A, Sinagra G, Carracedo A, Cummings SR, 
Nalls MA, Jula A, Kontula KK, Marjamaa A, Oikarinen L, Perola M, Porthan K, Erbel R, 
Hoffmann P, Jockel KH, Kalsch H, Nothen MM, den Hoed M, Loos RJ, Thelle DS, Gieger C, 
Meitinger T, Perz S, Peters A, Prucha H, Sinner MF, Waldenberger M, de Boer RA, Franke L, 
van der Vleuten PA, Beckmann BM, Martens E, Bardai A, Hofman N, Wilde AA, Behr ER, 
Dalageorgou C, Giudicessi JR, Medeiros-Domingo A, Barc J, Kyndt F, Probst V, Ghidoni A, 
Insolia R, Hamilton RM, Scherer SW, Brandimarto J, Margulies K, Moravec CE, del Greco MF, 
Fuchsberger C, O'Connell JR, Lee WK, Watt GC, Campbell H, Wild SH, El Mokhtari NE, Frey 
N, Asselbergs FW, Mateo Leach I, Navis G, van den Berg MP, van Veldhuisen DJ, Kellis M, 
Krijthe BP, Franco OH, Hofman A, Kors JA, Uitterlinden AG, Witteman JC, Kedenko L, 
Lamina C, Oostra BA, Abecasis GR, Lakatta EG, Mulas A, Orru M, Schlessinger D, Uda M, 
Markus MR, Volker U, Snieder H, Spector TD, Arnlov J, Lind L, Sundstrom J, Syvanen AC, 
Kivimaki M, Kahonen M, Mononen N, Raitakari OT, Viikari JS, Adamkova V, Kiechl S, Brion 
M, Nicolaides AN, Paulweber B, Haerting J, Dominiczak AF, Nyberg F, Whincup PH, 
Hingorani AD, Schott JJ, Bezzina CR, Ingelsson E, Ferrucci L, Gasparini P, Wilson JF, Rudan I, 
Franke A, Muhleisen TW, Pramstaller PP, Lehtimaki TJ, Paterson AD, Parsa A, Liu Y, van 
Duijn CM, Siscovick DS, Gudnason V, Jamshidi Y, Salomaa V, Felix SB, Sanna S, Ritchie MD, 
Stricker BH, Stefansson K, Boyer LA, Cappola TP, Olsen JV, Lage K, Schwartz PJ, Kaab S, 
Chakravarti A, Ackerman MJ, Pfeufer A, de Bakker PI, Newton-Cheh C. Genetic association 
study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. 
Nat Genet 2014;46:826-36. 
103. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Verkerk AO, 
Schwartz PJ, Crotti L, Dagradi F, Guicheney P, Fressart V, Leenhardt A, Antzelevitch C, 
Bartkowiak S, Borggrefe M, Schimpf R, Schulze-Bahr E, Zumhagen S, Behr ER, Bastiaenen R, 
	 182	
Tfelt-Hansen J, Olesen MS, Kaab S, Beckmann BM, Weeke P, Watanabe H, Endo N, Minamino 
T, Horie M, Ohno S, Hasegawa K, Makita N, Nogami A, Shimizu W, Aiba T, Froguel P, Balkau 
B, Lantieri O, Torchio M, Wiese C, Weber D, Wolswinkel R, Coronel R, Boukens BJ, Bezieau 
S, Charpentier E, Chatel S, Despres A, Gros F, Kyndt F, Lecointe S, Lindenbaum P, Portero V, 
Violleau J, Gessler M, Tan HL, Roden DM, Christoffels VM, Le Marec H, Wilde AA, Probst V, 
Schott JJ, Dina C, Redon R. Common variants at SCN5A-SCN10A and HEY2 are associated 
with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 
2013;45:1044-9. 
104. Hartman ME, Liu Y, Zhu WZ, Chien WM, Weldy CS, Fishman GI, Laflamme MA, Chin 
MT. Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action 
potential and mild conduction system expansion but does not alter conduction system function or 
promote spontaneous arrhythmias. FASEB J 2014;28:3007-15. 
105. Holm H, Gudbjartsson DF, Arnar DO, Thorleifsson G, Thorgeirsson G, Stefansdottir H, 
Gudjonsson SA, Jonasdottir A, Mathiesen EB, Njolstad I, Nyrnes A, Wilsgaard T, Hald EM, 
Hveem K, Stoltenberg C, Lochen ML, Kong A, Thorsteinsdottir U, Stefansson K. Several 
common variants modulate heart rate, PR interval and QRS duration. Nat Genet 2010;42:117-22. 
106. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: 
a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 
2008;24:2938-9. 
107. Behr ER, Savio-Galimberti E, Barc J, Holst AG, Petropoulou E, Prins BP, Jabbari J, 
Torchio M, Berthet M, Mizusawa Y, Yang T, Nannenberg EA, Dagradi F, Weeke P, Bastiaenan 
R, Ackerman MJ, Haunso S, Leenhardt A, Kaab S, Probst V, Redon R, Sharma S, Wilde A, 
Tfelt-Hansen J, Schwartz P, Roden DM, Bezzina CR, Olesen M, Darbar D, Guicheney P, Crotti 
L, Consortium UK, Jamshidi Y. Role of common and rare variants in SCN10A: results from the 
Brugada syndrome QRS locus gene discovery collaborative study. Cardiovasc Res 
2015;106:520-9. 
108. Park DS, Fishman GI. Nav-igating through a complex landscape: SCN10A and cardiac 
conduction. J Clin Invest 2014;124:1460-2. 
109. van den Boogaard M, Smemo S, Burnicka-Turek O, Arnolds DE, van de Werken HJ, 
Klous P, McKean D, Muehlschlegel JD, Moosmann J, Toka O, Yang XH, Koopmann TT, 
Adriaens ME, Bezzina CR, de Laat W, Seidman C, Seidman JG, Christoffels VM, Nobrega MA, 
Barnett P, Moskowitz IP. A common genetic variant within SCN10A modulates cardiac SCN5A 
expression. J Clin Invest 2014;124:1844-52. 
110. Probst V, Wilde AA, Barc J, Sacher F, Babuty D, Mabo P, Mansourati J, Le Scouarnec S, 
Kyndt F, Le Caignec C, Guicheney P, Gouas L, Albuisson J, Meregalli PG, Le Marec H, Tan 
HL, Schott JJ. SCN5A mutations and the role of genetic background in the pathophysiology of 
Brugada syndrome. Circ Cardiovasc Genet 2009;2:552-7. 
	 183	
111. Park JK, Martin LJ, Zhang X, Jegga AG, Benson DW. Genetic variants in SCN5A 
promoter are associated with arrhythmia phenotype severity in patients with heterozygous loss-
of-function mutation. Heart Rhythm 2012;9:1090-6. 
112. Yang P, Koopmann TT, Pfeufer A, Jalilzadeh S, Schulze-Bahr E, Kaab S, Wilde AA, 
Roden DM, Bezzina CR. Polymorphisms in the cardiac sodium channel promoter displaying 
variant in vitro expression activity. Eur J Hum Genet 2008;16:350-7. 
113. Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, Kamakura 
S, Roden DM, Wilde AA. Common sodium channel promoter haplotype in asian subjects 
underlies variability in cardiac conduction. Circulation 2006;113:338-44. 
114. Sotoodehnia N, Isaacs A, de Bakker PI, Dorr M, Newton-Cheh C, Nolte IM, van der 
Harst P, Muller M, Eijgelsheim M, Alonso A, Hicks AA, Padmanabhan S, Hayward C, Smith 
AV, Polasek O, Giovannone S, Fu J, Magnani JW, Marciante KD, Pfeufer A, Gharib SA, 
Teumer A, Li M, Bis JC, Rivadeneira F, Aspelund T, Kottgen A, Johnson T, Rice K, Sie MP, 
Wang YA, Klopp N, Fuchsberger C, Wild SH, Mateo Leach I, Estrada K, Volker U, Wright AF, 
Asselbergs FW, Qu J, Chakravarti A, Sinner MF, Kors JA, Petersmann A, Harris TB, Soliman 
EZ, Munroe PB, Psaty BM, Oostra BA, Cupples LA, Perz S, de Boer RA, Uitterlinden AG, 
Volzke H, Spector TD, Liu FY, Boerwinkle E, Dominiczak AF, Rotter JI, van Herpen G, Levy 
D, Wichmann HE, van Gilst WH, Witteman JC, Kroemer HK, Kao WH, Heckbert SR, Meitinger 
T, Hofman A, Campbell H, Folsom AR, van Veldhuisen DJ, Schwienbacher C, O'Donnell CJ, 
Volpato CB, Caulfield MJ, Connell JM, Launer L, Lu X, Franke L, Fehrmann RS, te Meerman 
G, Groen HJ, Weersma RK, van den Berg LH, Wijmenga C, Ophoff RA, Navis G, Rudan I, 
Snieder H, Wilson JF, Pramstaller PP, Siscovick DS, Wang TJ, Gudnason V, van Duijn CM, 
Felix SB, Fishman GI, Jamshidi Y, Stricker BH, Samani NJ, Kaab S, Arking DE. Common 
variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat 
Genet 2010;42:1068-76. 
115. Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A, 
Lam J, Wilde AA, Lekanne Deprez RH, Moorman AF. A gain-of-function TBX5 mutation is 
associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ Res 
2008;102:1433-42. 
116. Yang YQ, Wang MY, Zhang XL, Tan HW, Shi HF, Jiang WF, Wang XH, Fang WY, Liu 
X. GATA4 loss-of-function mutations in familial atrial fibrillation. Clin Chim Acta 
2011;412:1825-30. 
117. Jiang JQ, Shen FF, Fang WY, Liu X, Yang YQ. Novel GATA4 mutations in lone atrial 
fibrillation. Int J Mol Med 2011;28:1025-32. 
118. Wang ZC, Ji WH, Ruan CW, Liu XY, Qiu XB, Yuan F, Li RG, Xu YJ, Liu X, Huang 
RT, Xue S, Yang YQ. Prevalence and Spectrum of TBX5 Mutation in Patients with Lone Atrial 
Fibrillation. Int J Med Sci 2016;13:60-7. 
	 184	
119. Boldt LH, Posch MG, Perrot A, Polotzki M, Rolf S, Parwani AS, Huemer M, Wutzler A, 
Ozcelik C, Haverkamp W. Mutational analysis of the PITX2 and NKX2-5 genes in patients with 
idiopathic atrial fibrillation. Int J Cardiol 2010;145:316-7. 
120. Basson CT, Huang T, Lin RC, Bachinsky DR, Weremowicz S, Vaglio A, Bruzzone R, 
Quadrelli R, Lerone M, Romeo G, Silengo M, Pereira A, Krieger J, Mesquita SF, Kamisago M, 
Morton CC, Pierpont ME, Muller CW, Seidman JG, Seidman CE. Different TBX5 interactions 
in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl Acad Sci U S A 
1999;96:2919-24. 
121. Al-Qattan MM, Abou Al-Shaar H. Molecular basis of the clinical features of Holt-Oram 
syndrome resulting from missense and extended protein mutations of the TBX5 gene as well as 
TBX5 intragenic duplications. Gene 2015;560:129-36. 
122. Ghosh TK, Packham EA, Bonser AJ, Robinson TE, Cross SJ, Brook JD. Characterization 
of the TBX5 binding site and analysis of mutations that cause Holt-Oram syndrome. Hum Mol 
Genet 2001;10:1983-94. 
123. van den Boogaard M, Wong LY, Tessadori F, Bakker ML, Dreizehnter LK, Wakker V, 
Bezzina CR, t Hoen PA, Bakkers J, Barnett P, Christoffels VM. Genetic variation in T-box 
binding element functionally affects SCN5A/SCN10A enhancer. J Clin Invest 2012;122:2519-
30. 
124. Pradhan L, Gopal S, Li S, Ashur S, Suryanarayanan S, Kasahara H, Nam HJ. 
Intermolecular Interactions of Cardiac Transcription Factors NKX2.5 and TBX5. Biochemistry 
2016;55:1702-10. 
125. Boogerd CJ, Dooijes D, Ilgun A, Mathijssen IB, Hordijk R, van de Laar IM, Rump P, 
Veenstra-Knol HE, Moorman AF, Barnett P, Postma AV. Functional analysis of novel TBX5 T-
box mutations associated with Holt-Oram syndrome. Cardiovasc Res 2010;88:130-9. 
126. Stirnimann CU, Ptchelkine D, Grimm C, Muller CW. Structural basis of TBX5-DNA 
recognition: the T-box domain in its DNA-bound and -unbound form. J Mol Biol 2010;400:71-
81. 
127. Mori AD, Zhu Y, Vahora I, Nieman B, Koshiba-Takeuchi K, Davidson L, Pizard A, 
Seidman JG, Seidman CE, Chen XJ, Henkelman RM, Bruneau BG. Tbx5-dependent rheostatic 
control of cardiac gene expression and morphogenesis. Dev Biol 2006;297:566-86. 
128. Sun G, Lewis LE, Huang X, Nguyen Q, Price C, Huang T. TBX5, a gene mutated in 
Holt-Oram syndrome, is regulated through a GC box and T-box binding elements (TBEs). J Cell 
Biochem 2004;92:189-99. 
	 185	
129. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol 
2009;6:419-29. 
130. Wang F, Yang XY, Zhao JY, Yu LW, Zhang P, Duan WY, Chong M, Gui YH. miR-10a 
and miR-10b target the 3'-untranslated region of TBX5 to repress its expression. Pediatr Cardiol 
2014;35:1072-9. 
131. Jeong HS, Jung ES, Sim YJ, Kim SJ, Jang JW, Hong KS, Lee WY, Chung HM, Park KT, 
Jung YS, Kim CH, Kim KS. Fbxo25 controls Tbx5 and Nkx2-5 transcriptional activity to 
regulate cardiomyocyte development. Biochim Biophys Acta 2015;1849:709-21. 
132. Collavoli A, Hatcher CJ, He J, Okin D, Deo R, Basson CT. TBX5 nuclear localization is 
mediated by dual cooperative intramolecular signals. J Mol Cell Cardiol 2003;35:1191-5. 
133. Zaragoza MV, Lewis LE, Sun G, Wang E, Li L, Said-Salman I, Feucht L, Huang T. 
Identification of the TBX5 transactivating domain and the nuclear localization signal. Gene 
2004;330:9-18. 
134. Kulisz A, Simon HG. An evolutionarily conserved nuclear export signal facilitates 
cytoplasmic localization of the Tbx5 transcription factor. Mol Cell Biol 2008;28:1553-64. 
135. Lewandowski SL, Janardhan HP, Smee KM, Bachman M, Sun Z, Lazar MA, Trivedi 
CM. Histone deacetylase 3 modulates Tbx5 activity to regulate early cardiogenesis. Hum Mol 
Genet 2014;23:3801-9. 
136. Herrmann F, Bundschu K, Kuhl SJ, Kuhl M. Tbx5 overexpression favors a first heart 
field lineage in murine embryonic stem cells and in Xenopus laevis embryos. Dev Dyn 
2011;240:2634-45. 
137. Hiroi YK, Sumiya; Komuro, Issei. Tbx5 associates with Nkx2.5 and synergistically 
promotes cardiomyocyte differentiation. Nature 2001;28. 
138. Ghosh TK, Song FF, Packham EA, Buxton S, Robinson TE, Ronksley J, Self T, Bonser 
AJ, Brook JD. Physical interaction between TBX5 and MEF2C is required for early heart 
development. Mol Cell Biol 2009;29:2205-18. 
139. Wang CC, D; Wang, Q; Wang, D. Synergistic Activation of Cardiac Genes by 
Myocardin and Tbx5. PLoS one 2011;6. 
140. Linhares VL, Almeida NA, Menezes DC, Elliott DA, Lai D, Beyer EC, Campos de 
Carvalho AC, Costa MW. Transcriptional regulation of the murine Connexin40 promoter by 
cardiac factors Nkx2-5, GATA4 and Tbx5. Cardiovasc Res 2004;64:402-11. 
	 186	
141. Zhou W, Zhao L, Jiang JQ, Jiang WF, Yang YQ, Qiu XB. A novel TBX5 loss-of-
function mutation associated with sporadic dilated cardiomyopathy. Int J Mol Med 2015;36:282-
8. 
142. Yue MS, Plavicki JS, Li XY, Peterson RE, Heideman W. A co-culture assay of 
embryonic zebrafish hearts to assess migration of epicardial cells in vitro. BMC Dev Biol 
2015;15:50. 
143. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, 
Gessler M, Nemer M, Seidman CE, Seidman JG. A murine model of Holt-Oram syndrome 
defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 
2001;106:709-21. 
144. Moskowitz IP, Pizard A, Patel VV, Bruneau BG, Kim JB, Kupershmidt S, Roden D, 
Berul CI, Seidman CE, Seidman JG. The T-Box transcription factor Tbx5 is required for the 
patterning and maturation of the murine cardiac conduction system. Development 
2004;131:4107-16. 
145. Moskowitz IP, Kim JB, Moore ML, Wolf CM, Peterson MA, Shendure J, Nobrega MA, 
Yokota Y, Berul C, Izumo S, Seidman JG, Seidman CE. A molecular pathway including Id2, 
Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell 2007;129:1365-76. 
146. Nadeaua MG, Romain O. ; Laforest, Brigitte ; Yamaka, Abir; Lefebvrea, Chantal; 
Beauregard, Janie; Paradis, Pierre; Bruneaud, Benoit G. ; Andelfinger, Gregor; Nemer, Mona. 
An endocardial pathway involving Tbx5, Gata4, and Nos3 required for atrial septum formation. 
Proc Natl Acad Sci U S A 2010;107. 
147. Hatcher CJ, Goldstein MM, Mah CS, Delia CS, Basson CT. Identification and 
localization of TBX5 transcription factor during human cardiac morphogenesis. Dev Dyn 
2000;219:90-5. 
148. Arnolds DE, Liu F, Fahrenbach JP, Kim GH, Schillinger KJ, Smemo S, McNally EM, 
Nobrega MA, Patel VV, Moskowitz IP. TBX5 drives Scn5a expression to regulate cardiac 
conduction system function. J Clin Invest 2012;122:2509-18. 
149. Hata Y, Kinoshita K, Mizumaki K, Yamaguchi Y, Hirono K, Ichida F, Takasaki A, Mori 
H, Nishida N. Postmortem genetic analysis of sudden unexplained death syndrome under 50 
years of age: A next-generation sequencing study. Heart Rhythm 2016;13:1544-51. 
150. Zhang XL, Qiu XB, Yuan F, Wang J, Zhao CM, Li RG, Xu L, Xu YJ, Shi HY, Hou XM, 
Qu XK, Xu YW, Yang YQ. TBX5 loss-of-function mutation contributes to familial dilated 
cardiomyopathy. Biochem Biophys Res Commun 2015;459:166-71. 
	 187	
151. Tarazon E, Rosello-Lleti E, Rivera M, Ortega A, Molina-Navarro MM, Trivino JC, Lago 
F, Gonzalez-Juanatey JR, Orosa P, Montero JA, Salvador A, Portoles M. RNA sequencing 
analysis and atrial natriuretic peptide production in patients with dilated and ischemic 
cardiomyopathy. PLoS one 2014;9:e90157. 
152. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, 
Ballew JD, de Andrade M, Burnett JC, Jr., Olson TM. Atrial natriuretic peptide frameshift 
mutation in familial atrial fibrillation. N Engl J Med 2008;359:158-65. 
153. Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, Brezovsky J, 
Damborsky J. PredictSNP: robust and accurate consensus classifier for prediction of disease-
related mutations. PloS Computational Biology 2014;10. 
154. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general 
framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 
2014;46:310-5. 
155. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon 
E, Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the interpretation of 
sequence variants: a joint consensus recommendation of the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-
24. 
156. Van Driest SL, Wells QS, Stallings S, Bush WS, Gordon A, Nickerson DA, Kim JH, 
Crosslin DR, Jarvik GP, Carrell DS, Ralston JD, Larson EB, Bielinski SJ, Olson JE, Ye Z, Kullo 
IJ, Abul-Husn NS, Scott SA, Bottinger E, Almoguera B, Connolly J, Chiavacci R, Hakonarson 
H, Rasmussen-Torvik LJ, Pan V, Persell SD, Smith M, Chisholm RL, Kitchner TE, He MM, 
Brilliant MH, Wallace JR, Doheny KF, Shoemaker MB, Li R, Manolio TA, Callis TE, Macaya 
D, Williams MS, Carey D, Kapplinger JD, Ackerman MJ, Ritchie MD, Denny JC, Roden DM. 
Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic 
Medical Records. Jama 2016;315:47-57. 
157. Noda M, Shimizu S, Tanabe T, Takai T, Kayano T, Ikeda T, Takahashi H, Nakayama H, 
Kanaoka Y, Minamino N, et al. Primary structure of Electrophorus electricus sodium channel 
deduced from cDNA sequence. Nature 1984;312:121-7. 
158. Watanabe H, Yang T, Stroud DM, Lowe JS, Harris L, Atack TC, Wang DW, Hipkens 
SB, Leake B, Hall L, Kupershmidt S, Chopra N, Magnuson MA, Tanabe N, Knollmann BC, 
George AL, Jr., Roden DM. Striking In vivo phenotype of a disease-associated human SCN5A 
mutation producing minimal changes in vitro. Circulation 2011;124:1001-11. 
159. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in 
medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 1981;78:7634-8. 
	 188	
160. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, 
Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7. 
161. Condic ML, Rao M. Alternative sources of pluripotent stem cells: ethical and scientific 
issues revisited. Stem Cells Dev 2010;19:1121-9. 
162. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell 2006;126:663-76. 
163. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 
2007;131:861-72. 
164. Raab S, Klingenstein M, Liebau S, Linta L. A Comparative View on Human Somatic 
Cell Sources for iPSC Generation. Stem Cells Int 2014;2014:768391. 
165. Dowey SN, Huang X, Chou BK, Ye Z, Cheng L. Generation of integration-free human 
induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector 
expression. Nat Protoc 2012;7:2013-21. 
166. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp 
TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 
2009;104:e30-41. 
167. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber 
B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC. Chemically defined 
generation of human cardiomyocytes. Nat Methods 2014;11:855-60. 
168. Hoekstra M, Mummery CL, Wilde AA, Bezzina CR, Verkerk AO. Induced pluripotent 
stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol 2012;3:346. 
169. Tse HF, Ho JC, Choi SW, Lee YK, Butler AW, Ng KM, Siu CW, Simpson MA, Lai WH, 
Chan YC, Au KW, Zhang J, Lay KW, Esteban MA, Nicholls JM, Colman A, Sham PC. Patient-
specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic 
phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome 
sequencing. Hum Mol Genet 2013;22:1395-403. 
170. Moretti AM, M; Welling, A; Laugwitz, K. Patient-Specific Induced Pluripotent Stem- 
Cell Models for Long-QT Syndrome. New England Journal of Medicine 2010. 
171. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, 
Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. Modelling the long QT syndrome 
with induced pluripotent stem cells. Nature 2011;471:225-9. 
	 189	
172. Fatima A, Kaifeng S, Dittmann S, Xu G, Gupta MK, Linke M, Zechner U, Nguemo F, 
Milting H, Farr M, Hescheler J, Saric T. The disease-specific phenotype in cardiomyocytes 
derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLoS one 
2013;8:e83005. 
173. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to 
Fok I cleavage domain. Proc Natl Acad Sci U S A 1996;93:1156-60. 
174. Kim HJ, Lee HJ, Kim H, Cho SW, Kim JS. Targeted genome editing in human cells with 
zinc finger nucleases constructed via modular assembly. Genome Res 2009;19:1279-88. 
175. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, 
Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL 
effector-based constructs for DNA targeting. Nucleic Acids Res 2011;39:e82. 
176. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler 
P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F. Cpf1 is a single RNA-
guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015;163:759-71. 
177. Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromosomal cleavage and 
mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002;161:1169-75. 
178. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, 
Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction 
using designed zinc-finger nucleases. Nature 2005;435:646-51. 
179. Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, 
Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, 
Rebar EJ, Gregory PD, Zhang HS, Jaenisch R. Generation of isogenic pluripotent stem cells 
differing exclusively at two early onset Parkinson point mutations. Cell 2011;146:318-31. 
180. Bellin M, Mummery CL. Inherited heart disease: what can we expect from the second 
decade of human iPS cells research? FEBS Lett 2016. 
181. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, 
Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, 
Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM. Evolution 
and functional impact of rare coding variation from deep sequencing of human exomes. Science 
2012;337:64-9. 
182. Daber R, Sukhadia S, Morrissette JJ. Understanding the limitations of next generation 
sequencing informatics, an approach to clinical pipeline validation using artificial data sets. 
Cancer Genet 2013;206:441-8. 
	 190	
183. Chu C, Zhang J, Wu Y. GINDEL: accurate genotype calling of insertions and deletions 
from low coverage population sequence reads. PLoS one 2014;9:e113324. 
184. Hasan MS, Wu X, Zhang L. Performance evaluation of indel calling tools using real 
short-read data. Hum Genomics 2015;9:20. 
185. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. 
J Am Coll Cardiol 2000;36:1-12. 
186. Huang L, Bitner-Glindzicz M, Tranebjaerg L, Tinker A. A spectrum of functional effects 
for disease causing mutations in the Jervell and Lange-Nielsen syndrome. Cardiovasc Res 
2001;51:670-80. 
187. Wei J, Fish FA, Myerburg RJ, Roden DM, George AL, Jr. Novel KCNQ1 mutations 
associated with recessive and dominant congenital long QT syndromes: evidence for variable 
hearing phenotype associated with R518X. Hum Mutat 2000;15:387-8. 
188. Friedmann I, Fraser GR, Froggatt P. Pathology of the ear in the cardioauditory syndrome 
of Jervell and Lange-Nielsen (recessive deafness with electrocardiographic abnormalities). J 
Laryngol Otol 1966;80:451-70. 
189. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with 
prolongation of the Q-T interval and sudden death. Am Heart J 1957;54:59-68. 
190. Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, Shkolnikova M, 
Berul CI, Bitner-Glindzicz M, Toivonen L, Horie M, Schulze-Bahr E, Denjoy I. The Jervell and 
Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 
2006;113:783-90. 
191. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, Wilde AA, 
Ackerman MJ. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from 
benign variants. Circulation 2009;120:1752-60. 
192. Giudicessi JR, Ackerman MJ. Determinants of incomplete penetrance and variable 
expressivity in heritable cardiac arrhythmia syndromes. Transl Res 2013;161:1-14. 
193. Wilson AJ, Quinn KV, Graves FM, Bitner-Glindzicz M, Tinker A. Abnormal KCNQ1 
trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). 
Cardiovasc Res 2005;67:476-86. 
194. Kanki H, Kupershmidt S, Yang T, Wells S, Roden DM. A structural requirement for 
processing the cardiac K+ channel KCNQ1. J Biol Chem 2004;279:33976-83. 
	 191	
195. Tyson J, Tranebjaerg L, McEntagart M, Larsen LA, Christiansen M, Whiteford ML, 
Bathen J, Aslaksen B, Sorland SJ, Lund O, Pembrey ME, Malcolm S, Bitner-Glindzicz M. 
Mutational spectrum in the cardioauditory syndrome of Jervell and Lange-Nielsen. Hum Genet 
2000;107:499-503. 
196. Harmer SC, Mohal JS, Royal AA, McKenna WJ, Lambiase PD, Tinker A. Cellular 
mechanisms underlying the increased disease severity seen for patients with long QT syndrome 
caused by compound mutations in KCNQ1. Biochem J 2014;462:133-42. 
197. Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M. Jervell and Lange-Nielsen 
syndrome: a Norwegian perspective. Am J Med Genet 1999;89:137-46. 
198. Zehelein J, Kathoefer S, Khalil M, Alter M, Thomas D, Brockmeier K, Ulmer HE, Katus 
HA, Koenen M. Skipping of Exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen 
syndrome. J Biol Chem 2006;281:35397-403. 
199. Campuzano O, Sarquella-Brugada G, Mademont-Soler I, Allegue C, Cesar S, Ferrer-
Costa C, Coll M, Mates J, Iglesias A, Brugada J, Brugada R. Identification of Genetic 
Alterations, as Causative Genetic Defects in Long QT Syndrome, Using Next Generation 
Sequencing Technology. PLoS one 2014;9:e114894. 
200. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to 
detect break points of large deletions and medium sized insertions from paired-end short reads. 
Bioinformatics 2009;25:2865-71. 
201. Warden CD, Adamson AW, Neuhausen SL, Wu X. Detailed comparison of two popular 
variant calling packages for exome and targeted exon studies. PeerJ 2014;2:e600. 
202. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, 
Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce 
framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-
303. 
203. Ghoneim DH, Myers JR, Tuttle E, Paciorkowski AR. Comparison of insertion/deletion 
calling algorithms on human next-generation sequencing data. BMC Res Notes 2014;7:864. 
204. Jiang Y, Wang Y, Brudno M. PRISM: pair-read informed split-read mapping for base-
pair level detection of insertion, deletion and structural variants. Bioinformatics 2012;28:2576-
83. 
205. Qi J, Zhao F. inGAP-sv: a novel scheme to identify and visualize structural variation 
from paired end mapping data. Nucleic Acids Res 2011;39:W567-75. 
	 192	
206. Strauss BS. Frameshift mutation, microsatellites and mismatch repair. Mutat Res 
1999;437:195-203. 
207. Jurka J. Sequence patterns indicate an enzymatic involvement in integration of 
mammalian retroposons. Proc Natl Acad Sci U S A 1997;94:1872-7. 
208. Cost GJ, Boeke JD. Targeting of human retrotransposon integration is directed by the 
specificity of the L1 endonuclease for regions of unusual DNA structure. Biochemistry 
1998;37:18081-93. 
209. Chen JM, Masson E, Macek M, Jr., Raguenes O, Piskackova T, Fercot B, Fila L, Cooper 
DN, Audrezet MP, Ferec C. Detection of two Alu insertions in the CFTR gene. J Cyst Fibros 
2008;7:37-43. 
210. Chen JM, Ferec C, Cooper DN. Mechanism of Alu integration into the human genome. 
Genomic Med 2007;1:9-17. 
211. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet 
2002;3:370-9. 
212. Deininger PL, Batzer MA. Alu repeats and human disease. Mol Genet Metab 
1999;67:183-93. 
213. Wallace MR, Andersen LB, Saulino AM, Gregory PE, Glover TW, Collins FS. A de 
novo Alu insertion results in neurofibromatosis type 1. Nature 1991;353:864-6. 
214. Hancks DC, Kazazian HH, Jr. Active human retrotransposons: variation and disease. 
Curr Opin Genet Dev 2012;22:191-203. 
215. Wimmer K, Callens T, Wernstedt A, Messiaen L. The NF1 gene contains hotspots for L1 
endonuclease-dependent de novo insertion. PLoS Genet 2011;7:e1002371. 
216. Thung DT, de Ligt J, Vissers LE, Steehouwer M, Kroon M, de Vries P, Slagboom EP, Ye 
K, Veltman JA, Hehir-Kwa JY. Mobster: accurate detection of mobile element insertions in next 
generation sequencing data. Genome Biol 2014;15:488. 
217. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, 
French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE. Revised 
terminology and concepts for organization of seizures and epilepsies: report of the ILAE 
Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85. 
218. Berg AT, Loddenkemper T, Baca CB. Diagnostic delays in children with early onset 
epilepsy: impact, reasons, and opportunities to improve care. Epilepsia 2014;55:123-32. 
	 193	
219. Brunklaus A, Dorris L, Ellis R, Reavey E, Lee E, Forbes G, Appleton R, Cross JH, Ferrie 
C, Hughes I, Jollands A, King MD, Livingston J, Lynch B, Philip S, Scheffer IE, Williams R, 
Zuberi SM. The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy. Dev 
Med Child Neurol 2013;55:154-61. 
220. Hirose S, Scheffer IE, Marini C, De Jonghe P, Andermann E, Goldman AM, Kauffman 
M, Tan NC, Lowenstein DH, Sisodiya SM, Ottman R, Berkovic SF. SCN1A testing for epilepsy: 
application in clinical practice. Epilepsia 2013;54:946-52. 
221. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, 
Glauser T, Goldstein DB, Han Y, Heinzen EL, Hitomi Y, Howell KB, Johnson MR, Kuzniecky 
R, Lowenstein DH, Lu YF, Madou MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O'Brien TJ, 
Ottman R, Petrovski S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil 
B, Alldredge BK, Bautista JF, Berkovic SF, Boro A, Cascino GD, Consalvo D, Crumrine P, 
Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Friedman D, Geller EB, 
Glauser T, Glynn S, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton 
RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, McGuire SM, Motika PV, 
Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Scheffer IE, Shellhaas RA, 
Sherr EH, Shih JJ, Singh R, Sirven J, Smith MC, Sullivan J, Lin Thio L, Venkat A, Vining EP, 
Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR. De novo mutations in 
epileptic encephalopathies. Nature 2013;501:217-21. 
222. Carvill GL, Heavin SB, Yendle SC, McMahon JM, O'Roak BJ, Cook J, Khan A, 
Dorschner MO, Weaver M, Calvert S, Malone S, Wallace G, Stanley T, Bye AM, Bleasel A, 
Howell KB, Kivity S, Mackay MT, Rodriguez-Casero V, Webster R, Korczyn A, Afawi Z, 
Zelnick N, Lerman-Sagie T, Lev D, Moller RS, Gill D, Andrade DM, Freeman JL, Sadleir LG, 
Shendure J, Berkovic SF, Scheffer IE, Mefford HC. Targeted resequencing in epileptic 
encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 
2013;45:825-30. 
223. O'Brien JE, Meisler MH. Sodium channel SCN8A (Nav1.6): properties and de novo 
mutations in epileptic encephalopathy and intellectual disability. Front Genet 2013;4:213. 
224. Nava C, Dalle C, Rastetter A, Striano P, de Kovel CG, Nabbout R, Cances C, Ville D, 
Brilstra EH, Gobbi G, Raffo E, Bouteiller D, Marie Y, Trouillard O, Robbiano A, Keren B, 
Agher D, Roze E, Lesage S, Nicolas A, Brice A, Baulac M, Vogt C, El Hajj N, Schneider E, Suls 
A, Weckhuysen S, Gormley P, Lehesjoki AE, De Jonghe P, Helbig I, Baulac S, Zara F, 
Koeleman BP, Haaf T, LeGuern E, Depienne C. De novo mutations in HCN1 cause early 
infantile epileptic encephalopathy. Nat Genet 2014;46:640-5. 
225. Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, Barth-
Maron A, Greenberg ME, Stuhlmann T, Weinert S, Jentsch TJ, Pazzi M, Restifo LL, Talwar D, 
Erickson RP, Hammer MF. Exome sequencing reveals new causal mutations in children with 
epileptic encephalopathies. Epilepsia 2013;54:1270-81. 
	 194	
226. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, 
Smith JD, Turner EH, Stanaway IB, Vernot B, Malig M, Baker C, Reilly B, Akey JM, 
Borenstein E, Rieder MJ, Nickerson DA, Bernier R, Shendure J, Eichler EE. Sporadic autism 
exomes reveal a highly interconnected protein network of de novo mutations. Nature 
2012;485:246-50. 
227. Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, Albrecht B, 
Bartholdi D, Beygo J, Di Donato N, Dufke A, Cremer K, Hempel M, Horn D, Hoyer J, Joset P, 
Ropke A, Moog U, Riess A, Thiel CT, Tzschach A, Wiesener A, Wohlleber E, Zweier C, Ekici 
AB, Zink AM, Rump A, Meisinger C, Grallert H, Sticht H, Schenck A, Engels H, Rappold G, 
Schrock E, Wieacker P, Riess O, Meitinger T, Reis A, Strom TM. Range of genetic mutations 
associated with severe non-syndromic sporadic intellectual disability: an exome sequencing 
study. Lancet 2012;380:1674-82. 
228. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-
Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, Walker MF, Ober GT, Teran NA, Song Y, 
El-Fishawy P, Murtha RC, Choi M, Overton JD, Bjornson RD, Carriero NJ, Meyer KA, Bilguvar 
K, Mane SM, Sestan N, Lifton RP, Gunel M, Roeder K, Geschwind DH, Devlin B, State MW. 
De novo mutations revealed by whole-exome sequencing are strongly associated with autism. 
Nature 2012;485:237-41. 
229. Abou-Khalil B, Alldredge B, Bautista J, Berkovic S, Bluvstein J, Boro A, Cascino G, 
Consalvo D, Cristofaro S, Crumrine P, Devinsky O, Dlugos D, Epstein M, Fahlstrom R, Fiol M, 
Fountain N, Fox K, French J, Freyer Karn C, Friedman D, Geller E, Glauser T, Glynn S, Haas K, 
Haut S, Hayward J, Helmers S, Joshi S, Kanner A, Kirsch H, Knowlton R, Kossoff E, Kuperman 
R, Kuzniecky R, Lowenstein D, McGuire S, Motika P, Nesbitt G, Novotny E, Ottman R, 
Paolicchi J, Parent J, Park K, Poduri A, Risch N, Sadleir L, Scheffer I, Shellhaas R, Sherr E, 
Shih JJ, Shinnar S, Singh R, Sirven J, Smith M, Sullivan J, Thio LL, Venkat A, Vining E, von 
Allmen G, Weisenberg J, Widdess-Walsh P, Winawer M. The epilepsy phenome/genome 
project. Clin Trials 2013;10:568-86. 
230. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. 
Bioinformatics 2010;26:589-95. 
231. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, 
del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, 
Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. A framework for variation discovery and 
genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-8. 
232. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, 
Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S, 
DePristo MA. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit 
best practices pipeline. Curr Protoc Bioinformatics 2013;43:11.0.1-33. 
	 195	
233. Abyzov A, Urban AE, Snyder M, Gerstein M. CNVnator: an approach to discover, 
genotype, and characterize typical and atypical CNVs from family and population genome 
sequencing. Genome Res 2011;21:974-84. 
234. Chen YZ, Friedman JR, Chen DH, Chan GC, Bloss CS, Hisama FM, Topol SE, Carson 
AR, Pham PH, Bonkowski ES, Scott ER, Lee JK, Zhang G, Oliveira G, Xu J, Scott-Van Zeeland 
AA, Chen Q, Levy S, Topol EJ, Storm D, Swanson PD, Bird TD, Schork NJ, Raskind WH, 
Torkamani A. Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. 
Ann Neurol 2014;75:542-9. 
235. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis 
E, Schaffner SF, Yu F, Peltonen L, Dermitzakis E, Bonnen PE, Altshuler DM, Gibbs RA, de 
Bakker PI, Deloukas P, Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin M, 
Whittaker P, Yu F, Chang K, Hawes A, Lewis LR, Ren Y, Wheeler D, Gibbs RA, Muzny DM, 
Barnes C, Darvishi K, Hurles M, Korn JM, Kristiansson K, Lee C, McCarrol SA, Nemesh J, 
Dermitzakis E, Keinan A, Montgomery SB, Pollack S, Price AL, Soranzo N, Bonnen PE, Gibbs 
RA, Gonzaga-Jauregui C, Keinan A, Price AL, Yu F, Anttila V, Brodeur W, Daly MJ, Leslie S, 
McVean G, Moutsianas L, Nguyen H, Schaffner SF, Zhang Q, Ghori MJ, McGinnis R, McLaren 
W, Pollack S, Price AL, Schaffner SF, Takeuchi F, Grossman SR, Shlyakhter I, Hostetter EB, 
Sabeti PC, Adebamowo CA, Foster MW, Gordon DR, Licinio J, Manca MC, Marshall PA, 
Matsuda I, Ngare D, Wang VO, Reddy D, Rotimi CN, Royal CD, Sharp RR, Zeng C, Brooks 
LD, McEwen JE. Integrating common and rare genetic variation in diverse human populations. 
Nature 2010;467:52-8. 
236. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang 
HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human 
genomes. Nature 2012;491:56-65. 
237. Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, Schwartz S, Adams MD, Myers 
EW, Li PW, Eichler EE. Recent segmental duplications in the human genome. Science 
2002;297:1003-7. 
238. O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, 
Lee C, Ankenman K, Munson J, Hiatt JB, Turner EH, Levy R, O'Day DR, Krumm N, Coe BP, 
Martin BK, Borenstein E, Nickerson DA, Mefford HC, Doherty D, Akey JM, Bernier R, Eichler 
EE, Shendure J. Multiplex targeted sequencing identifies recurrently mutated genes in autism 
spectrum disorders. Science 2012;338:1619-22. 
239. Jorge BS, Campbell CM, Miller AR, Rutter ED, Gurnett CA, Vanoye CG, George AL, 
Jr., Kearney JA. Voltage-gated potassium channel KCNV2 (Kv8.2) contributes to epilepsy 
susceptibility. Proc Natl Acad Sci U S A 2011;108:5443-8. 
240. Hille B. Ionic channels: molecular pores of excitable membranes. Harvey Lect 
1986;82:47-69. 
	 196	
241. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, 
Remmert M, Soding J, Thompson JD, Higgins DG. Fast, scalable generation of high-quality 
protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011;7:539. 
242. Long SB, Tao X, Campbell EB, MacKinnon R. Atomic structure of a voltage-dependent 
K+ channel in a lipid membrane-like environment. Nature 2007;450:376-82. 
243. Consiglio JF, Andalib P, Korn SJ. Influence of pore residues on permeation properties in 
the Kv2.1 potassium channel. Evidence for a selective functional interaction of K+ with the outer 
vestibule. J Gen Physiol 2003;121:111-24. 
244. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel 
A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, 
Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing 
adenomas and hereditary hypertension. Science 2011;331:768-72. 
245. Dibb KM, Rose T, Makary SY, Claydon TW, Enkvetchakul D, Leach R, Nichols CG, 
Boyett MR. Molecular basis of ion selectivity, block, and rectification of the inward rectifier 
Kir3.1/Kir3.4 K(+) channel. J Biol Chem 2003;278:49537-48. 
246. Heginbotham L, Lu Z, Abramson T, MacKinnon R. Mutations in the K+ channel 
signature sequence. Biophys J 1994;66:1061-7. 
247. Navarro B, Kennedy ME, Velimirovic B, Bhat D, Peterson AS, Clapham DE. 
Nonselective and G betagamma-insensitive weaver K+ channels. Science 1996;272:1950-3. 
248. Du J, Haak LL, Phillips-Tansey E, Russell JT, McBain CJ. Frequency-dependent 
regulation of rat hippocampal somato-dendritic excitability by the K+ channel subunit Kv2.1. J 
Physiol 2000;522 Pt 1:19-31. 
249. Guan D, Tkatch T, Surmeier DJ, Armstrong WE, Foehring RC. Kv2 subunits underlie 
slowly inactivating potassium current in rat neocortical pyramidal neurons. J Physiol 
2007;581:941-60. 
250. Guan D, Horton LR, Armstrong WE, Foehring RC. Postnatal development of A-type and 
Kv1- and Kv2-mediated potassium channel currents in neocortical pyramidal neurons. J 
Neurophysiol 2011;105:2976-88. 
251. Guan D, Armstrong WE, Foehring RC. Kv2 channels regulate firing rate in pyramidal 
neurons from rat sensorimotor cortex. J Physiol 2013;591:4807-25. 
	 197	
252. Liu PW, Bean BP. Kv2 channel regulation of action potential repolarization and firing 
patterns in superior cervical ganglion neurons and hippocampal CA1 pyramidal neurons. J 
Neurosci 2014;34:4991-5002. 
253. Speca DJ, Ogata G, Mandikian D, Bishop HI, Wiler SW, Eum K, Wenzel HJ, Doisy ET, 
Matt L, Campi KL, Golub MS, Nerbonne JM, Hell JW, Trainor BC, Sack JT, Schwartzkroin PA, 
Trimmer JS. Deletion of the Kv2.1 delayed rectifier potassium channel leads to neuronal and 
behavioral hyperexcitability. Genes Brain Behav 2014;13:394-408. 
254. Orhan G, Bock M, Schepers D, Ilina EI, Reichel SN, Loffler H, Jezutkovic N, 
Weckhuysen S, Mandelstam S, Suls A, Danker T, Guenther E, Scheffer IE, De Jonghe P, Lerche 
H, Maljevic S. Dominant-negative effects of KCNQ2 mutations are associated with epileptic 
encephalopathy. Ann Neurol 2014;75:382-94. 
255. Brugada J, Brugada R, Brugada P. Right Bundle-Branch Block and ST-Segment 
Elevation in Leads V1 Through V3 : A Marker for Sudden Death in Patients Without 
Demonstrable Structural Heart Disease. Circulation 1998;97:457-60. 
256. Boczek NJ, Ye D, Jin F, Tester DJ, Huseby A, Bos JM, Johnson AJ, Kanter R, Ackerman 
MJ. Identification and Functional Characterization of a Novel CACNA1C-Mediated Cardiac 
Disorder Characterized by Prolonged QT Intervals With Hypertrophic Cardiomyopathy, 
Congenital Heart Defects, and Sudden Cardiac Death. Circ Arrhythm Electrophysiol 
2015;8:1122-32. 
257. Novak A, Barad L, Lorber A, Gherghiceanu M, Reiter I, Eisen B, Eldor L, Itskovitz-
Eldor J, Eldar M, Arad M, Binah O. Functional abnormalities in iPSC-derived cardiomyocytes 
generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. J 
Cell Mol Med 2015;19:2006-18. 
258. Mehta A, Sequiera GL, Ramachandra CJ, Sudibyo Y, Chung Y, Sheng J, Wong KY, Tan 
TH, Wong P, Liew R, Shim W. Re-trafficking of hERG reverses long QT syndrome 2 phenotype 
in human iPS-derived cardiomyocytes. Cardiovasc Res 2014;102:497-506. 
259. Zhang M, D'Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D, Piccini 
I, Freund C, Rao J, Seebohm G, Atsma DE, Schulze-Bahr E, Mummery CL, Greber B, Bellin M. 
Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-
Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A 
2014;111:E5383-92. 
260. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, 
Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setala K. 
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic 
characteristics in cell culture. Dis Model Mech 2012;5:220-30. 
	 198	
261. Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NB, Tan TH, Wong KY, Shim W, Wong P, 
Cook SA, Liew R. Modeling type 3 long QT syndrome with cardiomyocytes derived from 
patient-specific induced pluripotent stem cells. Int J Cardiol 2013;168:5277-86. 
262. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, 
Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL. Patient-specific 
induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397-409. 
263. Malan D, Friedrichs S, Fleischmann BK, Sasse P. Cardiomyocytes obtained from 
induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific 
features in vitro. Circ Res 2011;109:841-7. 
264. Gibson JK, Yue Y, Bronson J, Palmer C, Numann R. Human stem cell-derived 
cardiomyocytes detect drug-mediated changes in action potentials and ion currents. J Pharmacol 
Toxicol Methods 2014;70:255-67. 
265. Wang Y, Liang P, Lan F, Wu H, Lisowski L, Gu M, Hu S, Kay MA, Urnov FD, 
Shinnawi R, Gold JD, Gepstein L, Wu JC. Genome editing of isogenic human induced 
pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol 
2014;64:451-9. 
266. Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, Salvatori 
D, Oostwaard DW, Wilde AA, Bezzina CR, Verkerk AO, Freund C, Mummery CL. 
Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological 
characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 
2012;125:3079-91. 
267. Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen 
LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL. Isogenic human 
pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J 
2013;32:3161-75. 
268. Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, 
Kong CW, Rushing S, Hansen J, Ceholski D, Kolokathis F, Kremastinos D, Katoulis A, Ren L, 
Cohen N, Gho JM, Tsiapras D, Vink A, Wu JC, Asselbergs FW, Li RA, Hulot JS, Kranias EG, 
Hajjar RJ. Correction of human phospholamban R14del mutation associated with 
cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 2015;6:6955. 
269. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using 
the CRISPR-Cas9 system. Nat Protoc 2013;8:2281-308. 
270. Karmakar CK, Khandoker AH, Voss A, Palaniswami M. Sensitivity of temporal heart 
rate variability in Poincare plot to changes in parasympathetic nervous system activity. Biomed 
Eng Online 2011;10:17. 
	 199	
271. Fan C, Duhagon MA, Oberti C, Chen S, Hiroi Y, Komuro I, Duhagon PI, Canessa R, 
Wang Q. Novel TBX5 mutations and molecular mechanism for Holt-Oram syndrome. J Med 
Genet 2003;40. 
272. McDermott DA, Bressan MC, He J, Lee JS, Aftimos S, Brueckner M, Gilbert F, Graham 
GE, Hannibal MC, Innis JW, Pierpont ME, Raas-Rothschild A, Shanske AL, Smith WE, Spencer 
RH, St John-Sutton MG, van Maldergem L, Waggoner DJ, Weber M, Basson CT. TBX5 genetic 
testing validates strict clinical criteria for Holt-Oram syndrome. Pediatr Res 2005;58:981-6. 
273. Spranger S, Ulmer H, Troger J, Jansen O, Graf J, Meinck HM, Spranger M. Muscular 
involvement in the Holt-Oram syndrome. J Med Genet 1997;34:978-81. 
274. Fan C, Liu M, Wang Q. Functional analysis of TBX5 missense mutations associated with 
Holt-Oram syndrome. J Biol Chem 2003;278:8780-5. 
275. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, 
Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 
2007;315:1709-12. 
276. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the 
CRISPR RNA-guided endonuclease Cas9. Nature 2014;507:62-7. 
277. Sternberg SH, LaFrance B, Kaplan M, Doudna JA. Conformational control of DNA 
target cleavage by CRISPR-Cas9. Nature 2015;527:110-3. 
278. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara 
S, Mochizuki N, Makiyama T, Itoh H, Christiansen M, McKeown P, Miyamoto K, Kamakura S, 
Tsutsui H, Schwartz PJ, George AL, Jr., Roden DM. The E1784K mutation in SCN5A is 
associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 
2008;118:2219-29. 
279. Hummel YM, Wilde AA, Voors AA, Bugatti S, Hillege HL, van den Berg MP. 
Ventricular dysfunction in a family with long QT syndrome type 3. Europace 2013;15:1516-21. 
280. Sokolov S, Peters CH, Rajamani S, Ruben PC. Proton-dependent inhibition of the cardiac 
sodium channel Nav1.5 by ranolazine. Front Pharmacol 2013;4:78. 
281. Lowe JS, Stroud DM, Yang T, Hall L, Atack TC, Roden DM. Increased late sodium 
current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res 
2012;95:300-7. 
282. Kaneko T, Nomura F, Hamada T, Abe Y, Takamori H, Sakakura T, Takasuna K, 
Sanbuissho A, Hyllner J, Sartipy P, Yasuda K. On-chip in vitro cell-network pre-clinical cardiac 
	 200	
toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Sci Rep 
2014;4:4670. 
283. Kamen PW, Tonkin AM. Application of the Poincare plot to heart rate variability: a new 
measure of functional status in heart failure. Aust N Z J Med 1995;25:18-26. 
284. Szentandrassy N, Kistamas K, Hegyi B, Horvath B, Ruzsnavszky F, Vaczi K, Magyar J, 
Banyasz T, Varro A, Nanasi PP. Contribution of ion currents to beat-to-beat variability of action 
potential duration in canine ventricular myocytes. Pflugers Arch 2015;467:1431-43. 
285. Koesters A, Engisch KL, Rich MM. Decreased cardiac excitability secondary to 
reduction of sodium current may be a significant contributor to reduced contractility in a rat 
model of sepsis. Crit Care 2014;18:R54. 
286. Pueyo E, Corrias A, Virag L, Jost N, Szel T, Varro A, Szentandrassy N, Nanasi PP, 
Burrage K, Rodriguez B. A multiscale investigation of repolarization variability and its role in 
cardiac arrhythmogenesis. Biophys J 2011;101:2892-902. 
287. Doerr L, Thomas U, Guinot DR, Bot CT, Stoelzle-Feix S, Beckler M, George M, Fertig 
N. New easy-to-use hybrid system for extracellular potential and impedance recordings. J Lab 
Autom 2015;20:175-88. 
288. Pardo B, Gomez-Gonzalez B, Aguilera A. DNA repair in mammalian cells: DNA double-
strand break repair: how to fix a broken relationship. Cell Mol Life Sci 2009;66:1039-56. 
289. Yang J, Hu D, Xia J, Yang Y, Ying B, Hu J, Zhou X. Three novel TBX5 mutations in 
Chinese patients with Holt-Oram syndrome. Am J Med Genet 2000;92:237-40. 
290. Luna-Zurita L, Stirnimann CU, Glatt S, Kaynak BL, Thomas S, Baudin F, Samee MA, 
He D, Small EM, Mileikovsky M, Nagy A, Holloway AK, Pollard KS, Muller CW, Bruneau BG. 
Complex Interdependence Regulates Heterotypic Transcription Factor Distribution and 
Coordinates Cardiogenesis. Cell 2016;164:999-1014. 
291. Gourraud JB, Barc J, Thollet A, Le Scouarnec S, Le Marec H, Schott JJ, Redon R, Probst 
V. The Brugada Syndrome: A Rare Arrhythmia Disorder with Complex Inheritance. Front 
Cardiovasc Med 2016;3:9. 
292. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis 
with the PANTHER classification system. Nat Protoc 2013;8:1551-66. 
293. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM. 
Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late 
sodium current. Circulation 2014;130:224-34. 
	 201	
294. Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, Lin RZ. Suppression of 
phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long 
QT syndrome. Sci Transl Med 2012;4:131ra50. 
295. Lu Z, Jiang YP, Wu CY, Ballou LM, Liu S, Carpenter ES, Rosen MR, Cohen IS, Lin RZ. 
Increased persistent sodium current due to decreased PI3K signaling contributes to QT 
prolongation in the diabetic heart. Diabetes 2013;62:4257-65. 
296. Qiu XS, Chauveau S, Anyukhovsky EP, Rahim T, Jiang YP, Harleton E, Feinmark SJ, 
Lin RZ, Coronel R, Janse MJ, Opthof T, Rosen TS, Cohen IS, Rosen MR. Increased Late 
Sodium Current Contributes to the Electrophysiological Effects of Chronic, but Not Acute, 
Dofetilide Administration. Circ Arrhythm Electrophysiol 2016;9:e003655. 
297. Ballou LM, Lin RZ, Cohen IS. Control of cardiac repolarization by phosphoinositide 3-
kinase signaling to ion channels. Circ Res 2015;116:127-37. 
298. Jamsai D, Clark BJ, Smith SJ, Whittle B, Goodnow CC, Ormandy CJ, O'Bryan MK. A 
missense mutation in the transcription factor ETV5 leads to sterility, increased embryonic and 
perinatal death, postnatal growth restriction, renal asymmetry and polydactyly in the mouse. 
PLoS one 2013;8:e77311. 
299. Ma JF, Yang F, Mahida SN, Zhao L, Chen X, Zhang ML, Sun Z, Yao Y, Zhang YX, 
Zheng GY, Dong J, Feng MJ, Zhang R, Sun J, Li S, Wang QS, Cao H, Benjamin EJ, Ellinor PT, 
Li YG, Tian XL. TBX5 mutations contribute to early-onset atrial fibrillation in Chinese and 
Caucasians. Cardiovasc Res 2016;109:442-50. 
300. Chowdhury R, Ashraf H, Melanson M, Tanada Y, Nguyen M, Silberbach M, Wakimoto 
H, Benson DW, Anderson RH, Kasahara H. Mouse Model of Human Congenital Heart Disease: 
Progressive Atrioventricular Block Induced by a Heterozygous Nkx2-5 Homeodomain Missense 
Mutation. Circ Arrhythm Electrophysiol 2015;8:1255-64. 
301. Shoubridge C, Tan MH, Seiboth G, Gecz J. ARX homeodomain mutations abolish DNA 
binding and lead to a loss of transcriptional repression. Hum Mol Genet 2012;21:1639-47. 
302. Deniaud E, Baguet J, Chalard R, Blanquier B, Brinza L, Meunier J, Michallet MC, 
Laugraud A, Ah-Soon C, Wierinckx A, Castellazzi M, Lachuer J, Gautier C, Marvel J, Leverrier 
Y. Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell 
cycle inhibition. PLoS one 2009;4:e7035. 
303. Yao Z, Fong AP, Cao Y, Ruzzo WL, Gentleman RC, Tapscott SJ. Comparison of 
endogenous and overexpressed MyoD shows enhanced binding of physiologically bound sites. 
Skelet Muscle 2013;3:8. 
	 202	
304. Peters CH, Abdelsayed M, Ruben PC. Triggers for arrhythmogenesis in the Brugada and 
long QT 3 syndromes. Prog Biophys Mol Biol 2016;120:77-88. 
305. Wilde AA, Brugada R. Phenotypical manifestations of mutations in the genes encoding 
subunits of the cardiac sodium channel. Circ Res 2011;108:884-97. 
306. Ahern GP, Hsu SF, Klyachko VA, Jackson MB. Induction of persistent sodium current 
by exogenous and endogenous nitric oxide. J Biol Chem 2000;275:28810-5. 
307. Wagner S, Dybkova N, Rasenack EC, Jacobshagen C, Fabritz L, Kirchhof P, Maier SK, 
Zhang T, Hasenfuss G, Brown JH, Bers DM, Maier LS. Ca2+/calmodulin-dependent protein 
kinase II regulates cardiac Na+ channels. J Clin Invest 2006;116:3127-38. 
308. Qu Y, Rogers JC, Tanada TN, Catterall WA, Scheuer T. Phosphorylation of S1505 in the 
cardiac Na+ channel inactivation gate is required for modulation by protein kinase C. J Gen 
Physiol 1996;108:375-9. 
309. Hinterseer M, Beckmann BM, Thomsen MB, Pfeufer A, Ulbrich M, Sinner MF, Perz S, 
Wichmann HE, Lengyel C, Schimpf R, Maier SK, Varro A, Vos MA, Steinbeck G, Kaab S. 
Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and 
proarrhythmia in patients with nonischemic heart failure. Am J Cardiol 2010;106:216-20. 
310. Heijman J, Zaza A, Johnson DM, Rudy Y, Peeters RL, Volders PG, Westra RL. 
Determinants of beat-to-beat variability of repolarization duration in the canine ventricular 
myocyte: a computational analysis. PLoS Comput Biol 2013;9:e1003202. 
311. Iribe G, Kohl P, Noble D. Modulatory effect of calmodulin-dependent kinase II 
(CaMKII) on sarcoplasmic reticulum Ca2+ handling and interval-force relations: a modelling 
study. Philos Trans A Math Phys Eng Sci 2006;364:1107-33. 
312. Hiraoka M, Kawano S. Mechanism of increased amplitude and duration of the plateau 
with sudden shortening of diastolic intervals in rabbit ventricular cells. Circ Res 1987;60:14-26. 
313. Wu R, Patwardhan A. Restitution of action potential duration during sequential changes 
in diastolic intervals shows multimodal behavior. Circ Res 2004;94:634-41. 
314. Mahajan A, Sato D, Shiferaw Y, Baher A, Xie LH, Peralta R, Olcese R, Garfinkel A, Qu 
Z, Weiss JN. Modifying L-type calcium current kinetics: consequences for cardiac excitation and 
arrhythmia dynamics. Biophys J 2008;94:411-23. 
315. Goldhaber JI, Xie LH, Duong T, Motter C, Khuu K, Weiss JN. Action potential duration 
restitution and alternans in rabbit ventricular myocytes: the key role of intracellular calcium 
cycling. Circ Res 2005;96:459-66. 
	 203	
316. Ujhelyi MR, Creazzo TL. Action potentials that mimic fibrillation activate sodium 
current. J Mol Cell Cardiol 1999;31:1673-84. 
317. Sinnecker D, Goedel A, Laugwitz KL, Moretti A. Induced pluripotent stem cell-derived 
cardiomyocytes: a versatile tool for arrhythmia research. Circ Res 2013;112:961-8. 
318. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, 
Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC, Wu JC. Drug screening using a 
library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific 
patterns of cardiotoxicity. Circulation 2013;127:1677-91. 
319. Sosnay PR, Raraigh KS, Gibson RL. Molecular Genetics of Cystic Fibrosis 
Transmembrane Conductance Regulator: Genotype and Phenotype. Pediatr Clin North Am 
2016;63:585-98. 
320. Trujillano D, Weiss ME, Koster J, Papachristos EB, Werber M, Kandaswamy KK, 
Marais A, Eichler S, Creed J, Baysal E, Jaber IY, Mehaney DA, Farra C, Rolfs A. Validation of 
a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR. 
Mol Genet Genomic Med 2015;3:396-403. 
321. Feaster TK, Cadar AG, Wang L, Williams CH, Chun YW, Hempel JE, Bloodworth N, 
Merryman WD, Lim CC, Wu JC, Knollmann BC, Hong CC. Matrigel Mattress: A Method for 
the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived 
Cardiomyocytes. Circ Res 2015;117:995-1000. 
322. Hayashi K, Shuai W, Sakamoto Y, Higashida H, Yamagishi M, Kupershmidt S. 
Trafficking-competent KCNQ1 variably influences the function of HERG long QT alleles. Heart 
Rhythm 2010;7:973-80. 
323. Ren XQ, Liu GX, Organ-Darling LE, Zheng R, Roder K, Jindal HK, Centracchio J, 
McDonald TV, Koren G. Pore mutants of HERG and KvLQT1 downregulate the reciprocal 
currents in stable cell lines. Am J Physiol Heart Circ Physiol 2010;299:H1525-34. 
324. Guo J, Wang T, Yang T, Xu J, Li W, Fridman MD, Fisher JT, Zhang S. Interaction 
between the cardiac rapidly (IKr) and slowly (IKs) activating delayed rectifier potassium 
channels revealed by low K+-induced hERG endocytic degradation. J Biol Chem 
2011;286:34664-74. 
325. Zhang J, Klos M, Wilson GF, Herman AM, Lian X, Raval KK, Barron MR, Hou L, 
Soerens AG, Yu J, Palecek SP, Lyons GE, Thomson JA, Herron TJ, Jalife J, Kamp TJ. 
Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem 
cells: the matrix sandwich method. Circ Res 2012;111:1125-36. 
	 204	
326. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in 
cancer. Nat Rev Cancer 2004;4:118-32. 
327. Than BL, Goos JA, Sarver AL, O'Sullivan MG, Rod A, Starr TK, Fijneman RJ, Meijer 
GA, Zhao L, Zhang Y, Largaespada DA, Scott PM, Cormier RT. The role of KCNQ1 in mouse 
and human gastrointestinal cancers. Oncogene 2014;33:3861-8. 
328. Morokuma J, Blackiston D, Adams DS, Seebohm G, Trimmer B, Levin M. Modulation 
of potassium channel function confers a hyperproliferative invasive phenotype on embryonic 
stem cells. Proc Natl Acad Sci U S A 2008;105:16608-13. 
329. Parent JM, Anderson SA. Reprogramming patient-derived cells to study the epilepsies. 
Nat Neurosci 2015;18:360-6. 
330. Chen H, Qian K, Du Z, Cao J, Petersen A, Liu H, Blackbourn LWt, Huang CL, Errigo A, 
Yin Y, Lu J, Ayala M, Zhang SC. Modeling ALS with iPSCs reveals that mutant SOD1 
misregulates neurofilament balance in motor neurons. Cell Stem Cell 2014;14:796-809. 
331. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, 
Fressart V, Guerchicoff A, Harris-Kerr C, Kamakura S, Kyndt F, Koopmann TT, Miyamoto Y, 
Pfeiffer R, Pollevick GD, Probst V, Zumhagen S, Vatta M, Towbin JA, Shimizu W, Schulze-
Bahr E, Antzelevitch C, Salisbury BA, Guicheney P, Wilde AA, Brugada R, Schott JJ, 
Ackerman MJ. An international compendium of mutations in the SCN5A-encoded cardiac 
sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 
2010;7:33-46. 
332. He A, Kong SW, Ma Q, Pu WT. Co-occupancy by multiple cardiac transcription factors 
identifies transcriptional enhancers active in heart. Proc Natl Acad Sci U S A 2011;108:5632-7. 
333. Mazzoni EO, Mahony S, Iacovino M, Morrison CA, Mountoufaris G, Closser M, Whyte 
WA, Young RA, Kyba M, Gifford DK, Wichterle H. Embryonic stem cell-based mapping of 
developmental transcriptional programs. Nat Methods 2011;8:1056-8. 
334. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR RNA-guided 
activation of endogenous human genes. Nat Methods 2013;10:977-9. 
335. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore 
PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. 
RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 
2013;10:973-6. 
	 205	
336. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, 
Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR-mediated 
modular RNA-guided regulation of transcription in eukaryotes. Cell 2013;154:442-51. 
337. Luo Y, Rao M, Zou J. Generation of GFP Reporter Human Induced Pluripotent Stem 
Cells Using AAVS1 Safe Harbor Transcription Activator-Like Effector Nuclease. Curr Protoc 
Stem Cell Biol 2014;29:5a.7.1-18. 
338. Wang Y, Zhang WY, Hu S, Lan F, Lee AS, Huber B, Lisowski L, Liang P, Huang M, de 
Almeida PE, Won JH, Sun N, Robbins RC, Kay MA, Urnov FD, Wu JC. Genome editing of 
human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for 
cellular imaging. Circ Res 2012;111:1494-503. 
 
